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Abstract 	  
Tendon disorders - tendinopathies - are the primary reason for 
musculoskeletal consultation in primary care in the UK and the US. The molecular 
pathophysiology of tendinopathy remains difficult to interpret while inflammation 
and its role in tendinopathy have been historically ignored due to its absence in 
human surgical specimens. This thesis explores the role of inflammation in human 
tendinopathy and dissects potential molecular pathways involved in its initiation 
and perpetuation. 
Firstly I characterize inflammatory cell subtypes within a model of human 
tendinopathy highlighting a distinct inflammatory infiltrate particularly of mast cells 
and macrophages. Hypoxia and hypoxic cell death have been a long considered 
aetiology of tendon degeneration. In this thesis I demonstrate that hypoxia related 
proteins are present in early tendinopathy biopsies and thereafter in mechanistic 
studies demonstrate that hypoxia regulates inflammatory and apoptotic mediators 
in tendon cells associated with a significant shift in collagen matrix synthesis. 
The cytokines, interleukins 17 and 33 are emerging inflammatory mediators 
known to play key roles in fibroblast biology. I explored the cellular sources of IL-
17A in human tendinopathy with experiments revealing the majority of IL17A co-
localised to mast cells. Moreover IL-17A induced proinflammatory cytokines and 
apoptosis in vitro and again resulted in a significant switch in collagen extracellular 
matrix production. IL 33 is a new member of the IL-1 superfamily that signals 
through the ST2 receptor. Herein I demonstrate that IL-33 expression is up 
regulated in human tendinopathic biopsies whilst rhIL-33 promotes 
proinflammatory cytokine release and significantly shifts matrix production toward 
a collagen III phenotype. WT mice undergoing a tendon injury model showed 
significant up regulation of IL-33 and ST2 while ST2-/- mice exhibit a reduced 
collagen response and biomechanical tendon strength at early time points post 
injury Addition of rh-IL33 increased type III collagen production and reduced the 
biomechanical strength of WT tendons. Furthermore mechanistic investigations 
has highlighted a key role for the microRNA 29 family in the modulation of collagen 
regulation in tendinopathy but also in controlling IL-33 induced changes as a direct 
target of sST2. Based on these experiments I propose IL-33 as an important and 
influential alarmin in early tendon injury and tendinopathy, which may be influential 
in the balance between reparation and degeneration in tendon disease.
 Table of Contents 	  
Abstract ................................................................................................................... 2	  
Table of Contents .................................................................................................... 3	  
List of Tables ........................................................................................................... 6	  
List of Figures .......................................................................................................... 7	  
Acknowledgement ................................................................................................... 9	  
Author's declaration .............................................................................................. 10	  
Abbreviations ........................................................................................................ 11	  
Chapter 1 Introduction ........................................................................................... 13	  
1.1) Tendon Biology .......................................................................................... 14	  
1.1.1) Tendon ultrastructure ........................................................................... 16	  
1.1.2) Nerve supply ........................................................................................ 24	  
1.1.3) Blood supply ........................................................................................ 24	  
1.1.4) Biomechanics of tendon function ......................................................... 25	  
1.1.5) Injury and Healing of Tendon Tissue ................................................... 27	  
The Inflammatory Phase ................................................................................ 27	  
The Proliferation Phase ................................................................................. 28	  
The Remodelling Phase ................................................................................. 29	  
1.2) Tendinopathy .............................................................................................. 31	  
1.2.1) Aetiology of tendinopathy .................................................................... 31	  
1.2.2) Pathology of tendinopathy ................................................................... 37	  
1.2.3) Strategies for tendon healing ............................................................... 39	  
1.3) Models of tendon healing and tendinopathy ............................................... 43	  
1.3.1 Current animal models of tendon healing and tendinopathy ................. 43	  
1.4) Cytokines in health and disease ................................................................. 46	  
Inflammation in tendinopathy ......................................................................... 46	  
TNFα , IL-1β , and IL-6 in tendinopathy ......................................................... 47	  
1.4.1) Candidate cytokines to be explored ..................................................... 49	  
1.5) Novel regulation of cytokine production ..................................................... 75	  
Hypoxia and cytokine regulation .................................................................... 75	  
MicroRNA ....................................................................................................... 80	  
1.6) Aims of this Work ....................................................................................... 91	  
Chapter 2 Material and Methods ........................................................................... 92	  
2.1) General reagents & buffers ........................................................................ 93	  
Materials and reagents .................................................................................. 93	  
Buffers and culture media .............................................................................. 93	  
2.2) Patients ...................................................................................................... 94	  
2.3) Tendon explant biopsy ............................................................................... 95	  
2.4) Tissue preparation ...................................................................................... 97	  
Paraffin embedded tissue .............................................................................. 97	  
2.5) Immunohistochemistry (IHC) of paraffin embedded sections ..................... 98	  
Single staining for light microscopy ................................................................ 98	  
Double staining for light microscopy .............................................................. 98	  
Double staining for fluorescent microscopy ................................................... 99	  
Quantification of fluorescent IHC ................................................................. 102	  
2.6) ELISA and Luminex cytokine analysis ..................................................... 103	  
2.7) Signaling analysis ..................................................................................... 104	  
2.8) RNA extraction and Quantitative PCR analysis ....................................... 105	  
2.8.1) RNA isolation and quantitative real time PCR analysis of miRNA ..... 107	  
2.8.2) miRNA transfection ............................................................................ 107	  
4	  
2.8.3) Luciferase reporter assay for targeting Collagen I & III and soluble ST2
 ..................................................................................................................... 107	  
2.9) Matrix regulation analysis ......................................................................... 108	  
2.10) Cell culture ............................................................................................. 109	  
Culture of adherent cells .............................................................................. 109	  
Culture in Hypoxic conditions ....................................................................... 109	  
2.11) FACS analysis ........................................................................................ 110	  
2.12) Animals ................................................................................................... 111	  
Patellar tendon injury model ........................................................................ 111	  
Biomechanical analysis ................................................................................ 113	  
Cytokine injection model .............................................................................. 115	  
2.13	   Statistical analysis .............................................................................. 117	  
Chapter 3 Inflammation in human tendinopathy ................................................. 119	  
3.1) Aim and introduction ................................................................................. 120	  
3.2) Inflammatory staining in human tendinopathy .......................................... 121	  
3.2.1) Establishment of human 'model' of tendinopathy .............................. 124	  
3.2.2) Early human tendinopathy shows an increased inflammatory infiltrate
 ..................................................................................................................... 126	  
3.2.3) Increased vascularity in tendinopathy ................................................ 130	  
3.3) Discussion and Conclusions .................................................................... 132	  
Chapter 4 Hypoxia and Tendinopathy ................................................................. 135	  
4.1) Aims and introduction ............................................................................... 136	  
4.2)	   Early tendinopathy is associated with increased hypoxic and apoptotic 
markers ............................................................................................................ 138	  
4.3) Hypoxic induces apoptosis in tenocytes in vitro ....................................... 140	  
4.4) Hypoxia alters tenocyte collagen matrix regulation .................................. 142	  
4.5 ) Hypoxia promotes Cytokine production in tenocytes .............................. 145	  
4.6 ) Hypoxia, MAP Kinase expression and collagen synthesis ...................... 147	  
4.7) ERK and p38 inhibitors reduce proinflammatory cytokine / chemokine 
production but do not modulate apoptosis in tenocytes .................................. 149	  
4.8) Discussion ................................................................................................ 151	  
Chapter 5 Interleukin 17 in tendinopathy ............................................................ 155	  
5.1) Aims and Introduction ............................................................................... 156	  
5.2) Early tendinopathy shows increased IL-17A expression with localization 
particularly to mast cells .................................................................................. 157	  
5.3) IL-17A induces apoptosis in tenocytes in vitro ......................................... 161	  
5.4) IL-17A alters tenocyte collagen matrix regulation .................................... 163	  
5.5) IL-17A promotes cytokine production in tenocytes ................................... 165	  
5.6) MAP Kinases mediate some of the effects of IL-17A in tenocytes. .......... 167	  
5.7) Discussion and Conclusion ...................................................................... 169	  
Chapter 6 Interleukin 33 and related pathways in the pathogenesis of tendinopathy
 ............................................................................................................................ 173	  
Introduction ...................................................................................................... 174	  
6.2) IL-33 and ST2 is expressed in human tendinopathy ................................ 175	  
6.2.1) Expression of IL-33, ST2 and IL-1RAcP in tendon biopsies .............. 175	  
6.2.2) Co-localisation of IL-33/ST2 and endothelial markers ....................... 178	  
6.3) Induction of IL-33 in tenocytes ................................................................. 180	  
6.4) IL-33 induces collagen matrix changes and increased production of 
proinflammatory cytokines in vitro ................................................................... 183	  
6.5) Signalling mechanisms mediating rhIL-33 effects manifest in tenocytes in 
vitro .................................................................................................................. 186	  
6.6) ERK and NFκB inhibition abrogates collagen changes and reduces IL-33 
induced proinflammatory changes ................................................................... 188	  
6.7) IL-33 in tendon healing in vivo .................................................................. 191	  
5	  
6.7.1) Increased expression of IL-33/ST2 in early tendon healing ............... 192	  
6.7.2) Altered collagen synthesis responses in ST2-/- mice ........................ 195	  
6.7.3) ST2-/- mice showed reduced biomechanical tendon strength at early 
time points post injury .................................................................................. 198	  
6.7.4) Addition of rhIL-33 induces collagen matrix changes in vivo and 
reduces biomechanical strength .................................................................. 200	  
6.8) A role for micro RNA 29 in tendon healing ............................................... 203	  
6.8.1) Down regulation of miR 29 expression in tendinopathy ..................... 204	  
6.8.2) Altered collagen expression following over expression of miR29 a and b
 ..................................................................................................................... 206	  
6.8.3) Collagen I and III are directly targeted by miR29a and b ................... 208	  
6.8.4) IL-33 treated tenocytes show altered miR 29a expression ................ 210	  
6.8.5) Soluble ST2 is a direct target of miR29a ........................................... 213	  
6.8.6) miRNA 29 a & b altered in tendon healing in vivo ............................. 216	  
6.8.7) NFκB signalling modulates miR29a activity in IL-33 treated tenocytes
 ..................................................................................................................... 218	  
6.8.8) Addition of rhIL-33 alters miR 29 a and b expression in vivo ............. 220	  
6.9) Discussion and Conclusions .................................................................... 222	  
Chapter 7 Discussion and Future work ............................................................... 227	  
Chapter 8 References ......................................................................................... 230	  	  
6	  
List of Tables 	  
Table 1-1  Properties of the most abundant tendon proteoglycans ...................... 23	  
Table 1-2: Summary of healing process in tendons and ligament ........................ 30	  
Table 1-3.: Summary of pathology of normal versus tendinopathic tendon tissue 38	  
Table 1-4: Current treatment options for tendinopathy ......................................... 40	  
Table 1-5  Functions of Th-17 / IL-17 in disease processes ................................. 60	  
Table 1-6 MicroRNAs involved in inflammatory and autoimmune diseases ......... 86	  
Table 1-7 MicroRNAs involved in immune cell regulation ..................................... 87	  
Table 2-1 Antibodies for IHC ............................................................................... 100	  
Table 2-2 ELISAs used and  respective companies ........................................... 101	  
Table 2-3 Quantitative PCR primers ................................................................... 106	  
Table 3-1 Patient demographics and rotator cuff tear size ................................. 122	  
Table 3-2 Histological features in control, matched subscapularis and torn 
supraspinatus tendon samples ........................................................................... 131	  
 
 	  
7	  
List of Figures 	  
Figure 1-1  The hierarchical structure of tendon. .................................................. 15	  
Figure 1-2: The structure of type I and type III collagen molecules. ..................... 18	  
Figure 1-3 :Tenocytes and tenoblasts ................................................................... 21	  
Figure 1-4: Graph showing the stress–strain curve for tendon. ............................ 26	  
Figure 1-5 The biological responses of tendon fibroblasts to mechanical loading. 33	  
Figure 1-6: Histology of normal tendon and tendinopathy. ................................... 38	  
Figure 1-7: Effects of IL-17 on host defence, inflammation and tissue destruction54	  
Figure 1-8: T helper cell differentiation (overview). ............................................... 56	  
Figure 1-9  Structure of IL-33 HTH like motif ........................................................ 62	  
Figure 1-10: IL-33 structural components and cleavage sites. ............................. 64	  
Figure 1-11 IL-33 binding to ST2 and IL1RacP signals via MyD88 ...................... 67	  
Figure 1-12  Regulation of the hypoxia-inducible factor-1α (HIF-1α) and nuclear 
factor-κB (NF-κB) pathways by reactive oxygen species (ROS) and cytokine 
stimulation. ............................................................................................................ 78	  
Figure 1-13  A schematic representation of miRNA processing and activity. ....... 83	  
Figure 2-1 Illustration of  protocol for tendon explant tissue. ................................ 96	  
Figure 2-2 Mouse patellar tendon model ............................................................ 112	  
Figure 2-3 Biomechanical testing apparatus. ...................................................... 114	  
Figure 2-4  Overview of the mouse injection model. ........................................... 116	  
Figure 3-1 Anatomical locations of biopsied tendon. .......................................... 123	  
Figure 3-2 Bonar histological scoring for tendon biopsies. ................................. 125	  
Figure 3-3 Immunohistochemical staining for inflammatory cell surface markers. 
Staining for CD68 (pan macrophage) in sub intimal layers of tendon. CD3 (Tcells) 
are sparse but seem to be localised around lining layers and vascular regions. 
CD202 (M2 macrophages) are again sub intimal but are more readily localised to 
the vasculature. MCT (Mast cell tryptase) is highly expressed throughout the 
tissue with large expression patterns around vascular regions. .......................... 128	  
Figure 3-4  Correlation between tear size and inflammatory cell infiltrate. ......... 129	  
Figure 3-5  Immunohistochemical staining for CD34 Endothelial marker ........... 131	  
Figure 4-1 Apoptosis and hypoxic markers in tendon samples. .......................... 139	  
Figure 4-2 (A) Cell death after exposure to hypoxic conditions. ......................... 141	  
Figure 4-3 Collagen I and III mRNA in hypoxic conditions .................................. 143	  
Figure 4-4 Collagen I and III protein expression in hypoxic conditions ............... 144	  
Figure 4-5 Effects of hypoxia on cytokine production in cultured tenocytes. ...... 146	  
Figure 4-6 Hypoxia induced phosphorylation of MAPK in cultured tenocytes and 
matrix response to p38 and ERK inhibition ......................................................... 148	  
Figure 4-7 The effects of ERK and p38 MAPK inhibition on cytokine production 
and apoptosis. ..................................................................................................... 150	  
Figure 4-8 Schematic diagram illustrating the manner in which early tendinopathy 
may arise due to hypoxic injury. .......................................................................... 154	  
Figure 5-1Quantification of IL-17A in tendon biopsies ........................................ 158	  
Figure 5-2 Immunohistochemistry and double immunofluoroencse for IL-17A and 
CD68 ................................................................................................................... 159	  
Figure 5-3 Immunohistochemistry and double immunofluorensce for IL-17A and 
Mast cell tryptase ................................................................................................ 160	  
Figure 5-4 Apoptosis and IL-17A ........................................................................ 162	  
Figure 5-5 The effect of IL-17A on collagen matrix production ........................... 164	  
Figure 5-6 IL-17 induced cytokine production in cultured tenocytes ................... 166	  
Figure 5-7 IL-17 induced phosphorylation of MAPK in cultured tenocytes and 
matrix response to ERK and Atk inhibition .......................................................... 168	  
8	  
Figure 5-8 Schematic diagram illustrating the manner in which early tendinopathy 
may arise due to IL-17 induction. ........................................................................ 172	  
Figure 6-1 IL-33, ST2 and IL1-RacP  immunostaining ........................................ 177	  
Figure 6-2 Double immuofluroscence staining for IL33, ST2 and CD34 in tendon 
biopsies ............................................................................................................... 179	  
Figure 6-3. Immunostaining of explant cultures. ................................................. 181	  
Figure 6-4 Expression of IL-33 and ST2 with TNF/IL-1 stimulation .................... 182	  
Figure 6-5 IL-33 induced matrix changes in tenocytes. ...................................... 184	  
Figure 6-6 IL-33 induced COL I and III protein changes and cytokine production in 
cultured tenocytes ............................................................................................... 185	  
Figure 6-7 ERK and NFκB phosphorylation in IL-33 treated tenocytes .............. 187	  
Figure 6-8  ERK and NFκB inhibitors effects on collagen synthesis ................... 189	  
Figure 6-9 ERK and NFκB inhibitors effects of cytokine production in tenocytes 190	  
Figure 6-10. Relative expression of IL33, soluble and receptor ST2 in vivo ....... 193	  
Figure 6-11. Immunohistochemistry of IL-33 and ST2 expression in vivo. ......... 194	  
Figure 6-12.Total collagen production and Collagen III mRNA expression in vivo
 ............................................................................................................................ 196	  
Figure 6-13 Collagen changes in vivo ................................................................. 197	  
Figure 6-14 Biomechanical testing of tendon injury model in WT and ST2-/- mice
 ............................................................................................................................ 199	  
Figure 6-15 rhIL-33 and collagen matrix changes in vivo ................................... 201	  
Figure 6-16 Biomechanical testing of WT and ST2-/- mice treated with rhIL-33 . 202	  
Figure 6-17 Micro RNA 29 family expression in tendon biopsies ........................ 205	  
Figure 6-18 Collagen expression following transfection with miR 29a &b .......... 207	  
Figure 6-19 Collagen III is a direct target of miR29a ........................................... 209	  
Figure 6-20 The effects of IL-33 on miR 29a expression .................................... 211	  
Figure 6-21 The effects of mir 29a mimic ad IL-33 on Collagen expression ....... 212	  
Figure 6-22 Soluble ST2 is a direct target of miR29a ......................................... 214	  
Figure 6-23 miR29a targets soluble ST2 message and protein in tenocytes ...... 215	  
Figure 6-24 miRNA 29 a&b in tendon healing in vivo ......................................... 217	  
Figure 6-25 ERK and NFκB inhibitors effects on miR29a expression ................. 219	  
Figure 6-26 miRNA 29a following IL-33 treatment in vivo. .................................. 221	  
Figure 6-27 Schematic diagram illustrating the role of the IL33/ST2 axis in 
tendinopathy. ....................................................................................................... 226	  
 
 
9	  
Acknowledgement 
Without the support and guidance of Professor Iain McInnes my career to date 
including the submission of this thesis would never have happened. He has and still 
remains a truly inspirational supervisor always available to help in any manner. His 
scientific knowledge is unparalleled and his unwavering support in clinical mentorship 
despite my orthopaedic background has been magnificent . I would like to take this 
opportunity to thank him for taking a risk on an ‘orthopod’ and for everything he has 
and continues to do in supporting my career path. 
A huge part of my career has also been influenced by my international 
supervisor, Professor George Murrell. My time in Sydney working under his 
mentorship remains one of the most productive times of my short research career. An 
inspiring clinical academic orthopaedic surgeon who is humble and unassuming and 
has provided much support during my whole PhD despite being many thousand miles 
away.    
A thesis, whilst being your own work cannot come together without the help 
and support of many laboratory friends. Since my first introduction to Jim ‘Old Man’ 
Reilly as a young medical student he is without doubt a true gentleman and excellent 
teacher. Immunohistochemistry is an art form in his hands and he has become a true 
friend and mentor. Despite initially thinking she had destroyed an 
immunohistochemical run in our early days; the subsequent help and support of 
Shauna Kerr cannot go without mention. She constantly strives to be the best and has 
great insight into my psyche and thus keeps me well grounded when I start to rant. 
Other mentions must go to Ashley Gilmour aka ‘The Oracle’ whose help has been 
invaluable; Derek Gilchrist , the Lord Kelvin Scholar in molecular biology for his 
excellent support; Mariola Kurowska-Stolarska whose insight and support has helped 
throughout my time. A special thanks also goes to Mr David Large, Head of Training 
and Consultant Orthopaedic Surgeon whose steadfast support in my research efforts 
has been instrumental in allowing a local orthopaedic trainee to produce a PhD at 
Glasgow University for the first time in over 15 years.  
And finally but yet most importantly my wife Lauren and my two girls, Orla and 
Caoimhe. Lauren has constantly sacrificed many things in her own medical career to 
support her workaholic husband. I can never repay the many hours she has worked 
earning the real money so I could do my research and subsequent PhD. I will be 
forever grateful to her and ultimately believe what she has done for me over the years 
is more inspirational than this thesis. 
10	  
Author's declaration 
The work described in this thesis represents original work which has been 
generated through my own efforts and does not consist of work forming part of a 
thesis to be submitted elsewhere. Furthermore, no data has been given to me by 
anybody else to be submitted as part of my thesis. Where practical support has 
been provided by others appropriate acknowledgements have been made. 	  	  
 
............................................... 
Neal L Millar 
11	  
Abbreviations 
ACPA  Anti-Citrullinate Protein Antibodies 
ACR   American College of Rheumatology 
AS   Ankylosing Spondylitis 
CBM  Chromatin binding motif 
CIA   Collagen-Induced Arthritis 
CRP   C-Reactive Protein 
CTLA-4  Cytotoxic T Lymphocyte Associated Antigen 4 
CVD   Cardiovascular Disease 
DAMP  Danger-associated molecular pattern 
DMARD Disease modifying anti rheumatic drug 
EAE   Experimental Autoimmune Encephalomyelitis 
ELISA  Enzyme linked immunosorbent assay 
ER   Endoplasmic Reticulum 
ETA  Etanercept 
FCS   Foetal calf serum 
FLS  fibroblast like synoviocytes 
GM-CSF  Granulocyte Macrophage Colony Stimulating Factor 
HeLa   stromal tumor cell line derived from the patient Henrietta Largs 
HLA  Human leukocyte antigen 
HTH  helix turn helix 
IgG  Immunglobulin G 
IL   Interleukin 
LPS   Lipopolysaccharide 
MCSF  Macrophage colony stimulating factor 
MHA   1-mercaptoundec-11-yl)hexa(ethylene glycol) 
MMP   Matrix Metalloproteinase 
12	  
MNP  Magnetic nanoparticles 
MRI  Magnetic resonance imaging 
MTX  methotrexate 
NIR   Near infrared 
NLS  nucleus localisation site 
NP   Nanoparticle 
NT   Nanotag 
OA   Osteoarthritis 
PAMP  Pathogen-associated molecular pattern 
PBMCs  Peripheral Blood Mononuclear Cells 
PET  Positron emission tomography 
PsA   Psoriatic Arthritis 
RA   Rheumatoid Arthritis 
RANK  Receptor Activator of NF-kB 
RANKL  Receptor Activator of NF-kB Ligand 
RF   Rheumatoid Factor 
SEM   Scanning electron microscope OR standard error mean 
SERRS Surface enhanced resonance Raman scattering 
SERS  Surface enhanced Raman spectroscopy 
SNP   Single Nucleotide Polymorphism 
TcKs   Cytokine Activated T cells 
TLR4   Toll Like Receptor 4 
TNFα  Tumour Necrosis Factor 
TNFi  Tumour Necrosis Factor inhibitors 
TMB   3,3’,5,5’-tetramethylbenzidine 
TPA  Phorbol ester, 12-O-tetradecanoylphorbol-13-acetate 
13	  
Chapter 1 Introduction 	  
14	  
1.1) Tendon Biology 
Tendons are the connective tissue attaching muscle to bone; they allow the 
transduction of force from a contracting muscle to be exerted upon the attached 
skeletal structure at a distance from the muscle itself [1]. Force transduction in this 
way allows movement of the limbs, thorax, head and other structures during 
normal activity. Tendons also prevent joint displacement beyond anatomical 
barriers, thereby preventing injury and maintaining normal anatomical structure 
and function [2]. They consist primarily of water and type I collagen, with smaller 
amounts of other collagens and matrix materials, as well as various types of cells, 
most notably fibroblasts[3]. 
 Tendons are a complex, systematically organised tissue and comprise 
several distinct layers. At their core is collagen, organised (in increasing 
complexity) into fibrils, fibres, fibre bundles, and fascicles (Figure 1-1), which are 
surrounded by a layer of loose, collagenous and lipid-rich connective tissue matrix 
known as the endotenon [4]. At the musculo-tendinous junction, the endotenon is 
continuous with the perimysium of the proximal muscle and the periosteum of the 
distal bone. It contains blood vessels which supplies adjacent tissue, as well as 
local nerves and lymphatics. The epitenon encloses the entire tendon and is 
continuous with the endontenon. Depending on the localisation of the tendon in 
question, the surrounding layers can vary. Some tendons are encased in a 
synovial tendon sheath which allows smooth gliding, particularly in areas of abrupt 
directional change or flexion (such as joints), in which synovial fluid between 
tendon layers acts as lubrication. Gliding is facilitated in tendons in which a 
synovial sheath is not present by an elastic, loosely arranged tissue layer known 
as the paratenon.  
15	  	  
 
 
 
 
 
 
 
 
 
 
Figure 1-1  The hierarchical structure of tendon.  
(A) Representation of the macromolecular organisation of the extracellular matrix (adapted 
from Lin, et al. 2004[5]). (b) Collagen fibril organisation (adapted from Riley, (2005)[6]) . The 
collagen molecule takes a triple-helical formation which form up in staggered multimers to 
form microfibrils. Microfibrils organise together to form collagen fibrils, which pack together 
in fibres, fibre bundles, and fascicles. 
A	   B	  
C	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The insertion of tendon into the attached bone has been described as occurring by 
one of two modes. The first is by the uniform transition of the tendon to 
fibrocartilage, which becomes steadily more ossified until it merges with the bone 
[7]. The second is somewhat more complex and involves the periorteum as an 
intermediate structure and superficial fibrils becoming fixed into the periosteum 
and then deeper, directly into the bone known as the enthesis. The archetypal 
enthesis organ [8] is that of the Achilles tendon where intermittent contact between 
tendon and bone immediately proximal to the enthesis leads to the formation of 
fibrocartilages on the deep surface of the tendon and on the opposing calcaneal 
tuberosity, but similar functional modifications are widespread throughout the 
skeleton. Many entheses have bursae and fat near the insertion site and both of 
these serve to promote frictionless movement. Collectively, the fibrocartilages, 
bursa, fat pad and the enthesis itself constitute the enthesis organ. Stress 
concentration at the enthesis itself is dissipated at many sites by fibrous 
connections between one tendon or ligament and another, close to the insertion 
site [9]. At a microscopic level, enthesis fibrocartilage is of paramount importance 
in ensuring that fibre bending of the tendon or ligament is not focused at the hard 
tissue interface. Normal enthesis organs are avascular in their fibrocartilaginous 
regions, but tissue microdamage to entheses is common and appears to be 
associated with tissue repair responses and vessel ingrowth. 	  
1.1.1)	  Tendon	  ultrastructure	  	  
 Tendon is a roughly uniaxial composite composed mainly of type I collagen 
in an extracellular matrix (ECM) which comprises the majority of tendon volume 
providing strength and flexibility inherent in the tissue and essential for function. 
The main components of ECM include collagen, ground substance and 
neurovascular and connective tissue [10]. Tendons consist of 30% collagen and 
2% elastin embedded in an extracellular matrix. Type I collagen has a large 
diameter (40-60nm) and links together to form tight fibre bundles. Type III collagen 
is smaller in diameter (10-20nm) and forms looser more reticular bundles. 
Collagen comprises 30% of wet tendon and 80% of dry tendon and confers 
stiffness, rigidity and strength when loaded and flexibility when bent, compressed 
or  twisted [10].  
17	  
Collagen	  
 The structural unit of collagen is tropocollagen, a long, thin protein 280nm 
long and 1.5nm wide consisting mainly of Type I collagen (Figure 1-2). 
Tropocollagen is formed in the rough endoplasmic reticulum of tenocytes as 
procollagen and subsequently in the golgi apparatus procollagen forms a helix and 
is transported to and secreted from the cell membrane in vacuoles via the cellular 
skeletal system of microtubules and microfilaments[11]. Procollagen is converted 
to insoluble tropocollagen in the extra cellular compartment where it is contained 
within the ECM [11]. The 100 amino acids join to form an alpha chain. There are 3 
alpha chains which are surrounded by a thin layer of proteoglycans and 
glycosaminoglycans. Two of the alpha chains are identical and one differs slightly. 
The three polypeptide chains each form a left handed helix. The chains are 
connected by hydrogen bonds and wind together forming a rope like, right handed 
super helix giving collagen a rod like shape. Approximately two-thirds of the 
collagen molecule consists of 3 amino acids : glycine (33%), proline(15%) and 
hydroxyproline (15%) [12]. Collagen fibres acquire all their crosslink's shortly after 
synthesis. The key enzyme lysyl-oxidase is the rate limiting step forming the most 
prevalent hydroxylysin crosslinks which in turn provide tensile strength. Reduction 
of crosslinks results in an extremely weak, friable collagen fibre - crosslinking of 
collagen is one of the best biomarkers of aging. 
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Figure 1-2: The structure of type I and type III collagen molecules.  
The arrows indicate the sites for cleavage of amino- (PINP, PIIINP) and carboxyterminal 
(PICP) telopeptides. Thick arrow shows the structure of trivalently cross-linked ICTP 
molecule. The ICTP assay detects only fragments having two phenylalanine rich regios 
(solid box), which are brought together with a trivalent cross-link. N, aminoterminal end of 
the propeptide, C, carboxyterminalend of the propeptide, H, helical domain in the 
aminoterminal telopeptide, T, telopeptide domains at each end of the collagen molecule 
(modified from Kauppila S. 1998 and Risteli J. & Risteli L. 1999). 
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Elastin	  
 Elastin contributes to the flexibility of tendon. It is rich in glycine and proline 
but does not contain much hydroxyproline or lysine [13]. It has a large content of 
valine and contains desmosine and isodesmosine which form crosslinks between 
the polypeptides, but no hydroxylysine. Elastin does not form helices and is 
hydrophobic. 
Tenocytes	  
 Fibroblast-like cells are the major cell type in tendons, and have been 
histologically classified as elongated tenocytes or ovoid tenoblasts [14]             
(Figure 1-3). These cells are central for the maintenance of healthy tendon as they 
can proliferate, produce collagen and critically maintain the extracellular matrix 
[15]. Tenocytes are flat, tapered cells, spindle shaped longitudinally and stellate in 
cross section and are detected sparingly in rows between collagen fibres. They 
have elaborate cell processes forming a three dimensional network extending 
through the extracellular matrix and communicate via cell processes and may be 
motile. Tenoblasts are spindle shaped or stellate cells with long, tapering, 
eosinophilic flat nuclei and are motile and highly proliferative. they have well 
developed rough endoplasmic reticulum on which precursor polypeptides of 
collagen, elastin, proteoglycans and glycopeptides are synthesised. 
 During embryonic development, tenocytes originate from mesodermal 
compartments, as do skeletal myoblasts, chondrocytes and osteoblasts[16]. Some 
of the multipotent mesenchymal progenitor cells that arise from these 
compartments express the basic helix-loop-helix transcription factor scleraxis. 
However, once they are committed to become cells making up a specific tissue, 
only tendon progenitor cells and tenocytes retain the ability to express scleraxis. 
Therefore, scleraxis is a marker of tenogenic cells and mature differentiated 
tenocytes[17, 18]. The scleraxis gene is thus the first master gene found to be 
essential for establishing the tendon lineage during development. Tenomodulin is 
a type II transmembrane glycoprotein. Its robust expression is induced in mouse 
tendons in a late (embryonic day [E] 17.5) developmental phase and is also 
observed in adult tendons showing that tenomodulin is a marker of mature 
(differentiated) tenocytes[19]. In vitro experimental evidence shows that the genes 
composed of tendon-specific ECM are tightly regulated in tenocytes by mechanical 
forces. Very recently, tendon stem/progenitor cells have been discovered in 
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human and mouse tendon, and the proteoglycans biglycan and fibromodulin have 
been identified as essential elements in a microenvironment to keep phenotypes 
and differentiation of stem/progenitor cells[20]. However, the roles of these 
stem/progenitor cells in adult tendon homeostasis and/or wound healing remains 
unknown.
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Figure 1-3 :Tenocytes and tenoblasts  
Round tendon cells (A) and elongated tendon cells (B) were identified in healthy human 
patellar tendon by H and E staining. (modified from Chuen FS et al 2004) 
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Ground	  substance	  	  
Ground substance is a complex mixture of proteoglycans and glycoproteins 
surrounding collagen fibres. It has high viscosity thus providing structural support, 
lubrication and spacing of the fibres that is essential for gliding and cross-tissue 
interactions. 
 The proteoglycans and glycoproteins consist of two components, 
glycosaminoglycans and structural glycoproteins [21]. The main proteoglycans 
ithat are assocaited with glycosaminoglycans are dermatan sulfate, hyaluronic 
sulfates, chondroitin 4 sulfates, and chondroitin 6 sulfates. Other proteoglycans 
found in tendon include biglycan, decorin and aggrecan (Table 1-1).  
 Fibronectins are high-molecular weight, noncollagenous extracellular 
glycoproteins [22]. They play a role in cellular adhesion (cell-to-cell and cell-to-
substrate) and in cell migration. Fibronectin may be essential for organisation of 
collagen I and III fibrils into bundles and may act as a template for collagen fibre 
formation during the remodelling phase of healing. 
 The synthesis of proteoglycans begins in the rough endoplasmic reticulum, 
where the protein portion is synthesized. Glycosylation starts in the rough 
endoplasmic reticulum and is completed in the Golgi complex, where sulfation 
occurs. Proteoglycans in the ground substance seem to regulate fibril formation as 
the content of proteoglycans decreases in tendons when the tropocollagen has 
reached its ultimate size. An adequate amount of ground substance is necessary 
for the aggregation of collagenous proteins into the shape of fibrils.
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Proteoglycan 
 
Core 
Protein 
Size (kDa) 
 
 
Properties and Role in Tendon 
 
Decorin 
 
36 
 
Binds to fibrillar collagen, inhibits collagen 
fibrillogenesis, binds TGFβ‚ and EGF 
 
Biglycan 
 
38 
 
Binds to fibrillar collagen 
 
Fibromodulin 
 
42 
 
Binds to type I collagen, facilitates formation of 
mature large collagen fibrils, modulation of tendon 
strength 
 
Lumican 
 
38 
 
Binds to type I collagen, inhibits size of collagen 
fibrils, modulation of tendon strength 
 
Aggrecan 
 
220 
 
Linked to hyaluronan, provides resiliency, low 
levels in tensional parts of tendon, high levels in 
compressed regions, particularly in fibrocartilage 
Versican 265-370 Linked to hyaluronan, low levels in tensional parts 
of tendon, somewhat higher levels in compressed 
regions, increases viscoelasticity, maintains cell 
shape 
 
 
 
Table 1-1  Properties of the most abundant tendon proteoglycans
24	  
 	  
1.1.2)	  Nerve	  supply	  
Tendons are supplied by sensory nerve fibres from the overlying superficial 
nerves of from nearby deep nerves and are largely, but not exclusively, afferent 
[23].  The afferent receptors are found near the musculotendinous junction and the 
nerves tend to form a longitudinal plexus and enter via the septa of the endotenon 
or the mesotendon is there is a synovial shealth. 
 There are 4 types of receptors. Type I (Ruffini corpuscles) are pressure 
receptors that are extremely sensitive to stretch and adapt slowly. Type II (Vater-
Pacini corpuscles) are activated by movement,Type III ( Golgi Tendon organ) are 
mechanoreceptors and type IV are free nerve endings that act as pain receptors 
[24].  
1.1.3)	  Blood	  supply	  
The blood supply of tendons is very variable, and is usually described on 
the basis of three distinct anatomical regions: 1) the musculotendinous junction; 2) 
the length of the tendon; and 3) the tendon-bone junction. The blood vessels 
originate from the perimysium, periosteum or enter via the paratenon and 
mesotendon [25]. 
 The blood supply to the musculotendinous junction is from the superficial 
vessels in the surrounding tissues. The main blood supply to the middle portion of 
the tendon is via the paratenon. The small blood vessels in the paratenon run 
transversely towards the tendon, branching several times before running parallel 
to the long axis of the tendon [26]. Vessels supplying the bone-tendon junction 
supply the lower one third of the tendon. There is no direct communication 
between the vessels because of the fibrocartilaginous layer between the tendon 
and bone; but there is some indirect anastomosis between the vessels.  Blood 
supply is compromised at sites of friction, torsion or compression. This is found 
particularly in the tibialis posterior, supraspinatus and Achilles tendon.  	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1.1.4)	  Biomechanics	  of	  tendon	  function	  
 Tendons exhibit high mechanical strength, good flexibility and an optimal 
level of elasticity allowing them to perform their unique role. They are viscoelastic 
tissues that display stress relaxation and creep [27]. The mechanical behaviour of 
collagen depends on the number of intramolecular and intermolecular bonds. At 
rest, collagen fibres/fibrils display a crimped configuration (Figure 1-4) The initial 
concave portion of the stress strain curve where the tendon is strained up to 2% 
represents flattening of the crimp pattern. Beyond this point tendons deform in a 
linear fashion due to intramolecular sliding of collagen triple helices with the fibres 
becoming more parallel [27]. Microscopic failure occurs when the strain calculated 
by the mean deformation of the tendon exceeds 4%. Beyond 8-10%, macroscopic 
failure occurs from intrafibril damage[27]. Microscopic failure occurs when the 
strain exceeds 4%. Beyond 8-10%, macroscopic failure occurs from intrafibril 
damage by molecular slippage. As stress increases the gap between molecules 
increases leading eventually to slippage of adjoining molecules. Consequently, 
complete failure occurs rapidly and the fibres recoil at the ruptured end.  
 The ultimate tensile strength of tendons is related to thickness and collagen 
content (a tendon with an area of 1cm2 is capable of bearing 500-1000kg) [2]. 
During strenuous exercise very high loads are placed on tendons and the rate of 
loading plays an important role in tendon rupture.  
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Figure 1-4: Graph showing the stress–strain curve for tendon.  
Region I—the tendon has a wavy configuration at rest. The wavy configuration is lost when 
it is stretched more than 2%. Region II—collagen fibres exhibit a linear response to 
increasing strain as collagen fibres deform. Region III—one or two broken lines indicate that 
the collagen fibres are starting to slide past one another as the intermolecular cross-links 
fail. At strain levels greater than 8%, macroscopic rupture is produced by tensile failure. ( 
Reproduced from Sharma et al 2005 [28], © The Journal of Bone and Joint Surgery, Inc. with 
permission ) 	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1.1.5)	  Injury	  and	  Healing	  of	  Tendon	  Tissue	  
The process of tendon healing represents an interesting paradigm. Though 
most tendons have the ability to heal spontaneously after injury, the scar tissue 
that is formed is almost always mechanically inferior and therefore much less able 
to perform the functions of normal tendon; it is also more susceptible to further 
damage lending itself to perpetual damage repair cycles with predeliction for long 
term dysfunction in some patients as a result [29]. The formulation of effective 
treatments for tendon injuries has been based on traditional tissue-level reparative 
procedures, such as surgical reattachment. The lack of effective treatments has 
focused research toward understanding the mechanisms of tendon healing at the 
molecular level. This has ultimately been in an effort to develop therapies to 
facilitate tendon healing through the use of individual molecules or groups of 
molecules known to have beneficial roles in the process. 
 The process of tendon healing follows a pattern similar to that of other 
healing tissues [29] (Table 1-2), and can be roughly divided into three broad 
phases; that of inflammation, proliferation and remodelling. 
The	  Inflammatory	  Phase	  
 Upon tissue damage, blood vessels rupture and damage associated 
molecules and other extrinsic signalling moieties released by resident cells, 
together with the products of altered extracellular matrix trigger a coagulation 
cascade that will coordinate the formation of a clot around the injured area. The 
clot contains cells such as platelets that immediately begin to release a variety of 
molecules, most notably growth factors (such as PDGF, TGFβ, and IGF-I and -II), 
causing acute local inflammation and, within minutes to several hours, the influx of 
polymorphonuclear leukocytes and lymphocytes. Extrinsic cells are also attracted 
to the wound area by degradation products of extracellular matrix (ECM) 
components [30, 31]. The arrival of these cells initiates autocrine and paracrine 
signalling and begins to expand the inflammatory response, resulting in the 
recruitment of other types of cells to the wound, including a diverse immune cell 
population including mast cells, basophils and T cells. [32]. Cells recruited in this 
way adhere to the walls of vessels before passing through the basement 
membrane to invade the underlying tissue. Invasion by extrinsic cells such as 
neutrophils and macrophages will begin to ‘clean up’ necrotic debris by 
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phagocytosis, and as a result macrophages become the predominant cell type for 
several days. They also instigate granulation tissue formation and 
neovascularisation of the wound area through the proliferation of capillary 
endothelial buds by the secretion of various angiogenic growth factors. By the third 
day post-injury, the wound contains platelets, macrophages, polymorphonuclear 
leukocytes, lymphocytes, and multipotential mesenchymal cells, all of which 
secrete chemotactic and pro-proliferative cytokines [33], [34]. Together with 
intrinsic cells (such as endotenon and epitenon cells), these inflammatory cells will 
produce a second battery of cytokines to initiate the proliferative phase. At this 
stage type III collagen is the main matrix protein in production[28].  
The	  Proliferation	  Phase	  
 After several days the inflammatory phase is superceded by a period of 
vigorous cell growth and division of both intrinsic and extrinsic cells if competent to 
do so. The proliferative phase sees collagen deposition and further granulation 
tissue formation and neovascularisation, as well as extrinsic fibroblast migration 
and intrinsic fibroblast proliferation. The fibroblasts are thought to be recruited from 
surrounding tissue and the systemic circulation [35], and are responsible for 
synthesizing new extracellular matrix. This new matrix consists largely of collagens 
and glycosaminoglycan, though at this stage it generally remains poorly organised. 
Any type III collagen that was formed by intrinsic fibroblasts during the 
inflammatory period starts to be replaced by type I collagen, and the mechanical 
strength of the injured tissue begins to increase as this new matrix is deposited. 
Total collagen content is greater at this time than in normal tendon, though 
collagen concentration is lower. Throughout the healing process this extracellular 
matrix, particularly type I collagen, plays a variety of vital roles. It acts as not only a 
physical substrate on which cells adhere and migrate, but also has the ability to 
directly induce intracellular responses through integrin-mediated signaling, both in 
inflammatory cells [36] and in fibroblasts [37]. For example, monocytes can be 
induced to release tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and 
oxygen  free radicals simply by allowing them to come in contact with type I 
collagen [38]. These responses to extracellular matrix components are imperative 
for the progression of normal healing.  
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The	  Remodelling	  Phase	  
 Finally a remodelling phase begins, which sees decreases in the cellular 
and vascular content of the callus tissue, and further increases in collagen type I 
content and density. Eventually the collagen will become denser and more 
organised, and is longitudinally orientated and cross-linked with the healthy matrix 
outside the injury area. After 12-14 weeks, cellularity, vascularity, and collagen 
makeup will return to something approximating that of the normal tendon, though 
healing is not complete in the human for up to 1 year. Even after this time the 
diameters and covalent cross-linking of the collagen fibrils often remain inferior to 
normal tendon [39], and tensile strength remains diminished. This mechanically 
inferior repair tissue is more susceptible to tendon creep than uninjured tendon, 
and is therefore at higher risk of further damage [40]. It is not currently known why 
the tissue is unable to fully recover following acute injury, but is thought to be due 
to altered collagen ratios, proteoglycan levels or other unknown factors inherent to 
the healing process [41]. Throughout this phase although small amounts of 
collagen III is produced the main structural component of the matrix production is 
collagen I [28]. 
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Time 
(days) 
 
Phase 
 
Process 
 
0 
 
Immediately post-
injury 
 
Clot formation around the wound 
0-1 Inflammatory First cassette of growth factors and 
inflammatory molecules produced by cells 
within the blood clot. 
1-2 Inflammatory Invasion by extrinsic cells, phagocytosis 
2-4 Proliferation Further invasion by extrinsic cells, followed by 
a second cassette of growth factors that 
stimulate fibroblast proliferation 
4-7 Reparative Collagen deposition; granulation tissue 
formation; revascularisation 
7-14 Reparative Injury site becomes more organised; 
extracellular matrix is produced in large 
amounts 
14-21 Remodelling Decreases in cellular and vascular content; 
increases in collagen type I 
21+ Remodelling Collagen continues to become more organised 
and cross-linked with healthy matrix outside the 
injury area. Collagen ratios, water content and 
cellularity begin to approach normal levels. 
 
Table 1-2: Summary of healing process in tendons and ligament 	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1.2) Tendinopathy 
	  
Tendon injuries are common and account for up to 40% of musculoskeletal 
GP consultations in the UK [42]. Tendinopathy (often called tendinitis or 
tendinosis) is the most common tendon disorder. It is characterized by activity 
related pain, focal tendon tenderness and decreased strength and movement in 
the affected area. Tendinopathy can occur in almost any tendon. Common 
examples include plantar fasciitis, Achilles tendinitis, patellar tendinitis, tennis 
elbow (lateral epicondylitis), golfer’s elbow (medial epicondylitis) and 
supraspinatus tendinitis.  
1.2.1)	  Aetiology	  of	  tendinopathy	  
 The current cause of tendinopathy remains unclear and many theories have 
been suggested. They are multifactorial in origin and interaction between intrinsic 
and extrinsic factors comprise a common factor in many.   
Mechanical	  load	  
Excessive loading of tendons is regarded as the main pathological stimulus 
for degeneration [43]. Tendons respond to repetitive overload beyond the 
physiological threshold with either inflammation of their sheath or degeneration of 
their body, or a combination of both. Traditionally pathology is reported to be 
caused by repeated strain that represents a sub rupture force [3]. The strain is 
hypothesized to disrupt collagen cross-links with subsequent vessel disruption 
resulting in impaired metabolic and oxygen delivery [5]. Physiologically mechanical 
load has been shown to deform tendon cells with the cells responding with an 
increase in nitric oxide levels and cytosolic calcium. The presence of load is then 
communicated to adjacent cells via gap junctions. Mechanical stretching of human 
tendon fibroblasts also increased production of PGE2 and LTB4[44] and is thought 
that they may be involved in the development of tendinopathy [45]. The 
modulation of MMP-1 gene expression was also studied in rat tail tendons in 
culture [46]. Increasing static tensile stresses as much as 2.6 MPa gradually 
inhibited the MMP-1 mRNA expression, whereas stress-deprivation for 24 hours 
resulted in a significant up-regulation of MMP-1 expression. Arnoczky et al[46] 
also reported that a 1% strain decreased MMP-1 mRNA expression, whereas 3% 
and 6% strain completely inhibited it. This strain effect on MMP-1 mRNA 
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expression was dependent on stretching frequency [47]. This combined with load-
induced growth factor changes (state factors) are thought to be critical in the 
tendons response to excessive load.  Ultimately the amount of load (volume, 
intensity and frequency) that induces pathological tendon changes remains 
unclear; moreover load seems to be modulated by complex interactions between 
intrinsic factors such as genes, age, circulating and local cytokine production, 
gender, biomechanics and body composition.
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Figure 1-5 The biological responses of tendon fibroblasts to mechanical loading. 
Reproduced with permission from Lippincott Williams & Wilkins© , Wang et al 2006[48]. 
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Tendon	  impingement	  
Impingement is a form of mechanical load adding compressive and or 
shearing load to interact with a tendons’ normal tensile strength. This combination 
of loads may cause a tendon reaction to impingement resulting in cartilaginous 
and bony pathology [49]. Impingements in the Achilles tendon, rotator cuff, and the 
patellar tendon have been reported to cause tendinopathy. These tendon 
reactions may initiate of ultimately accelerate tendon damage alone or more likely 
in conjunction with other tendon responses. 
Thermal	  
The storage and then release of elastic energy within tendons results in the 
discharge of intratendinous heat - equine studies suggest a resultant increase in 
tendon temperature and subsequent cell death[50].The production of reactive 
oxygen species from hyperthermia has also been postulated to play a role in 
modulating tendon cell death[51]. 
Oxygen	  free	  radicals	  and	  Drugs	  
During tendon exercise and movement, bouts of ischaemia and reperfusion 
stimulate the formation of oxygen free radicals [52]. Tendon apoptosis has been 
shown to be induced with exposure to hydrogen peroxide [53] while peroxiredoxin, 
which eliminates hydrogen peroxide, has been shown to be up regulated in 
tenocytes in torn supraspinatus tendons [54]. The same group have highlighted 
the role of the short-lived oxygen free radical, nitric oxide in tendon disease [55]. 
Nitric oxide synthase peaks at day 7 and returns to baseline after rat Achilles 
tenotomise [56] in the same study inhibition of nitric oxide synthase reduced 
healing, reduced load failure and cross-sectional area. In an exercise overuse 
model of tendon degeneration in the rat, they found that iNOS, eNOS and bNOS 
mRNAs were overexpressed in the supraspinatus tendon of rats subjected to 
treadmill running at 14 days [57].These results suggest that NOS activity is 
induced as a result of tendon injury in this model, and/or that expression of NOS is 
a part of supraspinatus tendinopathy.  
  Many studies indicate a strong association between fluroquionolones and 
tendon pathology. Ciprofloxacin induces IL-1β mediated MMP-3 release [58] and 
reduces cell proliferation and collagen and matrix synthesis [59, 60] and thus may 
be a mechanism to induce tendinopathy. 
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Inflammation	  
Historically inflammation has not been demonstrated in tendon pathology in 
humans probably due to the end stage of disease that human biopsies represent 
[4, 61, 62]. End stage diseases in humans has shown no physiologic increase in 
PGE2 in tendinopathic tissues at several different sites compared to normal tendon 
[63]. However it is becoming increasingly clear that the absence of inflammatory 
mediators at the end stage disease does not preclude its involvement in early 
stage disease. Animal and human studies in tendinopathy and tendon rupture 
have increasingly shown the presence of inflammatory mediators – this has been 
particularly evident with the use of microarray technology.  The core paradox 
however resides in the essential nature of inflammation in the early phase of any 
injury and thereby the likelikhood that inflammatory pathways will be evident 
during injury –what has been difficult has been to estimate their overall functional 
importance. This area is discussed in more depth in Section 1.4.   
Hypoxia	  and	  vascular	  changes	  
Hypoxic injury has long been suggested as a cause of tendinopathy [64] 
although the exact mechanism remains to be defined. Hypoxic changes have been 
reported in tendon cells [65] and in the edge of tendon samples taken at the time 
of rotator cuff surgery [66]. However the hypoxic changes may have occurred 
anywhere during the sequence of pathology, rupture or post rupture and as such 
are difficult to define in terms of their functional and hierarchical import. The 
presence of hypoxia pre-rupture is supported by reports of increased lactate levels 
in Achilles tendinopathy compared to normal tendons [67] while recent in vivo work 
has shown decreased oxygen tension at the edge of torn rotator cuff sampled prior 
to surgical correction [68] and decreased microcirculation and vessels numbers in 
areas of degenration or rupture [69]. Increased vascularity has been demonstrated 
histopathologically [70] on Doppler Ultrasound [71] and laser flowmetry [72]. 
However the connection between hypoxia and changes in vascularity remains 
unclear with the contradicting element that while hypoxia is a powerful stimulant to 
angiogenesis, impaired vascularity itself may lead ultimately to hypoxia.  
Neural	  
As mentioned earlier the actual body of a tendon is poorly innervated however 
neurogenic inflammation and inflammation initiated by neuropeptides may also be 
important in tendon pathology. Neuropeptides substance P which induces mast 
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cell activation and calcitonin gene related peptide synthesis by a variety of cells 
which affects angiogenesis and vascular permeability have also been implicated in 
tendinopathy [73]. Microarray analysis of healing tendon with subsequent protein 
and mRNA analysis has also suggested a role for the neuropeptide glutamine, in 
the process of tendinopathy and tendon healing [74]. 
Apoptosis	  
Evidence for apoptosis and a potential role in pathology of tendinopathy 
was originally described in 2002 where the torn edge of ruptured supraspinatus 
tendons were examined and found to exhibit increased expression of tenocyte 
apoptosis compared to controls [75]. Lian et al [76] reported increased apoptosis 
in patellar tendinopathy in athletes and also showed tenocyte apoptosis could be 
induced by high-strain mechanical loading in a rat tibialis anterior model [77]. 
Activation of c-Jun N-terminal kinase (JNK) [78] and increase in cytochrome c-
related activation of caspase 3 [53] may be two further potential pathways involved 
in apoptosis induction in tendinopathy. Cyclical strain applied to canine flexor 
tendon cells induces stress activated protein kinases that in turn induced 
apoptosis [79].  
Matrix	  metalloprotineases	  
Matrix metalloprotineases (MMPs) are important regulators of ECM 
remodelling. Analysis of gene expression in human Achilles tendon showed that 
23 MMP and 19 ADAMTS (A Disintegrin And Metalloproteinase with 
Thrombospondin Motifs) were detectable in normal tendon with widely varied 
expression.  In a rat flexor tendon laceration model, the expression of MMP9 and 
MMP13 (collagenase 3) peaked between days 7 and 14 while MMP2 (gelatinase) 
and MMP3 (stromelysin) increased after surgery and remained high until day 28 
[80]. There are changes in the expression and activity in various MMPs, and 
changes in the levels of tissue inhibitors of metalloprotineases (TIMPs) that are 
consistent with increased proteolytic activity in degenerate tendon [81]. Pathologic 
rotator cuff tendons showed greatly increased MMP1 activity and reduced MMP2 
and MMP3 activity compared with normal tendons while ruptured tendons showed 
increased levels of MMP1, MMP9, MMP19, MMP25 and TIMP1 and decreased 
levels of MP3, MMP7, TIMP2, and TIMP3 [6]. More research is required to 
determine the mechanism of action and regulation of MMPs in tendinopathy to 
promote the development of specific therapeutic interventions.   
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1.2.2)	  Pathology	  of	  tendinopathy	  
 The histopathological changes in tendinopathy are well documented (Table 
1-3). Normal tendon is brilliant white in colour and has a firm fibroelastic 
consistency while tendinopathic tendon is grey or brown and is soft, thin and 
fragile. Microscopically collagen bundles are disorganised, there is increased 
ground substance and the nuclei are darkly stained, round and numerous in 
contrast to the highly organised parallel collagen bundles and spindle shaped 
tenocyte nuclei arrangement in normal tendon [82] (Figure 1-6). Electron 
microscopic evaluation reveals angulated collagen fibres which vary in diameter 
and orientation.  
 Changes consistent with hypoxia including lipid vacuoles, enlarged 
lysosomes and degranulated endoplasmic retanaculum are also observed [82] 
while tendinopathic tendon often exhibits vascular infiltration and upregulation of 
VGEF. Others have demonstrated in growth of small nerves with an increase of 
substance P (SP)-positive nerve fibres in painful tendinopathic samples compared 
to normal tendon samples while increased adrenergic receptors and 
catecholamines have also been reported [73]. 
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Findings 
 
Macroscopic 
 
Light microscopy 
 
    Ultrasound findings 
 
Normal 
Tendon 
 
• Brilliant 
white 
• Firm 
Fibroelastic 
texture 
 
• Organised parallel 
collagen bundles 
• Spindle shaped 
tenocyte nuclei 
• Parallel nuclei 
alignment 
 
• Regular uniform fibre 
structure 
• Parallel hyperechoic 
features 
 
Tendinopathy  
 
• Grey or 
brown 
• Thin tissue, 
fragile and 
disorganised 
• Loose 
texture 
 
• Disorganised collagen 
bundles 
• Round dark stained 
tenocyte nuclei 
• Increased number of 
nuclei with loss of 
parallel arrangement 
• Mucoid degeneration 
and vacuoles 
• Increase of vascular 
and nerve ingrowth 
• Increased ground 
substance and GAG 
 
 
• Local hypoechoic areas 
• Irregular fibre structure 
• Neovascularisation on 
power doppler 
• Widening of tendon 
 
Table 1-3.: Summary of pathology of normal versus tendinopathic tendon tissue 	  	  	  
	  
Figure 1-6: Histology of normal tendon and tendinopathy.  
(A) Normal tendon has parallel, longitudinal architecture with scattered elongated 
tenocytes. (B) Tendinopathy tendon shows disorganized collagen architecture, high 
cellularity of rounded tenocytes. (This figure was published in Soslowsky LJ, Thomopoulos 
S, Tun S, Flanagan CL, Keefer CC, Mastaw J, Carpenter JE. Neer Award 1999. Overuse 
activity injures the supraspinatus tendon in an animal model: a histologic and 
biomechanical study. J Shoulder Elbow Surg. 2000;9:79–84, © Elsevier 2000, with 
permission.)  	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1.2.3)	  Strategies	  for	  tendon	  healing	  
 As the investigation into the basic science underpinning tendinopathy has 
expanded over the past 20 years so too have the treatment modalities. A summary 
of current therapies are shown in Table 1-4. Whilst many of these modalities are in 
routine clinical use, only a few randomised controlled trials exist and much of the 
evidence is either ‘expert or eminence based, or remains at a pre-clinical stage.   
Many therapeutics are controversial – I interprete this as a lack of clear driving 
evidence to inform opinion, and this in part informs the biology exploration 
underpinning this thesis.  
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Treatment 
 
Possible mode of action 
 
Non-operative 
Rest/activity modification 
Eccentric exercising 
Orthotics 
Cryotherapy 
Heat treatment 
Extracorporeal shock wave therapy 
Ultrasound 
Laser Treatment 
 
Remove precipitating/aggravating factors 
Remove precipitating/aggravating factors 
Restoration of normal tissue architecture 
Remove precipitating/aggravating factors 
↓ inflammation  
↑ blood flow and cellular activity 
↓ neovascularization and ↓ nociception 
↑ blood flow and cellular activity 
Analgesic effects  
Drugs 
NSAID’s 
Corticosteroid injection 
Nitrate Patches 
Sclerosant injection 
Platelet Rich Plasma Injection 
Glycosaminoglycan polysulfate 
 
↓ inflammation through PGE2 
↓ inflammation  
↓ inflammation  
↓ neovascularization and ↓ nociception 
↑ growth factors and matrix synthesis 
↓ inflammation and MMP activity 
Operative 
Surgery 
Radiofrequency coblation (Topaz®) 
 
Excision of degenerative tissue 
↑ inflammation and cellular activity 
 
Table 1-4: Current treatment options for tendinopathy 
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Novel	  treatment	  areas	  	  
As a result of the deficiencies of current treatment there is great interest in 
investigating the potential role for cellular based therapies.  
 Increased levels of growth factors, including insulin growth factor-1, 
transforming growth factor-beta-1, and platelet-derived growth factor, occur after 
tendon injury in animal models [83, 84]. In addition, several preliminary studies 
suggest adding exogenous growth factors to an injured tendon can enhance 
healing and repair [85, 86]. For instance, the addition of cartilage-derived 
morphogenic protein-2 to an animal tendon repair model generated an increase in 
the strength and organization of the repaired tendon [87]. Although the application 
of growth factors to augment tendon repairs seems feasible, it is unclear whether 
there is a role for growth factors in the treatment of tendinopathy at a pragmatic 
clinical level. Increased levels of transforming growth factor-beta1 and insulin 
growth factor-1 have been demonstrated in areas of tendinopathy, but this does 
not appear sufficient to heal the tendon injury [88]. One possible method of 
introducing an assortment of growth factors to an area of tendinopathy is through 
the injection of platelet rich plasma or autologous blood however recently a 
randomised controlled human trial has failed to show any improvement in tendon 
pain or function [89]. 
  Stem cell technology in the treatment of degenerative conditions of the 
musculoskeletal system such as tendinopathy is appealing. In theory, pluripotent 
stem cells can be isolated and then delivered to an area of need such as an 
arthritic joint or degenerative tendon. Once the stem cells are in the desired 
location, either local signaling or the addition of exogenous factors can drive the 
pluripotent cells to differentiate into the needed cell line. Stem cell technology is 
currently being applied to the creation of tendon and ligament grafts and in 
enhancing graft incorporation [79, 88, 161]. Chong et al. applied bone marrow-
derived stem cells to a rabbit Achilles tendon repair model [34]. They reported the 
addition of the stem cells in a fibrin carrier resulted in an increased modulus and 
improved collagen organization compared with control tendons at 3 weeks. 
Interestingly, no major differences were noted at later time points. This early work 
suggests stem cell technology may have a role in tendon grafting and repair, but 
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whether this technology will successfully be applied to the treatment of 
tendinopathy remains to be seen. 
There are a number of studies, in both the human and the veterinary 
literature, suggesting that injection of glycosaminoglycan polysulphate (GAGPS) 
may lead to an improvement in disease of the human Achilles and equine 
superficial digital flexor tendon, respectively. In the human study, local injection of 
GAGPS was compared with oral indomethacin and at 1-yr follow-up two-thirds of 
the GAGPS group had a good response compared with only one-third of the 
indomethacin-treated group [181]. However, this study was confined to 
peritendinous lesions rather than lesions of the body of the Achilles and more data 
are needed in this area. 	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1.3) Models of tendon healing and tendinopathy 
Experimental in vitro studies allow the study of the effect of a single isolated 
factor. In vitro experiments are inexpensive and often serve as precursors for more 
complicated and expensive animal models, which may be simulated in vitro using 
different cell culture environments. In the case of tendon injury and repair, some 
examples of in vitro models have cultured flexor tendon cells [90, 91] and tested 
the strength of flexor tendon repair [92]. Additionally many in vitro studies have 
focused on the effect of applying cyclic loads to tendons [44, 93, 94].  
The majority of experimental research on tendon injury and repair has been 
performed in animal models, which possess advantages such as fewer ethical 
issues, less variability, and greater availability of numbers when compared to 
clinical trials. However, animal models also have their shortcomings as well and 
researchers must be cautious in applying their results to humans, just as care 
must be taken when extrapolating in vitro results for in vivo settings. Some 
disadvantages of animal models include inherent biologic variability, metabolic and 
hormonal differences from humans, anatomical differences, and potential difficulty 
in working with animals, such as noncompliance. The models of naturally 
occurring tendinopathy in horses and dogs are of some theoretical interest but in 
practice are not valuable for invasive or explorative research such as that planned 
here due to their large size and cost [95].  	  
1.3.1	  Current	  animal	  models	  of	  tendon	  healing	  and	  tendinopathy	  
 Numerous animal models have been generated and assessed for their 
utility to investigate tendon healing and tendinopathy. Whilst human studies 
provide the clinical characteristics of tendinopathy,  the aetiology of degeneration 
and injury remains uncertain. One reason is that human tissue can normally only 
be examined during the end stage of what is by definition a chronic pathology. It 
remains difficult to obtain early pathologic tendon tissue because these injuries are 
often initially asymptomatic or treated non operatively. By providing tissue 
throughout all time points of tendinopathy, animal models provide an excellent 
investigative approach to tendon injury and tendinopathy.  
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Tendinopathy	  in	  animal	  models	  
 Two general categories of animal tendinopathy models exist based on the 
mode of injury; mechanically induced versus chemically induced.   
 The most frequently used mechanical model is repetitive treadmill running. 
In particular this method has been extensively used to evaluate injury to the 
supraspinatus tendon of the rotator cuff. Rats are subjected to a repetitive exercise 
programme consisting of treadmill running at 17m/min on a 100 decline for 1 
hour/day, 5 days/week [96]. Following several weeks the supraspinatus tendons in 
exercised animals demonstrate significant changes consistent with tendinopathy. 
Despite large numbers of studies using this model the biological response to the 
overuse stimulus is still not well understood. Importantly this model has been 
unable to be translated to smaller rodents such as mice due to lack of compliance 
with the exercise regime and such as reduced the ability to use 'knock-out' models 
to study gene specific targets. Other mechanically induced models include a novel 
rat model of patellar tendinosis [97] where the patella and tibia are gripped and 
distracted to apply repetitive sub-failure loads to the patellar tendon and a rabbit 
model of FDP tendinosis [98] which applies electrical stimulation to the FDP 
muscle to recreate tendinosis. 
Tendon	  healing	  in	  animal	  models	  
 In order to study tendon healing in an animal model, a distinct and 
reproducible injury must be created. The two most common types of tendon 
transection models have been complete and partial transections. Complete 
transections are a better simulation of what occurs clinically, but the effect of 
sutures, which are necessary to reduce gap formation, must be taken into account. 
Partial transections can be made in the middle half or along one side of the tissue. 
Although they are unlikely to occur clinically, injuries only to the middle half leave 
the marginal fibres intact, circumventing the need for suture repair and allows for 
immediate postoperative tendon mobilization [99, 100].  
 Complete transections have been shown to be reproducible in location, 
pattern, and extent of damage that they induce [101]. As a result of a complete 
transection, there exists a gap between two free ends. Sutures are utilised to 
achieve tendon apposition in order to minimize scar tissue formation, hasten 
collagenisation, and minimise the presence of adjacent non-tendinous tissue 
between the two ends. Animal model studies have confirmed the clinical finding 
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that the highest suture strand technique from each study provided the highest 
tensile strength [102, 103]. When using sutures, other factors to consider include 
suture knot location, suture material, and suture size [104]. One disadvantage with 
using sutures is that they may disrupt the intrinsic blood supply and reduce overall 
tensile strength of the repair site [105]. 
 Animal models have also been used to study partial transections, which 
involve injuring a percentage of the tendon. Some examples include window 
defects, removal of the central third of the tendon, and transection of the medial 
half of the tendon. Although a partial transection injury is not as clinically relevant 
as a complete transection injury, it still allows the tendon healing response to be 
studied. In addition, partial injuries have the advantage of not requiring sutures to 
reduce gap formation since the tendon is still partially attached. The most 
commonly used model was developed by Lin et al [5] where a partial (0.75mm) 
transection is made with a punch biopsy and then animals resume normal cage 
activity and are then culled as per the protocol necessary to explore a given 
pathway. The advantage of this model has been its reproducibility in mice and thus 
has allowed the use of gene targeted or transgenic strains to study specific 
targets. 
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1.4) Cytokines in health and disease 
Cytokines are mediators that transmit signals between cells in an autocrine 
or paracrine manner acting either in soluble or membrane bound form. Initially, 
cytokine families were named for their origin—for example, lymphokines, 
monokines, and interleukins. However, as many of these molecules also act on 
and/or are produced by non-lymphoid cells, the term cytokine is more appropriate. 
Cytokines are divided into families reflecting either their core functional domains 
and/or their shared structural homology, including, for example, hematopoietins, 
chemokines, interferons, TNF superfamily, IL-6 superfamily, IL-10 superfamily, 
and the IL-12 superfamily. Cytokines may exist as monomers, homo- or 
heterodimers, trimers, or tetramers. Receptors mainly comprise heterodimers; 
cytokine receptor families often utilize common receptor subunits (e.g. common γ 
chain receptor and IL-1RAcP). Receptors, like cytokines, can exist as membrane-
signalling molecules, or may be released as soluble entities as a result of 
enzymatic cleavage from the cell membrane, or through the generation of 
alternatively spliced mRNA species. Soluble cytokine receptors can act as 
inhibitors of their ligands or act to facilitate signalling. Cytokine-receptor complexes 
may thereafter be internalized by endocytosis, fused with a lysosome where the 
cytokine will be destroyed in the proteasome. The receptor may either shuttle back 
to the cell surface or itself undergo degradation. 
 
Inflammation	  in	  tendinopathy	  
Historically the term tendinitis was used to describe chronic pain from 
tendons, thus implicating inflammation as a central pathological process.  
However, traditional treatment modalities aimed at modulating inflammation have 
limited success [106] and as previously mentioned histological lesions from 
surgical specimens have consistently shown the absence of inflammatory cells 
[107]. Insights into the role of inflammation in tendon disorders are however 
available from tendon healing models were inflammation is vital for the return of 
normal tendon function. Whilst not a perfect model for the study of tendinopathy 
they do provide us with some key steps in tendon repair biology. I described in 
section 1.1.5 that there is a huge influx of inflammatory cells particularly 
neutrophils at the site of tendon injury with the subsequent release of growth 
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factors and cytokines. These factors chemotactically attract leukocytes 
(neutrophils, lymphocytes and macrophages) to immigrate into the injured tissue 
[108] and to produce cytokines and growth factors (e.g. TGFβ1, insulin-like growth 
factor [IGF]-I, basic fibroblast growth factor [bFGF], platelet-derived growth factor 
[PDGF], growth and differentiation factor [GDF]). In addition, enhanced IL-1β 
expression was evident in ruptured tendon [109] and TNFα also seems to be 
involved in healing processes at this time, as analysed in a rat Achilles tendon 
healing model [110]. 
 Endogenous expression of various cytokines such as TNFα, IL-1β, IL-6, IL-
10, VEGF and TGFβ has been also demonstrated in tenocytes [111-114]. Heat 
stress in tenocytes induced TNFα but not IL-1β expression in equine tendon 
fibroblasts [115]. Increased amounts of  IL-1α, IL-1β, TNFα and IFNγ was 
demonstrated in inflamed native equine tendon [116]. Mechanical factors also 
influence tendon cytokine profile whereby cyclic strain has been shown to  induce 
VEGF expression in tenocytes [117] while stress deprivation lead to an over-
expression of IL-1β and TNFα and other cytokines such as TGFβ in the patellar 
tendon with subsequent mechanical deterioration of the tendon [118]. 
TNFα	  ,	  IL-­‐1β	  ,	  and	  IL-­‐6	  in	  tendinopathy	  	  
TNF is a homotrimeric cytokine that is typically produced by monocytes, 
fibroblasts, and endothelial cells but has been shown to be produced in a variety of 
key immune cells including macrophages, T-cells and B-lymphocytes, 
granulocytes and eosinophils [119]. Its core biology is in the regulation of immune 
cells. TNF, being an endogenous pyrogen, is able to induce fever, apoptotic cell 
death, sepsis (through IL-1 & IL-6 production), cachexia, inflammation and to 
inhibit tumorigenesis and viral replication [120]. Dysregulation of TNF production 
has been implicated in a variety of human diseases, including Alzheimer's 
disease, cancer, major depression, and inflammatory bowel disease (IBD) [121]. 
TNFα was found to be up-regulated in inflamed equine tendon and also expressed 
in scar-formed tendon [122] while TNFR1 and -R2 co-localized on the same 
tenocyte and could be up-regulated by TNFα in equine tenocytes suggesting auto-
amplification of the TNF response. TNFR-associated factor (TRAF)2 was also 
detected in tendon [123] while TNFR1 and -R2 co-localized on the same tenocyte 
were up-regulated by TNFα in equine tenocytes. Tenocytes can be highly 
activated by TNFα to produce further pro- and anti-inflammatory cytokines such as 
48	  
IL-1β, TNFα, IL-6 and IL-10 and matrix degradative enzymes such as MMP1[114] 
and these cytokines suppressed ECM synthesis such as that of type I collagen 
[124]. However, the expression of other ECM components such as elastin was up-
regulated by TNFα [114]. TNFα expression was lower in loaded compared with 
unloaded tendon repair callus during healing, which underlines the important 
influence of mechanobiology on healing [110]. Cytoskeletal alterations toward a 
more stellate shape and loss of F-actin fibers were also visible in tenocytes treated 
with TNFα [114]. Thus TNFα is considered detrimental to matrix remodelling and 
the ultimate strength of injured tendons. 
IL-1 exists within a family of structurally related trefoil molecules including 
IL-1α, IL-1β, IL-1Ra, IL-18 and IL-33.  IL-1 typically is produced by activated 
macrophages, as well as neutrophils, epithelial cells, and endothelial cells 
possessing many metabolic, physiological, haematopoietic activities, and plays 
one of the central roles in the regulation of the immune responses [125]. IL-1R 
comprises two distinct forms. The type I receptor is primarily responsible for 
transmitting the inflammatory effects of IL-1 while the type II receptors may act as 
a suppressor of IL-1 activity by competing for IL-1 binding. The IL-1 receptor 
accessory protein (IL-1RaCP) is a transmembrane protein that interacts with IL-1R 
and is required for IL-1 signal transduction [126]. In human tenocyte cultures, IL-
1β induced inflammatory and catabolic mediators such as cyclo-oxygenase 
(COX)-2, prostaglandin PGE2 and various MMPs while IL-1β regulated tenocytes 
cytoskeletal polymerization, and hence, cell stiffness, which was an important 
precondition for the cell adaptiveness to mechanical loading in tendon [124]. A 
disruption of cytoskeletal actin filaments leading to a more stellate cell shape and 
down-regulation of actin in IL-1β-treated tenocytes was observed whereby 
cytoskeletal tubulin was up-regulated [124]. Again IL-1β acts in a proinflammatory 
manner with an ultimate decrease in biomechanical strength. 
IL-6 is a pleiotropic cytokine with a wide range of biological activities in 
immune regulation, hematopoiesis, inflammation and oncogenesis [127]. The main 
sources in vivo are stimulated monocytes, fibroblasts, and endothelial cells. On 
target cells, IL-6 first binds to the IL-6 receptor (IL-6R). The complex of IL-6 and IL-
6R associates with the signal-transducing membrane protein gp130, thereby 
promoting its dimerization and the subsequent initiation of intracellular signaling 
[128]. Gp130 is expressed by most, if not all, cells in the body, whereas IL-6R is 
mainly expressed by hepatocytes, neutrophils, monocytes/macrophages, and 
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some lymphocytes [129]. A naturally occurring, soluble form of the IL-6R (sIL-6R), 
which has been found in various body fluids, is generated by two independent 
mechanisms: limited proteolysis of the membrane protein and translation from an 
alternatively spliced mRNA [130].  
Increased IL-6 production and activator of transcription (STAT3) 
phosphorylation was found in ruptured rotator cuff tendon [131]. IL-6 is a 
multifunctional cytokine, which exhibits immunoregulatory functions in tissues and 
is involved in matrix regulation. Mechanical properties of healing tendons in IL-6 
knock-out mice were inferior compared with normal controls while tendon healing 
was also impaired underlining an essential role of IL-6 in tendon healing [132]. IL-6 
was also up-regulated in tendon and peritendinous tissue during tendon exercise, 
while cyclic mechanical stretching enhanced the secretion of IL-6 in human tendon 
fibroblasts [133].Despite this, IL-6 did not induce its own expression or that of 
TNFα or IL-1β, however, it had a marginal but significant stimulatory effect on IL-
10 gene expression [114] which has been shown to modulate type I collagen and 
matrix metalloprotease gene expression in cultured human skin fibroblasts [134]. 
IL-6 was highly up-regulated by TNFα and IL-1β in tenocytes [112] and as 
reported in other cell types, produced then promoted the activation of the STAT3 
signalling pathway, which is implicated in cell proliferation and survival [135].  
 These facts underline the putative functions of pro-inflammatory cytokines 
in injured and healthy tendon. It is probable that pro-inflammatory cytokines are 
essential regulators of tendon healing simultaneously acting in a positive and 
negative manner acting as a regulatory link between several catabolic and 
anabolic systems. The application of cytokine inhibitors and anabolic cytokines 
e.g. by using gene therapeutic strategies has been proposed to support tendon 
healing. In this context, the involvement of multiple cytokines in overlapping 
phases of tendon healing and tendinopathy, has to be further considered.  	  
1.4.1)	  Candidate	  cytokines	  to	  be	  explored	  
The main thrust of this thesis, namely the role of cytokines in tendinopathy 
was born out of preliminary studies carried out in animal and human models of 
tendinopathy during a period of research in a collaborating laboratory in Sydney, 
Australia. There the running rodent model of tendinopathy was utilised and 
microarray analyses carried out in an attempt to identify genes and genetic 
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pathways that may contribute to the progression of degeneration and tendon 
damage [136]. Microarray analysis revealed several immune and stress response 
genes to be altered. Up regulation of cytokine genes including IL-18, and IL-17R 
were noted. Other key regulated genes included the apoptotic molecules, caspase 
3 and 7, and heat shock proteins 27 & 70 all of which are known to play key roles 
in programmed cell death. Several signalling pathways including the mitogen 
activated kinases (MAPK), and other regulatory machinery including hypoxic 
inducible factor 1 were also noted to be significantly altered. While microarray 
analysis can indicate novel transcripts, further validation is required to evaluate 
quantitative message and protein change. Therefore these experiments were 
extended to samples of tendon from patients undergoing rotator cuff repair which 
confirmed overproduction of key cytokines and apoptotic pathway related 
molecules in torn supraspinatus and intact matched subscapularis tendon samples 
[137]. Thus the premise for key inflammatory molecules involvement in 
tendinopathy was set. 
We know that fibroblasts are a diverse population of cells. Substantial 
evidence supports the concept that fibroblasts from different anatomic regions 
exhibit distinct phenotypes in culture. Characteristic expression patterns of 
receptors [138], gangliosides [139] [140], glycosaminoglycans [139, 141-143], 
plasminogen activator inhibitor type 1 [144-146], and PG endoperoxide H 
synthase-2 [147]  have recently been documented in different populations of 
fibroblasts. Moreover, fibroblasts are capable of responding to their 
microenvironment in a complex manner. In some tissues, such as the orbit and 
lung, fibroblasts can be subsetted on the basis of the surface expression of the 
glycoprotein Thy-1 [148]. Despite this heterogeneity, many phenotypic attributes 
are common to fibroblasts regardless of the tissue of origin. Thus, they are 
capable of expressing multiple regulatory and communicative molecules, including 
cytokines, prostanoids, growth factors and adhesion molecules [149-151]. When 
activated, they can express chemokines such as IL-8 [150], RANTES [152], 
monocyte chemotactic protein-1 and -2 [151]. Fibroblasts are also responsible for 
matrix homoeostasis, continuously synthesizing and degrading a diverse group of 
extracellular molecules and their receptors. Rates of turnover of matrix molecules 
and the proteases that degrade them are normally under the control of diverse 
chemical and mechanical cues, with cytokines, growth factors, proteases, lipid 
mediators and mechanical forces playing roles. The maintenance of this 
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homoeostasis is vital to the preservation of normal tissue function and is clearly 
lost in chronic diseases of the joints and tendon disorders where destruction and 
excessive deposition is seen. A key example in tendinopathy remains the ‘switch’ 
in collagen matrix synthesis from the biomechanically superior type I collagen to 
type III which is inferior and produced in a haphazard fashion. The mechanisms 
underlying how fibroblast - like tenocytes manages this change remain 
incompletely understood. Thus, the fibroblast can function as a key orchestrator of 
diverse aspects of tissue reorganization. The opportunity to further investigate the 
role of cytokines within tendon fibroblasts should allow further expansion of the 
diverse role of the fibroblast as a central regulator of inflammation and matrix 
regulation. 
Several IL-1 family members where detected as differentially expressed in 
the microarray and subsequent quantitative analysis. As introduced above, 
cytokines of the interleukin-1 (IL-1) family, such as IL-1α/β and IL-18, have 
important functions in host defence, immune regulation, and inflammation [153]. 
Investigation of their biological functions has led to novel therapeutic approaches 
to treat human inflammatory diseases [154]. Interleukin (IL)-33 is a novel member 
of the IL-1 family that exhibits close structural homology to IL-18. IL-33 is 
expressed mainly in endothelial cells and fibroblasts and as such is likely rapidly 
implicated in response to tissue insult, particularly its role as a novel alarmin. 
Furthermore its role in musculoskeletal pathogenetic processes such as 
rheumatoid arthritis and fibrosis [155] suggested that this cytokine may also be 
involved in the pathogenesis of tendinopathy. This thesis will directly address its 
role as an possible novel alarmin in tendon injury/damage. 
 The interleukin-17 (IL-17) family of cytokines is emerging as a key player in 
immune responses and increasing evidence shows that IL-17 family members play 
an active role in autoimmune and inflammatory diseases [156]. In humans, IL-17 is 
a potent inducer of other proinflammatory cytokines, such as TNF-α, IL-1β, IL-6 
and IL-8 from monocytes, macrophages or fibroblasts [157, 158]. IL-17 has been 
detected in synovial fluids and tissues of RA [159], inflammatory bowel disease 
[160] and psoriasis [161] patients. These findings suggest that IL-17 is an 
important cytokine located upstream of two pathways that are TNF-α-dependent 
and IL-6-dependent respectively [161]. It is notable that the organ systems that 
protect the host from the environment, specifically the lungs, intestinal mucosa and 
skin, seem to contain mostly IL-17	  producing innate cells [162]. We chose to 
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investigate IL-17 as the initial rodent microarray showed a modest up regulation of 
IL-17A receptor (1.2 fold up regulation, unpublished data Millar et al) and human 
microarray data has highlighted a role for IL-17F in chronic tendinopathy. This 
combined with parallel laboratory studies investigating the mast cell/IL-17 axis in 
rheumatoid arthritis patients  
In the following  sections, these novel cytokines will be introduced in the 
context of their cytokine family, their structure, expression and biology as well as 
their potential role in disease thus far elucidated.
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Interleukin	  17	  
IL-17 (IL-17A) was discovered in 1993 originally as a rodent T cell cDNA transcript 
cytotoxic T lymphocyte associated antigen 8 (CTLA8). Human IL-17 was 
subsequently discovered and to date five additional members of the IL-17 family 
has been identified and termed IL-17 B,C,D,E and F. While historic data suggest 
IL-17 is produced mainly by T-cells, its receptor is expressed ubiquitously on 
various cell types, including myeloid cells, epithelial cells and fibroblasts. Thus, IL-
17 exerts various biological functions in vivo, which might be involved in the 
pathogenesis of a wide range of infectious conditions and inflammatory disorders 
(Figure 1-7) 
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Figure 1-7: Effects of IL-17 on host defence, inflammation and tissue destruction  
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Th	  17	  cells	  
The differentiation of naive CD4+ T cells into effector T helper cells is 
initiated by engagement of their T cell receptor (TCR) (signal 1) and co stimulatory 
molecules (signal 2) in the presence of specific cytokines produced by the innate 
immune system upon recognition of particular pathogens. IL-12 initiates 
differentiation of Th1 cells that produce high levels of IFN-γ and are responsible for 
clearing intracellular pathogens. IL-4 triggers the differentiation of Th2 cells which 
organise host defence against extracellular pathogens and in help B cells to 
produce antibodies. The initial source of the differentiation factors for Th1 and Th2 
cells are cells of the innate immune system responding to microbial products, 
including bacterial, viral, fungal or parasitic antigens, or allergens; however the 
cytokines produced by Th1/2 cells are capable of feedback mechanisms to further 
enhance differentiation of the respective T cell subset. This model first proposed 
by Mosmann and Coffman helped explain many phenomena in adaptive immunity. 
Recently this model has been expanded following the discovery of further subsets 
called Th9 and Th17 cells, in addition to distinct regulatory T cell subsets (Treg) 
(Figure 1-8)  
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Figure 1-8: T helper cell differentiation (overview). 
Differentiation driven by various cytokines to either proinflammatory cells such as Th1 and 
Th17, but also regulatory cells (Tregs). 
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Th17 cells were identified as an independent subset of T helper cells by the 
identification of differentiation factors and transcription factors that are unique to 
Th17 cells. In mice, a series of studies have shown that IL-6 and/or IL-21 and 
TGF-β are key cytokines regulating the development of Th17 cells [163-165]. The 
Th17 lineage defining transcription factor was found to be RORγt [166]. 
Interestingly, key cytokines of Th1 and Th2 cells, namely IFN-γ and IL-4, block 
Th17 cell differentiation [167] commensurate with the existence of complex cross 
regulatory feedback loops in the effector T cell system. The cytokine IL-23 
(compromising the subunits IL-12p40 and IL-23p19) is essential for the 
maintenance and expansion of murine Th17 cells [168].  
 Similar to their mouse counterparts, human Th17 cells express RORC2, the 
human orthologs of RORγt [169] however development of human Th17 cells 
include more variables. Firstly, Th17 cell development depends on the T cell type, 
differing between naïve T cells and memory T cells. Naïve CD45RA+CD161+ T 
cells derived from umbilical cord blood differentiate to Th17 cells under the 
influence of IL-1β and IL-23 [170]. This process is TGF-β independent; however, it 
is thought that TGF-β supports Th17 differentiation by inhibiting T-bet and hence 
Th1 development [171]. 
In peripheral blood, differentiation of Th17 cells from naïve T cells is not 
fully elucidated as yet. Specifically, the need for TGF-β is controversial as serum 
containing media might be contaminated with platelets and TGF-β. Serum free 
approaches demonstrated an essential requirement for low dose TGF-β in 
conjunction with IL-1β and IL-23. However, the different approaches used in many 
of these studies, such as various purification techniques and culture conditions, 
make direct comparison of results difficult (reviewed in [172]). Interestingly, in 
human blood serum concentrations are usually higher than the concentrations 
which were used for culturing T cell in vitro in any of the described studies, and 
therefore most likely do not represent the in vivo situation. However, TGF-β is not 
the only cytokine involved in the differentiation and maintenance of Th17 cells.  
Other cytokines such as IL-6, IL-21 and TNF-α have also been shown to support 
Th17 polarisation from naïve Th cells. 
More clear is the development of Th17 cells from the memory pool. These 
effector cells can be identified by the combined expression of CCR4 and CCR6 
[173] - another group described a CD4+CD45RO+CCR7-CCR6+ population which 
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produce IL-17 [174]. CCR6 is thought to be involved in the recruitment of Th17 
cells to sites of inflammation via the ligand CCL20. IL-1β, IL-23 and IL-6 promoted 
production of IL-17; however, TGF-β inhibited IL-17 [174, 175] from this particular 
cell population. To summarize, due to a combination of ex vivo approaches 
including purification techniques and different cell culture conditions human Th17 
biology is still elusive. 
  
Biology	  of	  IL-­‐17	  
 Besides being produced by Th17 cells, both IL-17A and IL-17F are also 
produced by a variety of cells types, including γδ T cells, NKT cells, NK cells, 
neutrophils, eosinophils and mast cells. Thus IL-17 and IL-17F are effector 
cytokines produced by cells of both innate and adaptive immune systems. Indeed 
The IL-17 mediated immune pathway is induced within hours following epithelial 
cell injury or activation of pattern recognition receptors (PRRs) [176], which is not 
enough time for the development of TH17 cells. It is important to remember that 
the earliest reported functions of IL17A were its effects on innate immune 
responses [177]. 
One of the most important functions of IL-17 is the mobilization of 
neutrophils, which is mediated by the production of CXC chemokines, including IL-
8 (CXCL8) and growth regulated oncogene-alpha (GROα, CXCL1), and growth 
factors, including granulocyte colony-stimulating factor (G-CSF) and granulocyte 
macrophage colony stimulating factor (GM-CSF), from epithelial cells, smooth 
muscle cells and fibroblasts.  Murine models of infection have identified IL-17 in 
neutrophil mediated host defence against extracellular bacteria and fungi, such as 
Klebsiella pneumonia, Escherichia coli and Candida albicans. IL-17 also 
participates in the elimination of pathogens by inducing antimicrobial peptides, 
such as β-defensins, especially in co-operation with IL-22. All of the 
aforementioned chemokines and growth factors have been identified in rodent 
models of tendinopathy or tendon healing.   
 
IL-­‐17	  in	  inflammatory	  disease	  
IL-17 mediates various biological activities, which potentially cause tissue 
destruction and degeneration during chronic inflammation. IL-17 stimulates 
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macrophages to produce various cytokines such as IL-1β and TNFα. Furthermore, 
IL-17 acts synergistically with TNF-α in IL-6 and GM-CSF production from 
fibroblasts. In rheumatoid arthritis IL-17 induces cartilage destruction via induction 
of metalloproteinases and inhibition of proteoglycan synthesis while also inducing 
expression of RANKL on osteoblasts leading to bone destruction. IL-17 stimulates 
MMP, IL-6 and IL-8 production from cultured colonic subepithelial myofibroblasts 
in intestinal inflammation. Increased expression of IL-17 mRNA has been detected 
in biopsies from lesional psoriatic skin while IL-17 up regulates production of GM-
CSF, IL-6 and GRO-α from keratinocytes. A summary of current inflammatory 
diseases with IL-17 implicated pathology is shown in Table 1-5 
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Disease 
 
Role of IL-17 
 
References 
 
EAE(Experimental autoimmune 
encephalomyelitis)/Multiple sclerosis 
 
IL-17A KO mice have milder EAE 
Anti IL-17A antibody treatment 
attenuates EAE but does not 
abrogate disease 
IL-17 highly expressed in chronic MS 
lesions 
IL-17 found in CD4+ and CD8+ 
astrocytes of MS lesions 
 
[178-181] 
 
 
 
 
 
Inflammatory skin disease/Psoriasis 
 
Increased Th17 cells in psoriatic 
lesions 
Anti TNF therapy in psoriasis works 
by decreasing Th17 cells 
 
[182, 183] 
Inflammatory bowel disease 
 
IL-17 produced in healthy gut 
Anti IL-17A monoclonal antibody 
treatments aggravates DSS induced 
colitis 
Increased Th-17 related molecules in 
human IBD lesions 
[181, 184, 
185] 
Experimental arthritis/ 
rheumatoid arthritis 
IL-17 KO mice have reduced arthritis 
Vaccination against IL-17A reduces 
arthritis 
Expansion of Th17 cells in RA 
 
[186-188] 
	  
Table 1-5  Functions of Th-17 / IL-17 in disease processes
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Interleukin	  33	  
IL-33 (IL-1F11) is the latest IL-1 family member to be discovered. Initially 
described as nuclear factor of high endothelial venules (NF-HEV) by Girard and 
colleagues in 2003, Schmitz et al defined its function and role in the IL-1 family in 
2005 [189, 190]. This group described the IL33 gene after searching a 
computational derived database of the IL-1 family members where they identified a 
ligand for the then orphan receptor, ST2.  
The sequence of IL-33 has been mapped to human chromosome 9 
(9p24.1) and mouse chromosome 10 (19qC1). The cDNA encodes for 270 and 
266 amino acids for human and mouse, respectively, and are approximately 55% 
identical at the amino acid level [189]. Its molecular weight is ~ 30 kDa. Using 
sequence and secondary structure alignment, Girard and colleagues 
demonstrated that IL-33 consists of a homeodomain like helix turn helix motif 
(HTH) on the amino terminal side [190]. This is followed by a nuclear localisation 
signal and further 12 predicted β strands comprising an IL-1 like cytokine domain 
with a typical ß-trefoil structure (Figure 1-9). The 1-65 amino acid HTH motif of IL-
33 has homology with drosophila transcription factors showing the best match with 
Engrailed and these HTH motifs are known to be repressors of transcription. 
Engrailed is a Drosophila homeodomain protein required for proper segmentation 
and maintenance of the posterior compartment identity. The repressor activity of 
Engrailed lies in the sequence containing amino acids 1–298 which has been 
shown to confer transcriptional repression when fused to heterologous DNA 
binding domains. Use of dominant-negative transgenes has been successful in 
analysing certain pathways and using this technique to convert transcription 
factors into dominant repressors can be achieved by fusion to repressor domains 
such as Engrailed [191]. Accordingly, translational fusions with the Engrailed 
repressor domain have efficiently converted plant transcription factors, b-catenin 
and c-myb, into dominant-negative proteins. Also, in vivo, an airway-targeted 
GATA6-Engrailed dominant-negative fusion construct was able to alter epithelial 
differentiation [192].  
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Figure 1-9  Structure of IL-33 HTH like motif  
Example of HTH like motif in comparison to other HTH genes. Figure A demonstrates the 
structure of IL-33 HTH like part with three helices where the helix number 3 (arrow) is able to 
bind DNA; this figure has been altered from [190]. B demonstrates a schematic picture of a 
HTH in which one α-helix binds DNA in the major groove. Black arrow indicates the turn. 
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Carriere et al [193] demonstrated that IL-33, particularly the HTH like part is co-
located to heterochromatin. By truncation of IL-33 HTH-like part this 
heterochromatin association was abolished and IL-33 expression became 
unrelated to the heterochromatin. Thus, similar to Engrailed, IL-33 is thought to be 
a suppressor of transcription. More interestingly, by fusing IL-33 to the Gal4-DNA-
binding domain in gene reporter assays with a GAL4-responsive luciferase 
reporter, transcriptional activity was reduced illustrated by decreased luciferase 
activity. This could be re-established by mutating the DNA binding parts of IL-33 
[194].  
Next to the chromatin binding domain in the HTH like motif, IL-33 
possesses a nuclear localisation signal (NLS), near the N-terminal domain. 
Truncation of the NLS (e.g. a construct containing only IL-33112-270) leads to 
retention of IL-33 in the cytoplasm [193, 195]. The HTH like motif and NLS 
(important for nuclear localisation and DNA binding) are linked to the IL-1 like 
cytokine domain consisting of 12 β strands. The latter part has mainly been used 
to study biological effects of IL-33, as it has been assumed that IL-33 is cleaved by 
caspase-1 leading to “mature IL-33” (the IL-1 like cytokine domain) which is 
thought to be released in a similar way to IL-1 or IL-18 [189]. Interestingly, recent 
studies revealed that IL-33 is not cleaved by caspase-1, but instead cleaved by 
apoptosis associated caspases 3 and 7 as well as calpain and as a result is 
therefore inactivated rather than activated [196-198]. Although, caspase 3 treated 
IL-33 breakdown products are not able to bind ST2 (the IL-33 receptor), the N 
terminal part still translocates to the nucleus [196]. Moreover, different groups 
showed that full length IL-33 is bioactive and can be released by necrosis 
classifying IL-33 as an alarmin [197-200]. 
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Figure 1-10: IL-33 structural components and cleavage sites. 
N terminal domain shows HTH like motif including chromatin binding domain (CBM) with 
the specific amino acid motif and the nucleus localisation site (NLS). β1-12 demonstrates 
the IL-1 like cytokine domain with 12 β strands. At localisation amino acid 112 the initial 
described caspase-1 cleavage site from Schmitz et al [189] is shown. Further after the 
residue Asp178 Cayrol et al showed a truncation by caspase 1 and 3 which deactivated IL-
33 signalling through ST2 [199]. One month later, Luthi et al published truncation at Asp178 
by caspase 3 and 7, but did not confirm caspase 1 [200]. It should be emphasised that the 
structure in biological assay using recombinant IL-33 is a product reflecting the IL-1 like 
cytokine domain truncated at amino acid 112. 
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IL-­‐33	  receptor	  complex	  
IL-33 signals through a receptor complex comprising ST2L, a subunit that is 
specific for IL-33 [189] and IL-1R accessory protein ( IL-1RAcP) that is widely 
shared between other IL-1 receptor family members [201, 202]. ST2 (also named 
T1, IL1RL1, DER4, and FIT-1) was first described in 1989 [203]. Differential 
splicing leads to formation of 3 isoforms: transmembrane ST2, a soluble form 
(soluble ST2 or sST2) and a variant ST2. ST2 is a member of the IL-1 receptor 
family and has 38% amino acid homology to the IL-1 receptor [204]. 
Transmembrane ST2 is membrane-bound with 3 extracellular immunoglobulin-G 
domains, a single transmembrane domain, and an intracellular domain 
homologous to toll-like receptors and other IL-1 receptors. Soluble ST2 lacks the 
transmembrane domain as well as the intracellular domains and is thought to act 
as a decoy receptor for IL-33 signaling. ST2 deficient mice are healthy and display 
no overt phenotypic abnormalities [205]. The initial manuscript describing ST2 
deficiency demonstrated that mice challenged with a pulmonary parasite infection, 
exhibited significantly impaired levels of Th2 cytokine production. 
 ST2 is mainly expressed on mast cells and Th2 cells but not on Th1 or 
Th17 cells [205-207]. Further expression has been detected on many cell types 
including fibroblasts endothelial cells and other stromal cells  but also on dendritic 
cells, macrophages [208-210] and  basophils [211-213]. Both ST2L and IL-1RAcP 
seem essential for IL-33 action as mice deficient either for ST2 or IL-1RAcP are 
unresponsive to IL-33 administration, whereas wild type animals exhibit a marked 
inflammatory response [202]. Interestingly, soluble IL-1RAcP enhances the ability 
of sST2 to inhibit IL-33 signalling [214]. Signal transduction in ST2 and IL-1RAcP 
is mediated via the Toll-IL-1R (TIR) domain which is shared among the entire 
TLR/IL-1R receptor superfamily. Upon binding of IL-33 the TIR domain of IL-
1RAcP directly interacts with the TIR domain of ST2/IL-33 contributing to the IL-33 
mediated signal [202]. Downstream of the IL-33/ST2L/IL-1RAcP complex, the IL-
33 signal is transmitted via the recruitment of the myeloid differentiation primary 
response protein 88 (MyD88), and TNF receptor-associated factor (TRAF-6) to the 
TIR domain in the cytoplasmic portion of ST2L (and IL-1RAcP) where these 
molecules are activated [189]. This in turn leads to recruitment of IL-1R-associated 
kinase (IRAK) 1 and IRAK4 and TNFR-associated factor 6 (TRAF6) [189, 215]. 
MyD88 is essential for IL-33 signalling as MyD88 deficient mice do not respond to 
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IL-33 administration [202]. IL-33 stimulation also leads to phosphorylation of 
inhibitor of NF-κB (IκBα) as well as the kinases Erk1/2, p38, and JNK [189].  
Further key signalling events downstream of MyD88 are summarised as follows 
[216]:  
Further key signalling events downstream of  MyD88 include [216]: 
- MyD88 recruits IRAK1 and IRAK4; IRAK4 phosphorylates IRAK1 
- IRAK1 phosphorylates Pellino-1 (E3-ligase), this leads to IRAK1 
polyubiquination 
- further recruitment of NEMO/IKK1/IKK2 complexes 
- polyubiquitination of TRAF6 with TAK1 recruitment to the NEMO/IKK1/IKK2 
complex 
- activation of IKK2 by TAK1 
- TAK1 also couples to the upstream kinases for p38 and JUN N-terminal 
kinase-1 (JNK). 
 
However this intracellular activation cascade by IL-33 (or IL-1) is likely to be 
more complex [216]. Furthermore in mast cells, IL-33 triggers Ca2+ influx by the 
activation of phospholipase D and sphingosine kinase [217]. Although ST2 
receptor signalling is understood in the broad context, it is not clear why signalling 
cascades through MyD88 by different receptors leads to different cellular 
responses.  
67	  
	  	  	  
Figure 1-11 IL-33 binding to ST2 and IL1RacP signals via MyD88 
Schematic overview for binding and signalling of IL-33: nuclear IL-33 is released by 
necrosis and binds to ST2 which leads to recruitment of IL-1RAcP, MyD88, IRAK1, IRAK4. 
TRAF6 is necessary for recruitment of IRAK. This signalling complex leads through further 
events to activation of NF-κB and p38 and JNK pathways. These pathways induce gene 
expression leading to cytokine and chemokine synthesis
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Tissue	  localisation	  and	  cellular	  expression	  of	  IL-­‐33	  
To date most reports visualising IL-33 expression demonstrate that IL-33 is 
almost exclusively expressed in the nucleus. Using antibodies against the C 
terminal region (e.g. Nessy-1) most analyses demonstrate (in nearly every tissue) 
nuclear expression of IL-33 although a few notable exceptions exist.  IL-33 is 
localised within the cytoplasm of airway smooth muscle cell bundles from 
asthmatic patients. These cells also secrete small but significant amounts of IL-33 
[218]. Cytoplasmic IL-33 staining is also evident in intestinal epithelial cells taken 
from patients suffering from ulcerative colitis and Crohn’s disease with 
correspondingly high levels in serum from the same patients [219]. The nuclear 
expression pattern mainly occurs in stromal cells such as endothelial cells and 
epithelial cells. IL-33 was initially described as a “nuclear factor of high endothelial 
venules” consistent with this reported expression pattern. In addition, Schmitz et al 
reported IL-33 expression in cDNA libraries. They showed that IL-33 is broadly 
expressed across different tissues; however, on the cellular level differences 
emerge. Mouse organs expressing high levels of IL-33 cDNA include stomach, 
lung, spinal cord, brain, and skin. In humans, IL-33 cDNA was detected in 
adherent stromal cells like epithelial/endothelial cells, smooth muscle cells, 
fibroblasts, and keratinocytes where the latter two upregulated IL-33 after TNF-α 
and IL-1 stimulation [189].   
Kuchler et al demonstrated that IL-33 is globally expressed in nuclei of 
vascular endothelium in normal human tissues staining vessels in human skin, 
small intestine, umbilical cord and lung [220] and further show in vitro that vascular 
IL-33 is downregulated by proinflammatory cytokines IL-1β, TNF-α and VEGF. 
More surprisingly, IL-33 is strongly down-regulated in endothelium undergoing 
tumor or wound healing angiogenesis. These findings are distinct and contradict 
fibroblast derived data, where IL-1 and TNF-α upregulated IL-33 [210]. However, 
cell type and stromal origin could explain this difference, as could culture 
conditions as Kuchler et al used superconfluent cultures of human umbilical vein 
endothelial cells (HUVECs) and Xu et al used synovial fibroblasts with ~80% 
confluency. In contrast to IL-33 expression in endothelial cells, Choi et al studied 
the response of HUVECs to IL-33. They reported that IL-33 has a significant effect 
on angiogenesis and vascular permeability by rapidly increased endothelial nitric 
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oxide (NO) production [215]. Overall, a more careful dissection of the role of IL-33 
in endothelial cells is required. 
IL-­‐33	  release	  and	  nuclear	  function	  	  
Initial studies hypothesized that IL-33 is released in a caspase-1 dependent 
manner [189]. NLRP3 (NLR family, pyrin domain-containing 3) inflammasome 
activation by pathogen-associated molecular patterns (PAMPs) or damage-
associated molecular patterns (DAMPs) leads to oligomerisation of NLRP3 and 
clustering of pro-caspase-1. This results in caspase-1 auto-activation and 
caspase-1-dependent processing of cytoplasmic targets, including the pro-
inflammatory cytokines IL-1β and IL-18, which require this step to be biologically 
active and mediate repair/inflammation responses such as angiogenesis and 
neutrophil influx to remove cellular debris or fight pathogens [221]. Full length IL-
33 with ~30 kDa was reported initially to be cleaved to a 20-22 kDa product in a 
similar way to IL-1 and IL-18 [189]. However IL-33 orthologs from various other 
species lack conserved caspase I sites which cast doubt on the necessity of 
caspase I cleavage for bioactivity. Subsequent studies have shown that IL-33 like 
IL-1α is biologically active in its full length form and more importantly cleavage by 
caspase I resulted in a truncated form of IL-33 that was unable to signal [199]. IL-
33 is also cleaved by the apoptosis associated proteases, caspase 3 and 7 which 
attenuated IL-33’s ability to signal [200].  
IL-33 expression and active secretion have been observed in only a limited 
number of studies. It was shown that inflammatory cells including monocytes, 
macrophages, astrocytes and synovial fibroblasts, in response to stimulation with 
a range of pro-inflammatory signals including LPS, IL-1β and TNFα [198, 210, 
222] release IL-33. Increasing numbers of different groups established the fact that 
either chemical (H2O2, NaN3, Daunorubicin, TritonX100) or mechanical 
(scratching, freeze/thaw) necrosis of IL-33 expressing cells release full length IL-
33 into the media [199, 200]. Interestingly some investigators report increased 
extra-cellular IL-33 expression in diseases with high number of necrotic cells such 
as RA, SLE  [223, 224] but the mechanism/pathway as to how IL-33 is released in 
such disease states remains ill-defined. This has led to the suggestion that IL-33 
acts as a DAMP or alarmin whereby its passive release from damaged or dying 
cells sends a signal to cells of the innate immune system alerting them to the 
presence of potentially harmful pathogens. In this regard IL-33 is thought to act in 
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a similar manner to the archetypal alarmin, High mobility group box 1 ( HMGB1) as 
both are released from dying cells and both are nuclear factors with HMGB1 
having well characterized roles in gene regulation, chromatin remoulding, and 
DNA replication and repair [225]. Like HMGB1 IL-33 has also been shown to 
interact with heterochromatin and mitotic chromatin and is released from necrotic 
cells whilst being actively retained complexed within chromatin of apoptotic cells. 
In a similar fashion to IL-1β, IL-18 and HMGB1, IL-33 lacks a signal peptide 
and thus cannot be mobilized via the classical ER-Golgi exocytotic pathway. Some 
reports suggest that IL-33 secretion may involve similar processes to that for IL-1β 
and IL-18. The release of IL-1β and IL-18 requires two signals, an initial signal in 
the form of PAMP (e.g. LPS) which stimulates gene expression with subsequent 
exposure to ATP resulting in a influx of K+ via the nucleotide gated ion channel 
P2X7 which activates the inflammasome resulting in activation of caspase I with 
subsequent bioactivity and release [226]. Whilst as generally accepted it is unlikely 
IL-33 is a substrate of caspase I it may still be required for secretion as is the case 
for HMGB1 [227] with a recent study showing significant release of IL-33 from 
astrocytes treated with LPS and ATP [228]. This study showed that LPS induces 
expression with localization to the nucleus followed by mobilization of IL-33 from 
the nucleus to the cytoplasm with ATP incubation. However this does not hold true 
for all inflammatory cell types as while IL-33 expression could be induced by 
PAMP stimulation in primary human monocytes and a monocyte cell line [222], no 
secretion of IL-33 was detected upon incubation with ATP, conditions which 
elicited the secretion of both IL-1β and IL-18. 
One of the most interesting aspects surrounding the biology of IL-33 
remains its nuclear expression profile . It’s presence in the nucleus represents a 
significant barrier to its secretion as unlike its IL-1 family members , IL-1β and IL-
18 it must negotiate passage through both nuclear and cell membranes. HMGB1 
undertakes a similar passage by encoding a nuclear export sequence (NES) and a 
variety of post-translational modifications all of which serve to redirect HMGB1 out 
of the nucleus. IL-33 does not contain a NES and presently no post transitional 
modifications have been described. Although the nuclear functions of IL-33 remain 
to be fully investigated, the association of IL-33 with heterochromatin has been 
suggested to be functionally linked to transcriptional repression and chromatin 
compaction [193]. Recently nuclear IL-33 expression was reported in pancreatic 
stellate cells, where inhibition of IL-33 expression, mediated by small interfering 
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RNA, decreased cell proliferation [229]. Thus, like pro-IL-1α, IL-33 may act as a 
dual-function cytokine that exerts unique biological activities in the cell nucleus 
independently of cell-surface receptor binding.  One could further postulate 
complex intracellular interactions analogous to the internalization and subsequent 
signalling of some TLRs. 
Biological	  cellular	  function	  of	  IL-­‐33	  
Early studies showed selective expression of ST2L by TH2 but not TH1 cells 
[206, 230] and thus IL-33 was initially investigated in T cells. TH2 cells treated with 
IL-33 enhanced IL-5 and IL-13 production but not IL-4 [189] Further it acts as 
chemoattractant for human Th2 cells [231]. IL-33 also stimulates NK and NKT 
cells to produce IFN-γ [232]. DCs express low levels of ST2; however, upon 
stimulation with IL-33, DC can induce Th2 cytokines in CD4 T cells [209].  
 IL-33 is a potent inducer of cytokines and chemokines in mast cells (TNF, 
IL-1, IL-6, IL-13, CCL2 and CCL3) [233]. In particular it induces the degranulation 
of IgE primed mast cells and enhances mast cell maturation and survival [234]. 
Three reports describe basophils and their response to IL-33 [211-213]. Schneider 
et al studied murine basophils and found that cells express ST2 and respond in an 
unprimed state with the production of IL-4 and IL-6 [212]. In vivo indirect increase 
of GM-CSF and IL-5 promoted expansion of basophils. In humans, Smithgall et al 
and Suzukawa et al confirmed ST2 expression in basophils [211, 213]. Stimulated 
with IL-33, these cells produced IL-4, IL-5, IL-6 and IL-13 and increased their 
adhesive capability. 
 A role for IL-33 in the activation and maturation of other myeloid lineage 
cells is also emerging. IL-33 enhances the production of TNF by macrophages 
treated with lipopolysaccharide and lipoteichoic acid [235]. Importantly, IL-33 can 
amplify IL-13-mediated polarization of alternatively activated macrophages to 
produce increased levels of CCL17 and CCL24, which contribute to airway 
inflammation [236]. Dendritic cells (DCs) express ST2 at low levels but respond to 
IL-33 by upregulation of MHC class II molecules and the co-stimulatory molecule 
CD86 [209]. IL-33 can also activate DCs to produce IL-5, IL-6 and IL-13 by CD4+ 
T cells [209], suggesting an additional indirect role of IL-33 in the induction of 
adaptive immune responses. The ability of IL-33 to target various immune cell 
types highlights its potential in influencing the outcome of a wide range of 
diseases. 
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IL-­‐33	  in	  experimental	  models	  
 Mice treated with IL-33 exhibit splenomegaly, blood eosinophilia and 
increased levels of IgA and IgE. This relates to a Th2 phenotype with increased IL-
4, IL-5 and IL-13 [189]. Also anatomical changes of stomach and mucus- and bile-
filled duodenum as well as lung were observed with recruitment of myeloid cells 
and epithelial reaction with either hyperplasia (esophagus) or massive mucus 
production (lung). In contrast, IL-33 administration was beneficial in a model of 
atherosclerosis [237]. In ApoE deficient mice fed on a high fat diet, injection of IL-
33 significantly reduced atherosclerotic lesions in terms of size and leukocyte 
infiltration. Also serum levels were increased for IL-4, IL-5 (especially) and IL-13 
with decrease of IFN-γ suggesting a switch from a Th1 to Th2 phenotype. This 
atheroprotective effect could be blocked with anti-IL-5 suggesting rather indirect 
effect whereby IL-33 operated via modulated IL-5 production. IL-33 also induced 
antioxidized low-density lipoprotein (ox-LDL) antibodies which are thought to be 
atheroprotective. Interestingly, it has also been shown that IL-33/ST2 signalling is 
a crucial biomechanically activated system that controlled cardiomyocyte 
hypertrophy and cardiac fibrosis after pressure overload [238]. Soluble ST2 levels 
also negatively correlate with survival and directly with cardiac injury and 
microvascular injury post myocardial infarction [239]. 
 In a mouse model of RA, collagen induced arthritis was diminished in ST2 
deficient mice [210]. In addition, CIA mice treated with recombinant IL-33 led to 
exacerbation of disease. This had no effect in ST2 deficient mice. Furthermore, 
reconstituting ST2 deficient mice with mast cells (expressing normal levels of ST2) 
again led to exacerbation of arthritis [210]. This supports the important role of mast 
cells in proinflammatory cytokine production. It is interesting, that despite the Th2 
profile of mast cells, secretion of proinflammatory cytokines like IL-1, IL-6 and IL-
17 can bias the balance to a Th1/Th17 autoimmune phenotype. It is noteworthy, 
that Raza et al and Kokkonen et al detected increased Th2 cytokine patterns 
immediately after the onset of RA disease [240, 241]. The potency by which IL-33 
increases severity of CIA was confirmed by Palmer et al using anti-ST2-antibodies 
[242]. Furthermore they showed a decrease in IFN-γ as well as IL-17 production in 
the draining lymph nodes. Therefore IL-33 clearly drives Th1/Th17 responses in 
experimental arthritis. This is confirmed by higher levels of IFN-γ and IL-17 in the 
IL-33 treated CIA mice [210]. Focussing on autoantibody induced arthritis (AIA), 
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IL-33 exacerbated arthritis, where AIA in ST2 deficient mice developed attenuated 
disease [243]. 
Administration of IL-33 exacerbates experimental asthma and induces 
features of asthma in naïve animals. Furthermore blocking ST2 or IL-33 attenuates 
disease in some models [233]. More evidence is emerging that allergic IL-33/ST2 
pathology is antigen mediated with induction of antigen specific IL-5 expressing T 
cells [244]. Even more strikingly is the fact, that a SNP in a region flanking IL33 is 
associated as risk factor for asthma in a large-scale, consortium-based genome 
wide association study [245].  
 IL-33 deficiency did not influence the pathogenesis of experimental 
autoimmune encephalitis [246]. The severity of dextran sodium sulfate-induced 
colitis was attenuated in IL-33-deficient mice in the early stages of disease, but 
recovery was delayed in these mice [246]. Subcutaneous administration of IL-33 to 
wild-type mice led to the accumulation of inflammatory cells and the development 
of skin fibrosis, which was dependent on IL-13 and the presence of eosinophils 
[247]. Of note, IL-33 levels have been shown to correlate with collagen type III 
expression in this particular study which as previously mentioned is a key feature 
of collagen change in tendinopathy. 
IL-­‐33	  in	  human	  disease	  
Serum levels of IL-33 are significantly higher in patients with RA than in 
those with OA or in healthy individuals [223]. IL-33 levels correlated with RA 
disease activity [223], and with the presence and titre of rheumatoid factor and 
antibodies against cyclic citrullinated peptides [248]. In general, IL-33 is present 
primarily in the nuclei of endothelial cells and in some cases also in synovial 
fibroblasts, without any specific difference in IL-33 tissue expression pattern 
between RA, osteoarthritis and psoriatic arthritis [249]. In addition, the expression 
of ST2 on neutrophils is decreased in patients who respond to therapy with the 
TNF inhibitor infliximab [250], suggesting that both production of and cellular 
responses to IL-33 are modulated by proinflammatory cytokines. In early systemic 
sclerosis, nuclear expression of IL-33 in dermal endothelial cells and keratinocytes 
was down regulated; by contrast, IL-33 expression was enhanced in dermal and 
pulmonary fibroblasts [208]. Serum levels of IL-33 were comparable in patients 
with systemic lupus erythematosus (SLE) and healthy subjects in one study, 
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whereas other investigators have detected elevated levels in patients with SLE 
[251, 252].  
Serum concentrations of sST2 are elevated in patients suffering from 
disorders associated with an abnormal TH2-like immune response, including 
atopic dermatitis and asthma [253]. Indeed in endobronchial biopsies obtained 
from adults with varying severities of asthma, higher levels of IL-33 transcripts 
were detected in biopsies compared with control subjects [218] In the same study 
airway smooth muscle cells (ASMCs) showed IL-33 expression at both protein and 
mRNA levels and TNF-α up-regulated IL-33 expression by cultured ASMCs in a 
time- and dose-dependent manner with the authors proposing IL-33 as a novel 
inflammatory marker of severe and refractory asthma.  
IL-33 has also been linked with inflammatory bowel disease. IL-33 
production is increased in active lesions of ulcerative colitis but not in Crohn’s 
disease with subepithelial myofibroblasts  identified as the major cellular sources 
of IL-33 in ulcerative colitis lesions [254, 255].The TLR3 ligand polyinosinic–
polycytidylic acid, administered alone or in combination with transforming growth 
factor β, strongly induced IL-33 expression in myofibroblasts [254]. It is noteworthy 
that serum levels of IL-33 decreased following the administration of infliximab in 
patients with ulcerative colitis [219]. 
Overall these findings demonstrate clearly that IL-33 production is 
enhanced in several inflammatory diseases, and that resident cells, including 
epithelial cells, endothelial cells and fibroblasts, are major sources of IL-33.  
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1.5) Novel regulation of cytokine production 
Intercellular signalling by cytokines is a vital feature of the innate and 
adaptive immune system. Cells respond to extracellular stress or stimuli by driving 
intracellular signalling cascades that coordinate cellular gene expression through 
complex networks of kinase activation, protein phosphorylation, and activation of 
DNA-binding proteins that translate signals at the cell surface to actions of 
transcriptional regulation of cellular genes. Cytokines modulate communication 
between cells of the immune system and between immune cells and differentiated 
somatic cells. Upon binding to their cognate receptor on the cell surface, cytokines 
trigger transcriptional changes and balance cellular activities ranging from growth 
to differentiation and cell survival. Cytokine-directed transcriptional induction of yet 
other cytokines may further enhance the innate immune response in an 
increasingly entangled network of signals.  
Cytokines are heavily regulated at the transcriptional level, but emerging 
evidence suggests that regulatory mechanisms that operate after transcription play 
a key role in balancing the production of cytokines. Thus I wished to explore two 
more recently identified mechanisms, namely hypoxia and microRNA, promoting 
cytokine regulation which have been shown in similar fibroblast driven 
inflammatory disorders to have key functional consequences on cytokine 
production. The next section introduces these two regulatory pathways and their 
possible relevance to tissue damage in tendon disease. 
Hypoxia	  and	  cytokine	  regulation	  
Normal oxygen delivery is essential for survival of organisms and 
evolutionarily conserved mechanisms have been developed to maintain oxygen 
homeostasis. Changes in tissue oxygen levels in pathologic conditions are caused 
by an imbalance between cellular oxygen demand and tissue oxygen delivery. 
Thus, tissue hypoxia is a feature of a number of pathologic conditions ranging from 
cancer to inflammatory diseases. Oxygen homeostasis is largely maintained 
through a family of hypoxia-inducible transcription factors (HIFs), composed of a 
constitutively expressed HIF-1β subunit and a HIF-α subunit (HIF-1α and HIF-2α) 
that is tightly regulated by tissue oxygen levels [256]. Accumulation of the HIF-α 
subunit is triggered by a decrease in oxygen levels, with subsequent 
transcriptional activation of a number of genes whose products are involved in 
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pathways aimed at restoring oxygen delivery and maintaining energy 
requirements, including erythropoiesis, angiogenesis, and glycolytic metabolism.  
 Increasing evidence supports the concept that hypoxia can act as a 
regulator of innate and adaptive immunity. Intuitively this seem obvious a priori 
given the fundamental import of tissue oxygenation and the obvious importance of 
protecting tissue in the event of ischaemia. The extent however to which such 
regulatory interactions exist and can if modulated lead to immune perturbation is 
illuminating. Mice with HIF-1α deficient lymphocytes have elevated levels of anti-
double stranded DNA antibodies and rheumatoid factor in serum as well as 
proteinuria and depots of IgG and IgM in the kidney [257]. Hypoxia induced 
signalling pathways stimulate the differentiation and proliferation of regulatory T 
cells accompanied with and increase extracellular level of adenosine thus 
protecting the tissues by restricting effector functions of T cells [258]. Myeloid cells 
have HIF-dependent ways functioning in the hypoxic microenvironment. HIF-1α 
null phagocytes cannot efficiently eliminate bacterial loads instead forming 
persistent ulcerative lesions [259]. HIF-1α also prolongs the lifespan of neutrophils 
in hypoxia by inhibiting apoptosis [260]. Cross-talk between hypoxic and non-
hypoxic signalling pathways may further amplify inflammatory responses by 
activating HIF as well as other oxygen-sensitive transcription factors, for example 
nuclear factor-κB (NF-κB). Indeed, recent evidence indicates that NF-κB and HIF-
1α are linked in a regulatory loop that substantiates the involvement of hypoxia in 
innate immunity and inflammation [261]. Members of the NF-κB family interact with 
members of the prolyl hydroxylases (PHDs) - HIF pathway with mouse studies of 
inflammatory bowel disease showing that PHDs regulate anti apoptotic effects of 
NF-κB in intestinal inflammation [262]. Hypoxia also amplifies the NF-κB pathway 
by increasing the expression and signalling of TLRs, which subsequently enhance 
the production of antimicrobial factors stimulating phagocytosis and leukocyte 
recruitment [263]. 
Accumulating evidence suggests that pro-inflammatory cytokines can act as 
oxygen-sensitive mediators, indicating the potential to integrate oxygen-linked 
pathways mediated by cytokines via ROS-dependent mechanisms [264, 265]. 
ROS, for instance, can induce pro-inflammatory cytokine biosynthesis and this 
response can be abrogated by selective antioxidants, suggesting an integral role 
of endogenous ROS [266]. As such, cytokines could form a pivotal link in ROS-
dependent pathways leading to the activation of redox-sensitive transcription 
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factors, such as HIF-1α, whose up regulation determines the specificity of cellular 
responses to oxidative stress. TNF-α was reported to have a stimulatory effect on 
HIF-1 DNA binding activity in a manner similar to that of IL-1 [267]. In addition, the 
induction of adhesion molecules by hypoxia was reported to have been induced by 
IL-1 and TNF-α that was caused with anoxia/reperfusion [268]. This was 
corroborated with the observation that the upregulation of redox factor-1 (Ref-1), a 
transcription factor, promoted endothelial cell survival in response to hypoxia and 
TNF through NF-κB-independent and NF-κB-dependent signalling cascades, 
respectively, indicating that Ref-1 may act as a critical cofactor mediating the TNF-
induced NF-κB response in the vascular endothelium [269] . The expression of 
HIF-1 during acute inflammation has also been investigated in experimental 
wounds. HIF-1α induction in primary inflammatory cells was reported to be TNF-α-
dependent, the expression of which in early wounds may contribute to the 
regulation of iNOS and VEGF, two HIF-1-responsive genes intimately related to 
the process of repair [270]. Hypoxia and IL-1β were reported to stimulate VEGF 
production in human proximal tubular cells, ostensibly due to increased DNA 
binding of HIF-1 to hypoxia-responsive elements in the VEGF gene promoter, 
thereby contributing to microvascular leakage and monocyte extravasation [271]. 
The upregulation of IL-8 by hypoxia in human macrophages of the lung revealed a 
potential role in the pathogenesis of acute respiratory distress syndrome (ARDS). 
Several signal transduction pathways have been proposed to act 
downstream of putative oxygen sensors and lead to the activation of MAPK [272]. 
HIF, IL-1β and TNF-α, initiate a cascade of receptor-mediated mechanisms, which 
diverge at the level of G-coupled receptors (Ras), proximal kinases involved with 
the phosphorylation of MAPKp38/MAPKJNK, and phosphatidylinositol-3 kinase 
pathway [272]. Subsequent phosphorylation/activation mechanisms up regulate 
the biosynthesis of the α subunit of HIF, which couples with the constitutively 
expressed β subunit, thereby allowing nuclear translocation and transactivation of 
this transcription factor. The activation of HIF-1α requires phosphorylation. This 
scenario is likely provided with the normoxic induction by cytokines, which stabilize 
the α subunit, ostensibly via downregulation of VHL and/or up regulation of 
upstream kinases such as MAPKs. 
78	  
	  	  	  	  
Figure 1-12  Regulation of the hypoxia-inducible factor-1α (HIF-1α) and nuclear factor-κB 
(NF-κB) pathways by reactive oxygen species (ROS) and cytokine stimulation.  
The complex and interrelated activation of these two critical transcription factors is central 
to most of the processes that sustain inflammation in tissues, such as endothelial 
activation, leukocyte recruitment, angiogenesis, and enhanced cell survival. IL, interleukin; 
MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase; TNF, tumour 
necrosis factor. 
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One of the best characterized hypoxia-responsive genes is the angiogenic 
stimulus vascular endothelial growth factor (VEGF), expression of which is 
dramatically up regulated by hypoxia in many cells types. This has been 
particularly well explored in RA in which angiogenein e.g. VEGF, FGF, expression 
and intercurrent hypoxia have been closely compared. This has lead to an 
apparent paradox, whereby there is abundant synovial vasculature (particularly of 
neovessels expressing αvβ3 integrins) and angiogenin expression (which might be 
expected to restore oxygen levels to normal) occurring together with regions of 
substantial synovial hypoxia. It has been shown in a number of studies that 
vascular endothelial growth factor blockade is effective in animal models of 
arthritis; these findings suggest that hypoxia may activate the angiogenic cascade, 
thereby contributing to RA chronicity. Recent data also suggest that, as well as 
activating angiogenesis, hypoxia may regulate many other features that are 
important in RA, such as cell trafficking, matrix degradation and bone erosion 
[273].  
Thus hypoxia and inflammation are intertwined at the molecular and cellular 
levels. The prominent transcription factor HIF-1 is a key regulator of oxygen 
dependent gene expression, particularly in immune cells with subsequent cytokine 
dysregulation. Its prominence in wound healing and arthritis warrants its 
investigation in tendon disease as a possible mediator of tissue damage. 	  
Hypoxia	  and	  tendinopathy	  
Biopsy and in vivo model studies suggest that tendon hypoperfusion [274] 
and subsequent hypoxia [275] are central elements of tendon failure but few data 
have addressed this at a mechanistic level in humans. Hypoxia was first described 
in 1982 when Jozsa and colleagues [65] examined 34 tendons under the electron 
microscope, excised within 48 h after rupture of the tendons and showed marked 
hypoxic alterations in the tenocytes. This remained the foundation of the concept 
of hypoxic induced tendon damage for around 20 years until Sivakumara et al 
examined in vivo oxygen tension measurements of rheumatoid tendons at the time 
of hand surgery and also analysed tissue for the expression of HIF and cultured 
cells to assess cytokine production. Here profound hypoxia in the synovium of RA 
tendons and joints in vivo despite immunohistochemical evidence of markedly 
increased vascularity was noted as was markedly increased production of TNF in 
hypoxic cell cultures. In rodent models, cyclic strain regulates the expression of 
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the HIF-1α in rat tendon fibroblasts [117] and recently Benson et al [68] described 
hypoxic damage throughout the spectrum of rotator cuff disease. Experiments on 
primary cell cultures of normal human dermal fibroblasts in hypoxic conditions 
reveal up regulation of VGEF with early increases in Type I collagen that 
regresses at 48 hours suggesting a functional role for hypoxia in matrix adaption 
[276].  Microarray approaches exploring hypoxic versus normoxic synovial 
fibroblasts from healthy controls and RA patients show the number of differentially 
expressed genes to be significantly increased by hypoxia [277]. The main 
biological pathways modified by hypoxia include carbohydrate and lipid metabolic 
pathways both of which are established HIF targets. In particular this elegant study 
found the AMP-activated protein kinase pathway (AMPK) to be one of the most 
important canonical pathways induced by hypoxia in synovial fibroblasts. AMPK is 
HIF independent factor critical for maintaining energy homeostasis in cells 
exposed to stress or cytokines [278] and AMPK and its agonists can suppress 
proinflammatory signaling in models of inflammation [279, 280].     
To date no studies have explored the functional role of hypoxia in 
modulating apoptosis, inflammation and matrix regulation in tendinopathy. I was 
intrigued by this and as such this thesis has as one of its aims an endeavour to 
investigate the role of hypoxia and underlying molecular mechanisms of hypoxic 
induced tendon damage. 
MicroRNA	  
MicroRNA (miRNA) are a group of short non-coding RNA functioning as 
post transcriptional regulators of gene expression. It is estimated that there are 
more than 1200 human miRNAs that are believed to affect a large number of 
biological processes including cell differentiation and development. Typically, 
miRNAs are 19–24 nucleotide long, single-stranded molecules that suppress the 
expression of protein–coding genes at the posttranscriptional level by directing 
translational repression, mRNA destabilization, or a combination of the two [281]. 
miRNAs mediate their regulatory action through imperfect binding to the 3′ 
untranslated region (3′ UTR) of target mRNAs carrying complementary sites. The 
interaction of miRNAs and their target mRNAs is mediated primarily through 
nucleotides 2–7 in the 5′ region of the miRNA, although other nucleotides of the 
miRNAs probably also have a modifying effect. Moreover, each mRNA can be 
regulated by dozens of miRNAs (depending on the length of the 3′ UTR) that may 
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interact with each other by synergism or competition. It is estimated that 
expression of  ~8000 genes (30% of the human genome) are likely to be regulated 
by miRNAs. Thus, the gene regulatory effect of miRNAs is potentially enormous. 
 
MicroRNA	  expression	  and	  effector	  function	  
Most miRNAs are transcribed by RNA polymerase II enzyme as long, 
mRNA-like polyadenylated primary transcripts (pri-miRNA), which can be several 
thousand bases long [282]. In the first processing step, the RNAse III enzyme, 
Drosha, together with other proteins in the cell nucleus cleaves the long pri-miRNA 
to a shorter, 70 nucleotide stem-loop-structure known as the precursor miRNA 
(pre-miRNA) [283]. This is then exported from the nucleus by exportin 5 to the 
cytoplasm, where the second processing step is carried out. Another RNase III 
enzyme, Dicer, together with other proteins cleaves the pre-miRNA into a short 
(19–24 nt) double-stranded miRNA duplex that is processed further with one of the 
strands being incorporated into the RNA-induced silencing complex (RISC) [283, 
284], that directs miRNA to its target site on mRNA and leads to post-
transcriptional repression (Figure 1-13). An alternative pathway of miRNA 
biogenesis has been discovered involving splicing from introns. These ‘mitrons’ 
mimic the structural features of pre-miRNAs and are spliced without Drosha 
processing. 
 Similar to protein coding genes, miRNA may also be subject to post-
transcriptional regulation. For example, SMAD proteins, regulators which are 
induced by TGF family members, have been shown to enhance pre-miR-21 
processing from its primary transcript through SMAD association with Drosha and 
the p68 RNA helicase. It has also been shown that primary miRNA transcript 
processing van be inhibited whereby the developmentally regulated RNA binding 
protein, Lin28, binds pri-let-7 transcripts thus preventing processing in ES cells 
[285]. 
 Transcription factors (TFs) regulate gene expression responsible for various 
cell phenotypes and the response of cells to environmental stimuli. Increasing 
evidence supports the role of miRNAs in combination with TFs controlling the 
expression of thousands of mammalian genes in a so called ‘fine tuning’ of the 
transcriptional network. An example is c-Myc activated E2f1, a transcription factor, 
and miR-17-5-p and miR-20 [286]. E2F1 binds directly to the promoter of MiR-17-
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92 cluster and thus regulates its ultimate transcription [287]. The presence of 
multiple miRNA target site in immune genes and studies of miRNA expression in 
brain and haematopoietic cells may suggest that like TFs, codes of miRNAs may 
exist [288]. However TFs can act as either activators or repressors and due to 
their size and structure can simultaneously interact with distinct tissue specific 
proteins. miRNAs are primarily repressors, although recent data has suggested 
that miRNAs may activate certain genes in growth arrested cells [289]. Additionally 
others have shown that miRNAs can bind sites in promoters to activate 
transcription and that sites in 5’UTR may be capable of enhancing translation 
[290]. 
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Figure 1-13  A schematic representation of miRNA processing and activity.  
MicroRNAs are transcribed by RNA polymerase enzymes as part of primary miRNA 
molecules. Two dsRNA-specific ribonuclease, Drosha and Dicer sequentially cleave the 
long primary miRNA into the precursor hairpin miRNA and the mature miRNA. Adapted from 
University Of New South Wales Embrylogy Image Bank © Dr Mark Hill.
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miRNA	  mediated	  regulation	  of	  the	  immune	  system	  
The first studies implicating miRNAs in immunological processes originated 
from expression profiling of haematopoietic cells during their development. 
Systematic investigation of miRNA levels in hematopoietic cell lineages, using 
microarray profiling, cloning, northern blotting, and quantitative real-time 
polymerase chain reaction (PCR), has identified miRNAs that are now considered 
as “markers” of these lineages [291, 292]. These studies also showed that 
miRNAs are dynamically regulated during the development of T cells, B cells, and 
granulocytes, and are involved in the regulation of these processes. Recent 
investigations identified critical roles for miR-150 in B cell differentiation, by 
inhibiting the transition to the pro-B to the pre-B cell stage [293, 294]. Moreover, 
miR-181a was identified as a positive regulator of B lymphocyte differentiation 
[291]. miR-181a is also involved in thymic T cell differentiation, by defining the 
activation threshold of T cell receptors [295]. The miR-142s have also been 
demonstrated to be positive regulators of T cell differentiation [291]. miR-223 was 
identified as an essential modulator of granulocytic differentiation [296] . 
Collectively, these results demonstrate that miRNAs play critical roles in 
hematopoiesis. 
 Global downregulation of miRNAs was observed in antigen-induced T cell 
differentiation, suggesting that miRNAs are involved in the regulation of T cell 
responses [297]. Since activated T cells are metabolically active, it is thus 
plausible that downregulation of miRNAs is needed to allow the increased protein 
synthesis in these cells. These results also suggest that miRNAs may contribute to 
immune-mediated diseases known for inadequate T cell activation such as 
autoimmune conditions or chronic inflammation. 
miRNA	  and	  inflammatory	  diseases	  
As detailed above miRNAs has so far been shown to play an essential role 
in the development, homeostasis and function of both innate and adaptive 
immunity. Consequently the dysregulation of these processes can induce and be 
critical to inflammatory and autoimmune pathology. Table 1.5 summarises the 
current microRNA implicated in inflammatory and immune pathology. In an attempt 
to illustrate how microRNAs can regulate key signal pathways in inflammatory 
disorders I have chosen to focus on the role of miR155 in rheumatoid arthritis as I 
became involved with this work in the host laboratory during my PhD studies and it 
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was this that ultimately led to a hypothesis driven question concerning the role of 
miRNA in tendinopathy.  
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microRNA 
 
Disease 
 
 
Species 
 
References 
 
miR-155 
 
 
RA 
 
 
Human 
 
 
[298] 
miR-146a RA 
OA 
SLE 
Psoriasis 
 
Human [299] 
[300] 
[301] 
[302] 
miR-101 SLE 
 
Mouse [303] 
 
miR-21 Psoriasis 
Asthma 
 
Human 
Mouse 
[302] 
[304] 
miR-125b Psoriasis 
 
Human [302] 
miR-9 OA Human [305] 
    
miR-133a Asthma 
 
Human [306] 
miR-126 Cystic fibrosis Human [307] 
 
miR-203 
 
Peridontal Disease 
 
 
Human 
 
[308] 
 
 
Table 1-6 MicroRNAs involved in inflammatory and autoimmune diseases 
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microRNA Immune Function Transcriptional 
Target 
 
miR-16 
 
Binds to UA rich elements in the 30 
UTR and induces TNFα mRNA 
 
TNFα 
miR-17-5p In combination with miR-20a and 
miR-106a inhibits monocyte 
proliferation, 
AML-1 
miR125b Expression downregulated by LPS 
and oscillations in expression after 
NFkB 
TNFα 
miR-146b LPS induced expression induced in 
macrophages IRAK1 
TRAF6 
miR-155 Increased expression following 
activation of the innate immune 
response. 
AP-1 
miR-181a Positive regulator of B-cell 
development and CD4+ T-cell 
selection 
 
miR-17-92 Regulates pro- to pre- transition 
during B- and T-cell development 
PTEN 
 
Table 1-7 MicroRNAs involved in immune cell regulation
88	  
miRNA	  155	  in	  rheumatoid	  arthritis	  	  
miR-155 is the first miRNA whose function was investigated in transgenic 
mouse models and it is one of the best characterized microRNAs. To date, more 
than 130 articles have been published about miR-155. In vitro and in vivo studies 
implicated miR-155 in various immune functions involving innate as well as 
adaptive immune responses and the development of immune cells. Moreover, 
miR-155 has also been shown to be associated with several malignancies and it 
functions as an oncogene [309, 310]. However, miR-155 has all the characteristics 
that represent difficulties when trying to identify the function of a miRNA: it is 
expressed in many cell types and seems to have a different function and 
regulation in those, it has multiple targets that are regulated in a cell-type-specific 
manner, and it has relatively modest effects on the biological functions it has been 
associated with so far.  
 Two independent groups initially generated miR-155 knockout mice and 
showed the essential role of miR-155 in both B and T cell responses [291, 311]. 
Rodriguez et al. observed that miR-155-deficient mice had defects in dendritic 
cell–T cell interactions and  that T cells from miR-155-null mice displayed an 
increased tendency to differentiate into Th2 type cells when activated in vitro, as 
indicated by Th2-type cytokine and chemokine production. Most importantly, 
vaccination of miR-155-null mice with live attenuated vaccine against Salmonella 
typhimurinum failed to protect them against challenge with virulent Salmonella 
demonstrating that miR-155 is indispensable for normal adaptive immune 
responses [311]. Subsequently Thai et al. reported that miR-155 is required for 
germinal centre response. While miR-155-null mice developed fewer and smaller 
germinal centres in response to antigenic challenge in comparison to control mice 
[291], mice ectopically expressing miR-155 developed more and larger germinal 
centres with more class-switched antibody [291]. 
 Given the aberrant expression of miR-155 in RA patients we sought to 
focus on the functional contribution of miR-155 in clinical and experimental arthritis 
models. In situ hybridization revealed that miR-155 was strongly expressed in RA 
but not OA synovial biopsies, mainly in the lining layer and to a lesser extent in the 
sublining layer. Double immunofluorescence staining showed that miR-155 was 
expressed in a majority of CD68+ macrophages in the RA membrane lining. The 
increased expression of miR-155 in SF CD14+ cells was associated with lower 
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expression of the miR-155 target, SHIP-1, an inhibitor of inflammation. Similarly, 
SHIP-1 expression was decreased in synovial lining layer CD68+ cells in RA 
patients, compared to OA patients. Over-expression of miR-155 in PB CD14+ cells 
led to down-regulation of SHIP-1 and an increase in the production of pro-
inflammatory cytokines. Conversely, inhibition of miR-155 in RA synovial CD14+ 
cells reduced TNF-α production. Finally, miR-155-deficient mice are resistant to 
collagen-induced arthritis, with profound suppression of antigen-specific Th17 cell 
and autoantibody responses, and markedly reduced articular inflammation. The 
data produced from this study identified an unrecognized role of miR-155 in clinical 
and experimental arthritis.  
miRNA	  and	  tendinopathy	  
The above work was an obvious catalyst for me to investigate a possible 
role for miRNA regulation of cytokine and matrix dysregulation in tendinopathy. 
Whilst to date no work exists on the role or presence of miRNA in tendon disease 
some recent work in other disease processes where collagen changes 
predominate are pertinent. 
Dermal fibroblasts are critical components of the wound healing process, 
responsible for collagen and proteoglycan production in the remodelling phase. 
They regulate the activity of other key players in tissue repair by secreting growth 
factors promoting chemotaxis, cell proliferation, and angiogenesis [312]. Using 
expression profiling with miRNA micro assays, Gu and Lyer [313] analysed the 
alterations in miRNA expression in dermal fibroblasts during transition from 
quiescence to proliferation. A cluster of 33 miRNAs were identified, which were 
induced by both serum and fibroblast growth factor early in proliferation, 
suggesting the involvement of miRNAs in regulating the expression of genes 
important for the re-entry of fibroblasts in the cell cycle and for fibroblast 
proliferation. miRNA expression also correlated with the expression of genes 
encoding early transcription factors, including c-Myc, SRF, JUNB, EGR2 and 
EGR3. 
Transforming growth factor (TGF)-β isoforms are secreted by platelets, 
fibroblasts, and macrophages at the site of injury and act in various capacities, 
influencing keratinocyte, fibroblast and inflammatory cell action [314]. The effects 
of TGFβ are widespread in morphogenesis and adult tissue homeostasis, and 
specific miRNAs have emerged as key modulators of TGFβ signalling in several 
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cellular processes. miR-17-92, miR-24, and miR-224 have been implicated in 
TGFβ-mediated apoptosis [315], differentiation [316], and proliferation [317], 
respectively. Because of their effects on wound fibroblasts, TGFβ isoforms are key 
mediators of post-injury scar formation [318, 319], and emerging evidence 
supports miRNA involvement in TGFβ-mediated collagen synthesis and regulation 
of ECM [320-322]. 
Most relevant to this thesis however has been the very recent implication of 
miRNA in the regulation of collagen synthesis. Ogawa and colleagues [323] were 
the first to implicate mir29b as a suppressor of type I collagen at the mRNA and 
protein level via its direct binding to Col1A1 3'UTR. miR-29b also had an effect on 
SP1 expression suggested that miR-29b is involved in the regulation of type I 
collagen expression by interferon-alpha in hepatic stellate cells. Maurer and 
colleagues [324] then suggested mir 29 as a key regulator in collagen expression 
in systemic sclerosis. They found that miR-29a was strongly down-regulated in 
SSc fibroblasts and skin sections as compared with the healthy controls. 
Overexpression in SSc fibroblasts significantly decreased, and accordingly, 
knockdown in normal fibroblasts increased, the levels of messenger RNA and 
protein for type I and type III collagen. They suggest miR-29a as a 
posttranscriptional regulation of collagen and as such a therapeutic target in SSc. 
Thus although we are still in the preliminary stages of this area of research, 
there is convincing evidence available so far that miRNA provide a means to 
understanding the physiologic and pathologic processes in dysregulation matrix 
production which may ultimately translate into novel therapeutic approaches.  	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1.6) Aims of this Work 
 In this work I sought to define the role for inflammatory and regulatory 
cytokines in tendon disease with a focus on the novel entities IL-17 and IL-33. 
Further I sought to define their effector biology and to thereafter investigate the 
regulation of cytokine production in tendinopathy paying particular attention to 
hypoxia and post transcriptional microRNA biology.   
  Therefore, the ultimate aim of these studies was to generate new leads 
and novel ideas about several facets of tendon healing, with the intention of 
identifying new areas of research in the field with potential to be of interest in the 
future. 
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Chapter 2 Material and Methods 	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2.1) General reagents & buffers 
Materials	  and	  reagents	  
General chemicals: All chemicals were purchased from Sigma (Dorset,UK) 
unless otherwise stated. 
Plastics: All plastics used for cell culture were purchased from Corning and Gibco 
unless otherwise indicated. 
 
Buffers	  and	  culture	  media	  
Complete media: Basic media: RPMI1640, DMEM or IMEM 
plus10% heat inactivated foetal bovine calf serum, Penicillin (100 units/ml), 
Streptomycin (100 µg/ml) and L-Glutamine (2mM) (all at final concentration from 
Invitrogen). 
PBS: Phosphate buffered saline was purchased from Invitrogen. 
Tris-acetate-EDTA (TAE) buffer: 50x stock: 242 g of Tris base in 750 ml dH2O. 
Mixed with 57.2 ml glacial acetic acid and 100 ml 0.5 M EDTA (pH 8.0). Final 
volume was made up to 1000 ml with dH2O. Buffer was used at 1x concentration. 
TBS Tween (TBST): 10x TBS buffer was made using: 876.6 g NaCl, 121.1 g Tris, 
40 ml HCl and adjusted to pH pH 8.0. 10x solution was diluted 1:10 with dH2O and 
0.05% Tween added. 
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2.2) Patients 
South East Sydney Area Research Ethics Committee granted approval for 
sampling of shoulder tendon biopsies for cytokine and inflammation analysis in 
June 2004. Patients with rotator cuff tears or shoulder instability, who were greater 
than 18 years of age and capable of providing informed consent, were invited to 
take part in the project. Such patients were identified from the Orthopaedics 
Clinics in St George Orthopaedic Research Institute, Sydney Australia under the 
guidance of our collaborator Professor George Murrell. Tonsils were used as 
control tissue and were obtained by Mr Simpson, Stobhill Hospital, Glasgow. 
Demographic data were collected and stored in a password-protected database 
and samples were blinded to the researchers.  
 
Ethics Approval 
All procedures and protocols were approved by the South east Area 
Sydney Ethics Committee under ACEC No. 99/101 for collection of human 
supraspinatus and subscapularis tissue. Tissue for explant culture was obtained 
following patient informed consent to use any residual tendon tissue not utilised at 
the time of surgery under the NHS Greater Glasgow Residual Tissue consent 
procedures which is a Pan Glasgow Ethics facility.  
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2.3) Tendon explant biopsy 
	  
Patients between 18 and 25 years of age undergoing arthroscopic anterior 
cruciate ligament reconstruction using an autograft hamstring tendon graft were 
identified in the Orthopaedic department (Mr William J Leach and Mr Brian P 
Rooney), Western Infirmary, Glasgow prior to surgery . Having identified a suitable 
patient informed consent was sought to use any residual tendon tissue not utilised 
at the time of surgery under the NHS Greater Glasgow Residual Tissue consent 
procedures. During arthroscopic knee surgery performed under general 
anaesthesia a standard hamstring graft was obtained. The hamstring tendon used 
for a reconstruction often comes from one of the medial hamstrings, the 
semitendinosus or semimembranosus. The semitendinosus is most commonly 
used, because of its easily accessible insertion at the medial tibia. The tendon is 
harvested from an anterior-medial incision, and the tissue is dissected down to the 
tendon / bone interface (Figure 2-1).A tendon stripper is used to remove the 
tendon. Once the tendon is removed, it is folded over itself twice, producing a graft 
that is 4 layers thick. Following placement in the knee the standard hamstring 
tendon graft is cut flush to the bone and residual tendon is normally disposed of 
(Figure 2-1). It is this residual tendon, which was used for explant culture to 
establish tenocyte cultures.     
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Figure 2-1 Illustration of  protocol for tendon explant tissue.  
(A) Graft site highlighted illustrates the normal anatomical position of the semitendinosus 
or semimembranosus tendons used in hamstring ACL reconstruction. (B) Surgical incision 
on the anteromedial aspect of the knee joint is used to access the insertion site of the 
tendons. A tendon stripper is then used to retrieve these tendons for use as graft material. 
(C) The tendons are folded over making a ‘four strand’ section. Area highlighted with black 
arrow is excess surgical tissue and it is this section which is used for explant culture. 
C B A 
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2.4) Tissue preparation  
 For cell harvest, explant tissue was transferred to complete medium and 
cultured at 37oC in 5%CO2/95% O2 to generate fibroblast-like tenocytes (FLT) 
following prolonged incubation and passage of cells. 
 
Paraffin	  embedded	  tissue	  
 Tissue sections were prepared and stored for future analysis of tissue 
protein e.g. cytokine expression by immunohistochemistry (IHC). For paraffin 
embedded sections, tissue was stored in formalin for 24 h and transferred to 70% 
ethanol to retard the fixation process. Tissues were paraffin embedded and 
subsequently cut to thickness of 5 µm. A minimum of 2 sections were mounted on 
one slide to facilitate isotype staining on the same slide in IHC protocols. For back-
to-back sections, single sections were mounted on a slide with the next section 
being used on a different slide having the same surface in common. Sections for 
isotypes were added subsequently. Haematoxylin and eosin (H&E) staining was 
performed on one of the serial sections to allow tissue morphology to be 
assessed.  
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2.5) Immunohistochemistry (IHC) of paraffin embedded sections 
Single	  staining	  for	  light	  microscopy	  
 Sections were prepared as previously mentioned (Section 2.4). Slides 
containing paraffin embedded sections were heated to 65°C for 35 minutes 
followed by dewaxing in xylene and rehydration through ethanol to TBS Tween 
(TBST). Endogenous peroxidase activity was blocked using H2O2/methanol 
(5%/95%). To expose the relevant antigen, sections were then microwaved in 
0.5M citrate buffer, pH 6 for 8 min. The sections were blocked for 1 h at RT in 
2.5% serum TBST of the species in which the secondary antibody was raised. The 
relevant primary antibody was applied overnight at 4°C 2.5% serum TBST (see 
working concentrations and companies in Table 2-1, page 100). The following day 
the sections were washed with TBST, incubated with relevant secondary antibody 
for 30 minutes in 5% horse serum containing TBST, washed twice with TBST then 
incubated with substrate Vector ABC (Vector, Peterborough, UK) for 30 minutes. 
Sections were washed twice with TBST before developing with 0.6mg/ml 3,3’-
diaminobenzidine tetrahydrochloride (DAB) (Sigma) with 0.01% H2O2 for up to 5 
min at RT until brown reaction product was apparent. Sections were then washed 
in water and counterstained using Harris’s haematoxylin (BDH Ltd. Lutterworth, 
Leicester, UK). Finally sections were dehydrated in ethanol, cleared in xylene and 
finally mounted in DPX mountant (both from BDH Ltd.). 
 Alternatively, the second day staining protocol was altered by using the 
ImmPRESS kit (Vector) in which sections were incubated with a species specific 
polymer for 30 min replacing the secondary antibody. Sections were washed with 
TBST and then developed with ImmPACT DAB (Vector) for up to 2 mins. Further 
staining of the sections was carried out as described above. 
  
Double	  staining	  for	  light	  microscopy	  
 Similar to single staining the 0.5% hydrogen peroxidase/methanol 
incubation and heat retrieval in 0.5M citrate buffer (pH 6) was followed by 
incubation in 2.5% species/2.5% human serum with AvidinD (4 drops/ml) (Vector 
Laboratories, Petersborough, U.K.). Surface expression of CD68 was detected by 
staining with a mouse anti-CD68 antibody in the presence of Biotin (4 drops/ml, 
Vector) in 2.5% horse serum TBST for 1 h at RT, 2 washes with TBST, followed by 
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a biotinylated secondary antibody for 30 min (1:200; Vector Laboratories). The 
reaction was developed using VIP. Following incubation for 1 h in 2.5% 
species/2.5% human serum, goat anti–IL-17 in TBST was added overnight at 4°C. 
On the following day sections were washed with TBST, and then incubated with a 
biotinylated antibody for 30 min and stain developed using either DAB or Nickel-
DAB. The chosen counterstain for DAB was methyl green whereas Nickel-DAB 
sections were left unstained. Sections were washed dH2O, dehydrated in serial 
ethanol (from 70%, 90% to 100%), cleared in xylene and mounted in DPX. 
 
Double	  staining	  for	  fluorescent	  microscopy	  
 Sections were prepared as described above. For double immunofluoroscent 
staining ten paraffin embedded samples were incubated  for 1 h with Abs (mouse 
anti-CD3 [1.25 µg/ml; Vector Laboratories], mouse anti-CD4 [7.56 µg/ml; Dako 
UK, Cambridgeshire, U.K.], mouse anti-mast cell tryptase [MCT] [0.43 µg/ml; Dako 
UK], or mouse anti-CD68 [1 µg/ml; Dako UK]) followed by 30 min incubation with 
biotinylated Abs (1:200; Vector Laboratories) with subsequent staining with 
streptavidin DyLight Fluor  (1:500; Invitrogen, Paisley, U.K.) for 45 min. Goat anti–
IL-17 (5 µg/ml; R&D Systems, Abingdon, U.K.) was added overnight at 4°C, then 
incubated with a biotinylated Ab for 30 min, and stained with Avidin FITC (1:500; 
Vector Laboratories) for 45 min. Slides were mounted with Vectashield containing 
DAPI (Vector Laboratories) and analyzed on a fluorescent imaging microscope 
(BX50; Olympus, Essex, U.K.). Images were captured using Apple Open 
laboratory software. 
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Antibody	   Manufacturer	  
and	  clone	  
Source	   Working	  
Concentration	  
CD3	   Vector	   mouse	  monoclonal	   1.25 µg/ml	  
CD4	   Dako	   mouse	  monoclonal	   7.56	  µg/ml	  
MCT	  (Mast	  cell	  tryptase)	   Dako	   mouse	  monoclonal	   0.43	  µg/ml	  
Anti	  Histamine	  
	  (	  mouse	  mast	  cells)	  
Sigma	   rabbit	  polyclonal	   1	  µg/ml	  
CD34	   Vector	   mouse	  monclonal	   0.5	  µg/ml	  
CD68	   Dako	  clone	  PG-­‐M1	   mouse	  monoclonal	   1	  µg/ml	  
CD206	   R&D	  	   goat	  polyclonal	   5	  µg/ml	  
Collagen	  I	   Abcam	   mouse	  monoclonal	   2	  µg/ml	  
Collagen	  III	   Abcam	   mouse	  monoclonal	   13	  µg/ml	  
F4/80	   Serotec	   mouse	  monoclonal	   1	  µg/ml	  
IL-­‐17A	   R&D	   goat	  polyclonal	   5	  µg/ml	  
IL-­‐1RAcP	   ProSci	   Rabbit	  polyclonal	   1	  µg/ml	  
IL-­‐33	   Alexis	  (nessy-­‐1)	   mouse	  monoclonal	   5	  µg/ml	  
ST2	  
IL-­‐33	  
Sigma-­‐Aldrich	  R&D	   rabbit	  polyclonal	  mouse	  monoclonal	   1	  µg/ml	  10 µg/ml	  
Clusterin	   R&D	   Goat	  	   10	  µg/ml	  
HIF	  	   R&D	   rabbit	  polyclonal	   2 µg/ml 
BNIP-­‐3	   Abcam	   rabbit	  polyclonal	   2.5 µg/ml	  
VEGF	   Abcam	   mouse	  monoclonal	   20 µg/ml	  
Isotype	   various	   various	   various	  
Table 2-1 Antibodies for IHC 
Shown are surface marker or cytokine antibodies using in IHC. Left column shows antibody 
target, 2nd column manufacturer, 3rd the source and right column the working concentration. 
Dilutions were not mentioned as stock concentration of antibodies can vary. 
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Target molecule  Company 
human sST2 R&D systems 
human COL I Biosource 
human COL III Biosource 
mouse COL I Biosource 
mouse COL III  Biosource 
 
Table 2-2 ELISAs used and  respective companies 
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Quantification	  of	  fluorescent	  IHC	  
Images were captured digitally and the total number of IL-17A+, ST2+ and 
IL33+ found within duplicate tissue areas (two representative 10x fields) of 0.52 
mm2 was calculated. Double staining allowed the calculation of the proportion of 
IL-17A, ST2 or IL33 expressing cells per cell surface marker. Four tissues were 
double stained for all markers (mouse and human CD68 and MCT) with studies 
performed on a further 6 tissues to confirm the co-expression with MCT and CD68. 
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2.6) ELISA and Luminex cytokine analysis 
Cytokine expression was tested in culture supernatant. ELISAs were 
carried out according to the manufacturer’s protocol (summarized in Table 2-2) A 
25-Plex human cytokine assay performed on supernatants from cultured human 
tenocytes was performed according to manufacturers’ instructions. 
 
104	  
2.7) Signaling analysis 
 Phosphorylation status of mitogen-activated protein kinases (MAPKs), 
extracellular signal regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNKs) 
and p38 isoforms were evaluated using the Human Phospho-MAPK Array (R & D 
Systems Europe ,UK) as per the manufacturer's instructions. The ERK inhibitor 
(FR180204) and Atk inhibitor (1L6-Hydroxymethyl-chiro-inositol-2-(R)-2-O-methyl-
3-O-octadecyl-sn-glycerocarbonate) were purchased from CalbioChem (Merck 
KGaA, Germany) and used at IC50= 10µM, a concentration previously determined 
to offer optimal specific inhibition relative to off target effects which was used 
previously in our laboratory [244]. 
 Phosphorylation of NFΚβ p65 was assessed using the InstantOne ELISA in 
cell lysates from treated and untreated tenocytes. NF kappa B is a family of 
transcription factors with five members that includes Rel (c-Rel), RelA (p65), RelB, 
NFκB1 (p50 and its precursor p105), and NF kappa B2 (p52 and its precursor 
p100). NF kappa B dimers containing p65 are activators of transcription. In a 
majority of unstimulated cells, NF kappa B remains in its inactive form and is 
retained in the cytoplasm by the bound inhibitory IkB proteins. Upon stimulation by 
inducers such as TNFα, IkBa is phosphorylated and degraded. This results in the 
release of the NF kappa B complex from the IKK complex and the p105 subunit is 
cleaved into its active p50 form. Subsequently the p50/p65 translocates to the 
nucleus where it activates transcription of many genes, including its own inhibitor I 
kappa B alpha, causing an auto-regulatory mechanism of NF kappa B. The 
absorbance was measured at 450 nm by microplate reader with positive and 
negative controls supplied by the manufacturer. The relative absorbance of 
stimulated versus unstimulated cells was used to assess the total or 
phosphorylated NFΚβ p65 in each sample. 	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2.8) RNA extraction and Quantitative PCR analysis 
The cells isolated from the normoxic or hypoxic experiments were placed in  
Trizol prior to mRNA extraction. QIAgen mini columns (Qiagen Ltd, Crawley UK) 
were used for the RNA clean-up with an incorporated on column DNAse step as 
per manufactures instructions. RNA purity and concentration was assessed using 
the Nanodrop 2000 machine. cDNA was prepared from RNA samples according to 
AffinityScript™ (Agilent Technologies, CA, USA) multiple temperature cDNA 
synthesis kit as per manufactures instructions. SYBR green Real time PCR was 
performed using SYBR green mastermix (Applied Biosystems, CA,USA). Prior to 
setting up the SYBR green the cDNA was diluted 1 in 5 using RNase-free water. 
Each sample was analysed in triplicate. Primers (Integrated DNA Technologies, 
Belgium) used are shown in. Conventional PCR was undertaken to test the 
respective primers with cDNA from diseased synovial fibroblasts that were known 
to express many inflammatory genes. After ensuring a band was present the 
primers were again tested on the quantitative machine were melt curves were 
performed on all primers to ensure specificity.  
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Gene 
 
 
Primers 
 
Human IL-33 
 
 
Mouse IL-33 
 
 
Human ST2 
 
 
Human sST2 
 
 
 
 
Human ST2L 
 
 
 
 
Mouse sST2 
 
 
 
 
Mouse ST2L 
 
 
 
 
Heat shock protein 72 
 
GGAAGAACACAGCAAGCAAAGCCT (f) 
TAAGGCCAGAGCGGAGCTTCATAA (r) 
 
GGAAGAACACAGCAAGCAAAGCCT (f) 
TAAGGCCAGAGCGGAGCTTCATAA (r) 
 
ACAACTGGACAGCACCTCTTGAGT (f) 
ACCTGCGTCCTCAGTCATCACATT (r) 
 
GAGACCTGCCACGATTACAC (f) 
TGT TAA ACC CTG AGT TCC CAC (r) 
CCC CAC ACC CCT ATC CTT TCT CCT 
(probe) 
 
ACAAAGTGCTCTACACGACTG (f) 
TGTTCTGGATTGAGGCCAC (r) 
CCCCATCTGTACTGGATTTGTAGTTCC G 
(probe) 
 
TCTGCTATTCTGGATACTGCTTTC (f) 
TCTGTGGAGTACTTTGTT CAC C (r) 
AGA GAC CTG TTA CCTGGGCAAGAT G 
(probe) 
 
CCAATGTCCCTTGTAGTCGG (f)   
CTT GTT CTC CCC GCA GTC (r) 
TCC CCA TCT CCT CAC CTC CCT TAA T 
(probe) 
 
TGCTGGACAAGTGTCAAGAGGTCA (f) 
TCCTCTTGTGCTCAAACTCGTCCT (r) 
 
Heat shock protein 27 
 
AGACCTCAAACACCGCCTGCTAAA (f) 
TGCTCTGGACGTCTGCTCAGAAA (r) 
 
HIF-1α 
 
 
Col 3A Human 
 
 
 
 
TTGGCAGCAACGACACAGAAACTG (f) 
TTGAGTGCAGGGTCAGCACTACTT (r) 
 
TATCGAACACGCAAGGCTGTGAGA (f) 
GGCCAACGTCCACACCAAATTCTT (r) 
Col 3A Mouse 
 
 
COL 1A1 Human 
 
 
COL 1A1 Mouse 
 
 
Smac 
GCTTTGTGCAAAGTGGAACCTGG (f) 
CAAGGTGGCTGCATCCCAATTCAT (r) 
 
CCATGCTGCCCTTTCTGCTCCTTT (f) 
CACTTGGGTGTTTGAGCATTGCCT (r) 
 
TTCTCCTGGCAAAGACGGACTCAA (f) 
GGAAGCTGAAGTCATAACCGCCA (r) 
 
TGCTGGCCAAGTGACAAGACGTCA (f) 
CAAGGAGGCTGCCTCCCAATTCAG (r) 
 
 
 
 
Table 2-3 Quantitative PCR primers 
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2.8.1)	  RNA	  isolation	  and	  quantitative	  real	  time	  PCR	  analysis	  of	  miRNA	  
 Total RNA was isolated by miRNeasy kit (Qiagen). miScript Reverse 
Transcription Kit (Qiagen) was used for cDNA preparation. TaqMan mRNA assays 
(Applied Biosystems) or miScript primer assay (Qiagen) were used for semi-
quantitative determination of the expression of human miR-29a( MS  
(MS00001701) 29b (MS00006566) and c (MS00009303)  and mouse 29a 
(MS00003262), 29b(MS00005936) and c (MS00001379). The expressions of U6B 
small nuclear RNA or beta-actin were used as endogenous controls.  
2.8.2)	  miRNA	  transfection	  	  
 Cells were transfected with synthetic precursors miRNA (pre-miR) for miR 
29 a&b or with negative controls (pre-miR mimic negative labelled control, Thermo 
Scientific Inc ) at a final concentration of 20nM with the use of Dharmacon® 
DharmaFECT® 3 siRNA transfection reagents (Thermo Scientific Inc). At 48 hours 
after transfection cellular lysates were collected to analyse the expression of 
genes of interest. 
Transfection efficiency was assessed by flow cytometry using the labelled D547 
mimic and confirmed by quantitative PCR of control scrambled mimic and the 
respective miR29 family mimic. 
2.8.3)	  Luciferase	  reporter	  assay	  for	  targeting	  Collagen	  I	  &	  III	  and	  soluble	  ST2	  
The human 2 miRNA target site was generated by annealing the oligos: for 
COL I & III and soluble ST2 3’UTR’s which were cloned in both sense and anti-
sense orientations downstream of the luciferase gene in pMIR-REPORT luciferase 
vector (Ambion). These constructs were sequenced to confirm inserts and named 
pMIR-COL I/COL III/ sST2-miR29a/b/c and pMIR(A/S)- COL I/COL III/ sST2-
miR29a/b/c, and used for transfection of HEK293 cells. HEK293 cells were 
cultured in 96-well plates and transfected with 0.1 µg of either pMIR-COL I/COL III/ 
sST2-miR29a/b/c, pMIR(A/S)- COL I/COL III/ sST2-miR29a/b/c or pMIR-REPORT, 
together with 0.01 µg of pRL-TK vector (Promega) containing Renilla luciferase 
and 40 nM of miR-155 or scrambled miRNA (Thermo Scientific Dharmacon®). 
Transfections were done using Effectene (Qiagen) according manufacturer’s 
instructions. Twenty-four hours after transfection, luciferase activity was measured 
using the Dual-Luciferase Reporter Assay (Promega). 
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2.9) Matrix regulation analysis 
 Tenocytes were evaluated for immunocytochemical staining of Collagen I, 
and Collagen III (Abcam, Cambridge UK) to assess tenocyte matrix production. 
Total soluble collagen was measured from cell culture supernatants and from 
digested mouse tendon samples using the Sircol assay kit (Biocolor Ltd, 
Carrickfergus, Northern Ireland) according to the manufacturer's protocol. 1 ml of 
Sircol dye reagent was added to 100 µl test sample and mixed for 30 min at room 
temperature. The collagen-dye complex was precipitated by centrifugation at 
10,000 × g for 10 min; and then washed twice with 500 µl of ethanol. The pellet 
was dissolved in 500 µl of alkali reagent. The absorbance was measured at 540 
nm by microplate reader. The calibration curve was set up on the basis of collagen 
standard provided by the manufacturer. Additionally the concentration of human 
and mouse Collagen I and III was assessed using ELISA with colour change 
measured at 450 nm by microplate reader along with standards supplier by the 
manufacturer (USCNK Life Science Inc).  
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2.10) Cell culture 
Culture	  of	  adherent	  cells	  
Primary tenocytes, were cultured in tissue culture flasks with appropriate 
complete media (RPMI,) and split when cells reached 80% confluence. 
Detachment of cells was achieved by incubation with 0.5 – 1 ml 5% trypsin in PBS 
for 5 min. Trypsinization was stopped by adding media containing 10 % FCS, cells 
were washed, counted and reseeded to a final concentration of 105/ml.  
 
Culture	  in	  Hypoxic	  conditions	  
The tenocyte cells were filtered through nylon mesh, and were plated at 1 × 
106/ml into 75 cm2 culture flasks (BD Falcon, Leuven, Belgium) under normoxic 
(21% oxygen) or hypoxic (1% oxygen) conditions using an air-tight hypoxic 
incubator with inflow and outflow valves (Wolf Laboratories Limited, York, UK). 
Oxygen concentrations were continuously measured with a built-in oxygen sensor 
and the percentage of oxygen was adjusted by addition of nitrogen. To ensure 
these conditions were reflective of hypoxia cell lysates were then analysed at 24 
and 48 hours by quantitative PCR to ensure upregulation of HIF-1α. 	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2.11) FACS analysis 
The expression of ST2 on cultured human tenocytes was analysed by 
FACS. To this end 0.5 x 106 cells were washed and unspecific antibody binding to 
Fc-receptors was block by incubating cells with 50 µl Fc-Block (Sigma) for 15 min. 
5 µl of anti-ST2 FITC were added and incubated for 15 min at RT in the dark. Cells 
were washed with PBS EDTA and analysed using a FACS calibur machine (BD). 
To test cell death of tenocytes due to both recombinant cytokine and hypoxic 
conditions cells were stained with Annexin-V and 7-AAD (Apoptosis kit, BD 
biosciences) according to manufacturer’s instructions. FACS data were analysed 
using FlowJo software (TreeStar). 
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2.12) Animals 
 Mice were maintained at the Central Research Facility, University of 
Glasgow. All animal experimentation and husbandry was under the authority of a 
UK Government Home Office Project License. All protocols were approved by the 
Glasgow University local Ethical Review Panel. Normally, mice were used at the 
age of 10- 12 weeks and were age-matched for each independent experiment. 
Control mice(BALB/c) were bought from Charles River.  ST2-/- mice were kindly 
provided by Prof McKenzie (Cambridge) and Prof Liew (Glasgow). 
Patellar	  tendon	  injury	  model	  
In preparation for the surgical procedure, mice were anesthetised with a 
mixture of isofluorane (3%) and oxygen (1%) and both hind limbs were shaved. 
During the surgical procedure, anaesthesia was delivered via a nose cone with the 
level of isofluorane reduced to 1% with the oxygen. Following a skin incision, two 
cuts parallel to the tendon were made in the retinaculum on each side, a set of flat 
faced scissors were then placed underneath the patellar tendon. With the scissor 
blades serving as a support, a 0.75mm diameter biopsy punch (World Precision 
Instruments) was used to create a full thickness partial transection in the right 
patellar tendon. The left patellar tendon underwent a sham procedure, which 
consisted of only placing the plastic backing underneath the tendon without 
creating and injury. The skin wounds were closed with skin staples and the mice 
were sacrificed at 1 day, 3 days 7 and 21 days post-surgery. Mice were sacrificed 
by CO2 inhalation and immediately weighed. Mice from two groups BALB/c control 
(CTL) and ST2-/- BALB/c were used. Each group contained 30 mice (n=30 ST2-/- 
BALB/c and 30 BALB/c). This set experiments was repeated on two separate 
occasions. 
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Figure 2-2 Mouse patellar tendon model 
(A) Images of various steps in surgical protocol. (1) Exposure of patellar tendon, (2) 
Dissection of retinaculum and placement of dissecting scissors behind patellar tendon, (3) 
placement of 0.75mm biopsy punch over midportion of patellar tendon and (4) post injury 
with small defect left in midportion of tendon.   
(B) Timeline for patellar tendon model. n=30 mice per group, 30 ST2-/- Balb/c and 30 Control 
Balb/c with 6 mice culled in each group on Day 1,3,7 and 21 post injury. On each cull day 
tendon was dissected and used in biomechanical (n=3), Histological/ Immunohistochemical 
(n=2) and quantitative PCR (n=2)
A 
B 
1 2 
3 4 
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  Biomechanical	  analysis	  
 For the biomechanical analysis, the patellar tendons of mice from each 
group were injured and three mice sacrificed at one of four time points for 
mechanical testing as described previously by Lin et al [132]. Briefly, the patellar 
tendons were dissected and cleaned, leaving only the patella, patellar tendon and 
tibia as one unit. Tendon width and thickness were then quantified and cross 
sectional area was calculated as the product of the two. The tibia was the 
embedded in Isopon p38 (High Build Cellulose Filler) in a custom designed fixture 
and secured in place in a metal clamp. The patella was held in place by vice grips 
used with the BOSE ElectroForce® 3200 test instrument. Each tendon specimen 
underwent the following protocol immersed in a 370C saline bath – reloaded to 
0.02N, preconditioned for 10 cycles from 0.02 to 0.04 at a rate of 0.1%/s 
(0.003mm/s), and held for 10s. Immediately following, a stress relaxation 
experiment was performed by elongating the tendon to a strain of 5% (0.15mm) at 
a rate of 25% (0.75mm/s), followed by a relaxation for 600s. Finally a ramp to 
failure was applied at a rate of 0.1%/s (0.003mm/s). From these tests, maximum 
stress was determined and modulus was calculated using linear regression from 
the near linear region of the stress strain curve. 
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Figure 2-3 Biomechanical testing apparatus.  
(A) Image of patella, patellar tendon and tibia complex embedded in Isopon cellular filler 
prior to mechanical testing, (B) BOSE ElectroForce® 3200 test instruments feature with 
saline bath at 370C and (C) image of mounted patellar tendon and tibia in saline bath prior to 
testing
A B 
C 
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Cytokine	  injection	  model	  	  
 To test if IL-33 induces tendon matrix dysregulation a cytokine injection 
model was established. IL-33 was tested in a previously reported model initially 
described for the application of IL-23 or IL-22 [325, 326]. ST2-/- mice (n = 
6/group/treatment/experiment) were injected i.p. daily with IL-33 (0.2 µg per 
mouse diluted in 100 µL PBS) on days-3, -2, -1 and the day of injury. 24 hours 
following the final injection mice the cull protocol was followed (Figure 2-4).Control 
mice similarly received an equal volume of PBS.   
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Figure 2-4  Overview of the mouse injection model.  
(A) Injection of recombinant IL-33. n=16 mice per group, ST2-/- Balbc and Control Balbc. 6 
mice culled in each group on days 1,3, and 7 post injury. 	  
A 
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2.13 Statistical analysis 
The statistics used in each chapter are summarised below :-  
 
Chapter 3  
Results are reported as mean values ± SEM. Comparisons between groups 
were made with two-way paired Student's t tests (parametric), Mann Whitney U 
tests (non-parametric) and Kruskal-Wallis One Way Analysis of Variance on 
Ranks, using Graph Pad Prism 5 software. A power analysis was performed with 
the beta error set at 0.2 (power = 0.8) as previously described. Based on the 
results of the power analysis, it was determined that each group required 10 tissue 
samples to detect a difference of 20% between each of the groups with regard to 
inflammatory cell subset expression. Pearson’s correlation coefficient was used to 
calculate the relationship between inflammatory infiltrate and rotator cuff tear size. 
In addition the inter rater reliability of our Modified Bonar score was calculated 
using intraclass correlation calculation (Graph pad Prism) with five independent 
observers between two international centres. 
 
Chapter 4 
Results are reported as mean values ± SEM/SD. Comparisons between 
groups were made with two-way paired Student's t tests, Mann Whitney U tests 
and Kruskal-Wallis One Way Analysis of Variance on Ranks, using Graph Pad 
Prism 5 software. Statistics reported on real time PCR data represent the mean of 
each experiment repeated in triplicate and then the pooled mean of n=3 or 5 
depending on the experiment undertaken (see figure legends). Once again a 
similar power analysis to chapter 3 was performed requiring a minimum of 10 
tissue samples to detect a 20% difference in hypoxic markers. Pearson’s 
correlation coefficient was used to calculate the relationship between hypoxic cell 
markers, inflammatory infiltrate and rotator cuff tear size. 
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Chapter 5 
 Results are reported as mean values ± SEM/SD. Comparisons 
between groups were made with two-way paired Student's t tests, Mann-Whitney 
U tests and Kruskal-Wallis One Way Analysis of Variance on Ranks, using Graph 
Pad Prism 5 software. Analysis of IL-17 and immune cell staining was using the 
pooled mean of ten HPF per patient sample.  Statistics reported on real time PCR 
data represent the mean of each experiment repeated in triplicate and then the 
pooled mean of n=3 or 5 depending on the experiment undertaken (see figure 
legends).  
 
Chapter 6 
 Once again results are reported as mean values ± SEM/SD. 
Comparisons between groups were made with two-way paired Student's t tests, 
Mann Whitney U tests and Kruskal-Wallis One Way Analysis of Variance on 
Ranks, using Graph Pad Prism 5 software. Analysis for IL-33/ST2/IL-1RAcP 
immunostaining was using the pooled mean of each samples mean of ten high 
powered fields microscope examination. Statistics reported on real time PCR data 
represent the mean of each experiment repeated in triplicate and then the pooled 
mean of n=3 or 5 depending on the experiment undertaken (see figure legends). 
Analysis of mouse biomechanical data was based on the pooled mean of 3 or 4 
mice depending on the experiment (See figure legend).   
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Chapter 3 Inflammation in human tendinopathy 
 
Content of this chapter has been published in the following manuscripts: 
 
Millar NL, Hueber AJ, Reilly JH, Xu Y, Fazzi UG, Murrell GA, McInnes IB. 
Inflammation is present in early human tendinopathy. 
Am J Sports Med. 2010 Oct;38(10):2085-91. 
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3.1) Aim and introduction 
 Overuse tendon injuries, namely tendinopathies, pose a significant problem 
in sports and exercise medicine [327]. The intrinsic pathogenetic mechanisms 
underlying the development of tendinopathies are largely unknown and debate 
remains as to whether inflammatory processes play a prominent role in the 
disease process [328]. Empirically, by dint of the ‘danger hypothesis’ [329], innate 
immune mechanisms should subserve, prima fasciae, core effector biology upon 
early damage mediated by biomechanical stress. Historically, ‘tendinitis’ was used 
to describe chronic pain from a symptomatic tendon [330] implying that 
inflammation was a central pathological process. However, traditional treatment 
modalities aimed at modulating inflammation have enjoyed limited success [331, 
332].  Histological studies that focussed on symptomatic (late) biopsy components 
reveal few or absent inflammatory cells but rather implicated substantial 
degenerative changes comprising hypoxia, hyaline, mucoid or myxoid 
degenerations in over 85% of biopsy specimens [333, 334]. 	  
 In contrast to the foregoing, recent studies implicate an early, important 
inflammatory component in disease processes. Molloy et al [74] performed 
microarray studies on a running rat supraspinatus tendinopathy model and 
showed upregulation of key inflammatory cell receptors and immunoglobulin’s. 
Barbe and colleagues [335] using a cumulative trauma disorder rodent model 
showed increased infiltrating macrophages compared to controls. Human tissue 
biopsy samples from small rotator cuff tears taken at the time of surgery show a 
significant inflammatory infiltrate, consisting of macrophages and mast cells, 
compared to larger tears reflecting a more degenerative picture [66].    
 One of the major limitations of human studies is that tendon biopsies are 
usually obtained when patients are symptomatic and therefore biopsy material is 
likely to represent chronic, rather than early phase tendinopathy. We previously 
suggested that matched subscapularis tendon from patients with full thickness 
rotator cuff tears may be a model of early human tendinopathy based on 
histological appearances and significantly increased levels of cytokines and 
apoptotic markers in these tissues [137]. The purpose of this part of my thesis 
was to formally characterize inflammatory cell subtypes within this putative 
model.  
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3.2) Inflammatory staining in human tendinopathy 
 Twenty supraspinatus tendon samples were collected from patients with 
rotator cuff tears undergoing shoulder surgery (Table 3-1). The mean age of the 
rotator cuff ruptured patients was 57 years (range, 39-75 years) - the mean tear 
size was 2.8cm2. Samples of the subscapularis tendon were also collected from 
the same patients. Patients were only included if there was no clinically detectable 
evidence of subscapularis tendinopathy on a preoperative MRI scan or 
macroscopic damage to the subscapularis tendon at the time of arthroscopy – by 
these criteria they represented a truly pre-clinical cohort. An independent control 
group was obtained comprising 10 samples of subscapularis tendon collected from 
patients undergoing arthroscopic surgery for shoulder stabilization without rotator 
cuff tears. The absence of rotator cuff tears was confirmed by arthroscopic 
examination. The mean age of the control group was 35 years (range, 20-41 
years). 
We obtained specimens through arthroscopic repair of the rotator cuff which 
was carried out using the standard three-portal technique as described by Xu el al 
[336]. The cross-sectional size of the rotator cuff tear was estimated and recorded 
as described previously [337]. The subscapularis tendon was harvested 
arthroscopically from the superior border of the tendon 1 cm lateral to the glenoid 
labrum. The supraspinatus tendon was harvested from within 1.5 cm of the edge 
of the tear prior to surgical repair (Figure 3-1) . For immunohistochemical staining 
the tissue samples were immediately fixed in 10% (v/v) formalin for 4 to 6 hours 
and then embedded in paraffin. Sections were cut to 5µm thickness using a Leica-
LM microtome (Leica Microsystems, Germany) and placed onto Superfrost Ultra 
Plus glass slides (Gerhard Menzel, Germany). The paraffin was removed from the 
tissue sections with xylene, rehydrated in graded alcohol and used for histological 
and immunohistochemical staining per previously stated methodologies [338].  
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Table 3-1 Patient demographics and rotator cuff tear size  
 
Tear Size 
 
 
Control 
 
Small 
(<1cm2) 
 
Medium 
(>1-3cm2) 
 
Large  
(>3-5cm2) 
 
Massive  
(>5cm2) 
 
Number of cases 
 
 
10 
 
6 
 
7 
 
4 
 
3 
 
Mean age in  
years(range) 
 
 
35 (20-41) 
 
51 (39-60) 
 
57 (48-64) 
 
55 (47-60) 
 
63 (50-75) 
 
Mean duration of 
symptoms in 
months (range) 
 
 
 
8.3 (1-14) 
 
 
7.8 (2-18) 
 
 
7.0 (3-13) 
 
 
8.8 (4-22) 
 
 
6.3 (2-15) 
 
Mean number of 
steroid injections 
 
 
0 
 
1.2 
 
1.6 
 
1.5 
 
1.8 
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Figure 3-1 Anatomical locations of biopsied tendon.  
Area A shows the torn edge of supraspinatus which is obtained at time of surgery. In the 
same patient a biopsy is taken from Area B, the matched subscapularis tendon, which has 
no changes on MRI and looks macroscopically normal at the time of arthroscopy. Control 
tendon is taken from a separate cohort of patients with no rotator cuff tear. These patients 
have a biopsy of area B taken at the time of instability surgery. (Reproduced with 
permission from Professor George Murrell, Orthopaedic Research Institute, Sydney 
Australia) 
A	  
B	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3.2.1)	  Establishment	  of	  human	  'model'	  of	  tendinopathy	   	  
 Sections were stained with haematoxylin and eosin and toluidine blue for 
determination of the degree of tendinopathy as assessed by a modified version of 
the Bonar score [339] (Grade 4= marked tendinopathy, Grade 3 = advanced 
tendinopathy, 2= moderate degeneration 1= mild degeneration 0 = normal 
tendon). This included the presence or absence of oedema and degeneration 
together with the degree of fibroblast cellularity and chondroid metaplasia. We 
have previously described a novel ‘early human model’ of tendinopathy based on 
surprising findings when investigating the histology of matched subscapularis 
tendon samples [340]. We used the same biopsy techniques and scoring system 
as utilized in this previous study. 
 All torn supraspinatus samples showed Grade 4 changes consistent with 
marked degeneration, mucoid change and frank chondroid metaplasia. The 
massive tears had reduced fibroblast cellularity and greater chondroid metaplasia 
compared to all other tears (p<0.05).  Despite their normal MRI and arthroscopic 
appearances, matched subscapularis tendon showed Grade 2-3 changes 
indicative of moderate-advanced tendinopathy (Figure 3-2). All control samples 
were classified as Grade 1 consistent with normal fibrotendinous tissue with large 
distinct collagen fibrils. There were no significant correlations between Bonar 
score [339] and the mean duration of symptoms or age of the patient cohort. 
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Figure 3-2 Bonar histological scoring for tendon biopsies.  
The majority of torn tendons showed classical features of advanced to marked 
tendinopathy. Subscapularis tendon showed mainly features of mild-moderate tendon 
disease in keeping with an ‘early model’ of tendinopathy. Bonar score Grade 4= marked 
tendinopathy, Grade 3 = advanced tendinopathy, 2= moderate degeneration 1= mild 
degeneration 0 = normal tendon.  
TSup= Torn Supraspinatus, MSub =Matched Subscapularis tendon, Ctl= Control tendon. 
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3.2.2)	  Early	  human	  tendinopathy	  shows	  an	  increased	  inflammatory	  infiltrate	  	  
We applied a novel scoring system based on previous methods[14] to 
quantify the immunohistochemical staining. Ten random high power fields (x400) 
were evaluated by three independent assessors. In each field the number of 
positive and negatively stained cells were counted and the percentage of positive 
cells calculated giving the following semi-quantitative grading; Grade 0= no 
staining, Grade 1= <10% cells stained positive, 2= 10-20% cells stained positive, 
Grade 3= >20% cells positive. In addition the blood vessel numbers were 
assessed in the same random high power fields. Intra-rater reliability was good 
reflected in r= 0.82. Additionally the same fields were photographed  and 
evaluated by collaborators in Sydney, Australia. These included Dr Fiona Bonar, 
Consultant Pathologist,  whose original scoring system [341] the above 
methodology was based on and is seen as one of the fields preeminent authorities 
on tendon pathology. The results were readily reproducible by these collaborators.      
 I initially chose to investigate the staining profile of mast cells and 
macrophages in each cohort due to previous reports of these cells in torn rotator 
cuff samples [66]. Following this I expanded the staining to include T cells and 
specially CD34 as a marker of endothelial/vasculature to specifically assess 
whether mast cell staining was co-localised around neovascularisation. 
Additionally due to parallel studies in the laboratory I chose CD206 as an M2 
macrophage marker in an attempt to stratify the macrophage infiltrate.        
 The cohort of subscapularis tendon samples exhibited significantly greater 
(p < 0.01) staining for macrophages, mast cells and T cells compared to both 
matched torn supraspinatus samples and control tissue (Figure 3-3). Macrophages 
were scattered mainly throughout the subintimal layers although some were 
present in a peri-vascular cuff. The majority of mast cells were located around the 
vasculature with the remainder residing in the synovial lining or scattered 
throughout the tissue. Inflammatory cell infiltrate correlated inversely (r2 = 0.8, p < 
0.01) to rotator cuff tear size in the torn supraspinatus biopsies with larger tears 
showing a marked reduction in all cell types. In particular mast cells and M2 
macrophages were seen in specimens with increased fibroblast cellularity and 
decreased markedly in number as the fibroblast cellularity of the specimen 
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decreased (Figure 3-4). No significant associations were noted between 
inflammatory infiltrate and the age of patients or duration of symptoms.  
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Figure 3-3 Immunohistochemical staining for inflammatory cell surface markers. Staining 
for CD68 (pan macrophage) in sub intimal layers of tendon. CD3 (Tcells) are sparse but 
seem to be localised around lining layers and vascular regions. CD202 (M2 macrophages) 
are again sub intimal but are more readily localised to the vasculature. MCT (Mast cell 
tryptase) is highly expressed throughout the tissue with large expression patterns around 
vascular regions. 
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Figure 3-4  Correlation between tear size and inflammatory cell infiltrate.  
Inflammatory infiltrate is graded Grade 0= no staining, Grade 1= <10% cells stained positive, 
2= 10-20% cells stained positive, Grade 3= 21-50% cells positive, Grade 4 > 50% cells 
positive per high power field (HPF). Thus as tear size decreases there is an increase in 
inflammatory infiltrate. 
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3.2.3)	  Increased	  vascularity	  in	  tendinopathy	  
 CD34 positive vessels were found in the greatest quantity in matched 
subscapularis samples (Figure 3-5) compared to all other groups with a mean 
vessel count of 38 ± 2 in subscapularis compared with 15 ±3 in matched torn 
biopsies or 6 ± 1 in control tissues. As tear size increased in the supraspinatus 
samples, there was a significant (p <0.05) reduction in vascularity suggesting an 
inverse relationship. The mean vessel count was significantly (p < 0.01) different 
between all tear groups (Table 3-2). There was a moderate but significant 
correlation between mast cells and CD34 expression (r = 0.4, p < 0.01). 
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Figure 3-5  Immunohistochemical staining for CD34 Endothelial marker 
 
 
 
Table 3-2 Histological features in control, matched subscapularis and torn supraspinatus 
tendon samples 
† mean number of vessels in ten high power fields of view (magnification x400) 
‡ mean number of cells in ten high power fields of view (magnification x400) 
 
 
 
 
 
 
 
 
Feature 
 
 
 
Control 
(n=10) 
 
Matched 
subscapularis 
(n=20) 
   
    Torn Supraspinatus 
  
   Overall 
(n=20) 
Small 
(n=6) 
Medium  
(n=6) 
Large 
(n=4) 
Massive 
(n=4) 
 
Mean vessel 
Count †  
 
 
6 ± 1 
 
38 ± 2 
 
15 ± 3 
 
28 ± 2 
 
17 ± 2 
 
6 ±1 
 
1 ± 1 
 
Inflammatory cell 
count ‡    
 
Macrophages  
Mast Cells 
M2 Macrophages 
T cells 
 
 
 
 
 
4 ± 1 
0 ± 0.5 
2 ± 1 
1 ± 1 
 
 
 
 
30 ± 4 
25 ± 3 
26 ± 3 
12 ± 2 
 
 
 
 
13 ± 2 
10 ± 3 
9 ± 2 
6 ± 2 
 
 
 
 
 
23 ± 1 
18 ± 4 
15 ± 2 
9 ± 2 
 
 
 
 
 
14 ± 2 
11 ± 1 
13 ± 2 
7 ± 1 
 
 
 
 
5 ± 1 
4 ± 1 
7 ± 2 
3 ± 1 
 
 
 
 
3 ± 1 
4 ± 2 
2 ± 1 
2 ± 1 
x10 X40 
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3.3) Discussion and Conclusions 
These experiments provide convincing evidence of an inflammatory cell 
infiltrate in early mild/moderate human supraspinatus tendinopathy. Our data are 
novel and therefore directly inform the controversy that surrounds the role for 
inflammation in the development of tendinopathies.   
Experimental models provide good evidence of an early inflammatory response. A 
running rodent model of tendinopathy is associated with up regulation of key 
inflammatory modulator s[74] including the 5-lipoxygenase activating protein 
(FLAP) and cyclo-oxygenase at early and intermediate time points [342]. In rabbit 
and equine models excessive mechanical load induces acute inflammatory cell 
infiltrates [93, 343]. Human studies are less convincing. Whereas some studies 
describe the presence of increased cytokine expression [112, 137, 344, 345] as 
proof of an inflammatory component, virtually all histological studies in human 
tissue have failed to demonstrate inflammatory cells in tendinopathic samples [82, 
333, 334, 339, 346]. One of the previous limitations has been that such tissues 
were from patients with advanced disease, presumably dominated pathologically 
by chronic degenerative changes. Recent human biopsy work in smaller tears [66] 
with a less degenerative picture revealed a significant inflammatory infiltrate of 
mast cells and macrophages. Inflammation is also intimately linked to the Fas/Fas 
ligand system of apoptosis, which has been found in excessive amounts in a 
range of tendinopathies [76, 347, 348]. Our data provide convincing evidence that 
inflammation is indeed present and could therefore provide a molecular link to key 
pathological events in tendinopathy. 
Our previous work on matched subscapularis tendon biopsies from patients 
with a full thickness supraspinatus tear produced unexpected results[340]. We 
found that despite normal MRI or arthroscopic appearances, at the histological 
level, the tendon had mild/moderate tendinopathic changes. These samples 
contained increased expression of proinflammatory cytokines compared to 
controls assessed at the mRNA level [137]. We have now extended these 
observations to include a detailed cellular analysis. Macrophages play a critical 
role in the initiation, maintenance and resolution of inflammation [349]. In response 
to cytokines and microbial products, mononuclear phagocytes develop specialized 
and polarized functional properties within functionally discrete M1 or M2 subsets 
[350]. M1 macrophages are efficient producers of effector moieties, including 
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reactive oxygen and nitrogen intermediates and inflammatory cytokines and 
chemokines, whereas in general, M2 macrophages act to dampen inflammatory 
responses and scavenge debris as well as promote angiogenesis.  M2 
macrophages express fibronectin and IGF-1; key signals for tissue repair [351] 
and recent work has shown that defective M2 polarization resulted in impaired 
muscle tissue repair mechanisms [352]. We detected a significant proportion of 
macrophages expressing CD206, compatible with an M2 phenotype. Inflammation 
in early tendinopathy could in part reflect an attempt at tissue repair. The 
associated higher blood vessel density in back to back sections of tendon samples 
is compatible with this hypothesis.  
 Of particular interest is the large number of mast cells present in early 
tendinopathy. Mast cells play a key role in the inflammatory process - they rapidly 
release characteristic granules and various mediators that mediate the recruitment 
and activation of monocytes, neutrophils, dendritic cells, B and T cells [353, 354] 
and have recently been linked to neoangiogenesis [355]. They are associated with 
inflammatory diseases including atopic dermatitis [356], scleroderma [357] and 
rheumatoid arthritis [358]. Scott et al [359] found significantly increased mast cell 
numbers in human patellar tendinosis and correlated this with symptom duration 
and vascular hyperplasia while studies in rabbits have shown that mast cells and 
their mediators influence fibroblast activity and vascular permeability [360]. In 
keeping with these previous studies, our findings are suggestive of a pro-
angiogenic role for mast cells in tendinopathies. Indeed mast cells could 
theoretically play a role in ‘stress induced’ tendinopathy by degranulating in 
response to mechanical stress thereby releasing mast cell tryptase and other 
vasoactive and angiogenic mediators which are important in the balance between 
repair and further degeneration. This observation warrants further mechanistic 
studies to understand how mast cells interact with tenocytes and regulate matrix 
synthesis. 
 Limitations exist in this set of experiments. Firstly, age-related changes 
within the tendon samples could contribute to the degenerative picture and 
inflammatory cell expression seen in the matched subscapularis tendons. 
However the lack of degenerative change on MRI and arthroscopic examinations 
suggests that the differences are truly at the cellular level as suggested by our 
work. Secondly, subscapularis tendon is functionally and organizationally distinct 
from supraspinatus and thus responds to mechanical loading in a different manner 
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which may alter its cellular profile. It is reassuring however that we found the same 
inflammatory and vascular cell subtypes in matched subscapularis tissue 
indicating that the inflammatory response may be uniform within joints subjected to 
tendon degeneration. In addition having subscapularis samples from the same 
patient eliminates bias that may result from variation between individuals and has 
been previously shown to be useful method in sampling of tissues. 
 In summary we have found a distinct inflammatory infiltrate in early human 
tendinopathy. This data suggests that inflammation may play a crucial role in 
tendon healing - better understanding of this inflammatory cascade may lead to 
the development of cell targeted treatment modalities for early supraspinatus 
tendinopathy.  I next sought to characterise a plausible candidate mechanism that 
could promote the inflammatory changes that I observed in these studies, namely 
hypoxia. 
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Chapter 4 Hypoxia and Tendinopathy 
 
Content of this chapter has been published in the following manuscripts: 
 
Millar NL, Reilly JH,Kerr SC, Campbell AL Little KJ, Leach WJ, Rooney BP, 
Murrell GA, McInnes IB.  
Hypoxia: a critical regulator in early human tendinopathy 
Annals of Rheumatic Diseases 2012 Feb;71(2):302-10. Epub 2011 Oct 4. 
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4.1) Aims and introduction 
 The intrinsic pathogenetic mechanisms underlying the development of 
tendinopathies are largely unknown however excessive apoptosis (programmed 
cell death) and inflammation have recently been shown to be functionally 
important in several models systems [74, 342, 360]. In particular, data contained in 
my previous chapter clearly provide evidence of early inflammation in 
tendinopathy. The interaction between apoptosis and inflammation is critical to 
tissue homeostasis in a variety of tissues and is known to play a key role in 
inflammatory articular [361], neoplastic [362], neurodegenerative [363] and 
cardiovascular diseases [364].   
 Apoptosis may be induced by many stimuli, including hypoxia. The 
magnitude and duration of the hypoxic microenvironment largely determines 
whether cells become apoptotic or adapt and survive [365]. Hypoxia inducible 
factor 1 (HIF-1α), is a critical regulator in this process. Whereas HIF-1α can initiate 
apoptosis by inducing high concentrations of proapoptotic proteins [366], such as 
caspase 3, during hypoxia, HIF-1α induces antiapoptotic proteins [367], such as 
Clusterin and Bcl-2, while the proapoptotic protein Bax is downregulated. HIF-1α is 
also recognised to control key aspects of inflammation particularly leukocyte 
recruitment and subsequent cytokine production [368]. 
 Biopsy and in vivo model studies suggest that tendon hypoperfusion [274] 
and subsequent hypoxia [275] are central elements of tendon failure but few data 
have addressed this at a  mechanistic level in humans. In rodent models, cyclic 
strain regulates the expression of the HIF-1α in rat tendon fibroblasts [117]. 
Increased hypoxia in the tenosynovium of rheumatoid arthritis patients is observed 
compared to controls [369], and recently Benson et al [68] described hypoxic 
damage throughout the spectrum of rotator cuff disease.  To date no studies have 
explored the functional role of hypoxia in modulating apoptosis, inflammation and 
matrix regulation in tendinopathy.  
 One of the major limitations of human studies is that tendon biopsies are 
usually obtained when patients are symptomatic and therefore biopsy material 
likely represents chronic, rather than early phase disease. Medical intervention at 
this early stage may offer considerable therapeutic advantage over later surgical 
approaches. We previously demonstrated that matched subscapularis tendon from 
patients with full thickness rotator cuff tears represents a model of early human 
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tendinopathy based on histological appearances and significantly increased levels 
of cytokines and apoptotic markers in these tissues [137]. The purpose of this 
section of my thesis was to formally assess the presence and magnitude of 
expression of hypoxic markers within this early phase human model ex vivo 
and thereafter to explore the mechanistic outcome of tissue hypoxia on 
apoptosis, inflammation and matrix production in tenocytes in vitro.   
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4.2) Early tendinopathy is associated with increased hypoxic 
and apoptotic markers 
 Torn supraspinatus samples exhibited marked degeneration, mucoid 
change and frank chondroid metaplasia (Grade 4) whereas matched 
subscapularis tendon biopsies had Grade 2-3 changes indicative of early 
tendinopathy. All control samples were classified as Grade 1 consistent with 
normal fibrotendinous tissue with large distinct collagen fibrils. There were no 
significant correlations between Bonar score and the mean duration of symptoms 
or patient age. However subscapularis tendon samples exhibited significantly 
greater staining for HIF 1α, clusterin, Bcl-2, BNIP-3 and VEGF compared to either 
matched torn supraspinatus samples or control tissue (Figure 4-1). Subscapularis 
tendon samples exhibited significantly greater (p < 0.01) numbers of 
macrophages, mast cells and T cells compared to either matched torn 
supraspinatus samples and control tissue. Inflammatory cell infiltrate and 
apoptosis markers correlated inversely (r = 0.4, p < 0.01) with rotator cuff tear size 
in the torn supraspinatus biopsies, with larger tears showing a marked reduction in 
inflammatory cell types and hypoxic/apoptotic markers.  
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Figure 4-1 Apoptosis and hypoxic markers in tendon samples. 
Subscapularis tendon stained for  HIF-1α, Clusterin, Bnip-3 and VEGF ( magnification x10 
and x40). Isotype IgG in bottom right corner. Graphs illustrate relative expression of 
corresponding proteins in human tendon samples. Histological scoring system, 0= no 
staining, 1= <10% cells positive, 2= 10-20% cells positive, Grade 3 = >20 % cells positive. 
Data displayed as mean +/- SEM, n=15 for supraspinatus and matched subscapularis, n=10 
for control group. (*=p<0.05, ** =p<0.01) 
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4.3) Hypoxic induces apoptosis in tenocytes in vitro 
 To explore the physiological significance of these findings, we first 
established an ex vivo primary human tenocyte culture system in which ambient 
oxygen concentrations could be meticulously controlled as required. Hypoxia 
significantly increased the number of cells undergoing apoptosis assessed by 
annexin V FACS staining at 12 hours (normoxia; mean 5 ± 2% apoptosis, hypoxia; 
mean 23± 8%), 24 hours (normoxia; mean 3 ± 2%, hypoxia; mean 58± 10% and 
48 hours (normoxia; mean 8 ± 4%, hypoxia; mean 60 ± 15%) (Figure 4-2A). This 
was confirmed by TUNEL staining showing increased levels of apoptosis in 1% 
conditions (Figure 4-2B). Limited proteomic profiling revealed relative over 
expression of Bcl-2, HIF 1α, clusterin, pro and cleaved caspase 3 and heat shock 
proteins 70, in hypoxic conditions (Figure 4-2C; p<0.01). These protein expression 
changes were confirmed at the mRNA level by quantitative PCR that confirmed 
significantly elevated expression of HIF 1α, caspases 3 & 7, clusterin, Bcl-2 and 
HSP 70 compared to normoxic conditions (Figure 4-2 D). 
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Figure 4-2 (A) Cell death after exposure to hypoxic conditions.  
Apoptosis was evaluated after treating tenocytes with 24h of normoxic (24% O2) and 
hypoxic (1% O2) conditions. Flow cytometry profile represents Annexin V-FITC staining in x 
axis and 7-AAD in y axis.(B)  Cultured tendon fibroblasts underwent a TUNEL assay to 
detect nuclear DNA degradation, a feature of apoptotic cells. Cells with brown stained nuclei 
are positive for DNA degradation. Samples displayed include 24% O2,1% O2 and +ve 
controls treated with H2O2-. Whole cell lysates from normoxic (24% O2) and hypoxic (1% O2) 
conditions were harvested and apoptotic markers evaluated using an apoptotic proteome 
profiler (C). The fold change of apoptotic proteins was determined by densitometry and 
normalised to the control sample on the array (D). Data are shown as the mean fold change 
± SD of duplicate samples and are representative of experiments using five individual 
donors of tendon explant tissue. 
A 
B 
 
C D 
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4.4) Hypoxia alters tenocyte collagen matrix regulation  
 Since disproportionate type III collagen expression is a characteristic 
feature of tendinopathy, we next considered whether hypoxic changes noted 
above might alter differential collagen synthesis by tenocytes and whether 
collagen matrix changes were present in tendon biopsies noted to have increased 
hypoxic markers. Collagen III was significantly (p<0.05) elevated in torn 
supraspinatus and matched subscapularis samples compared to controls (Figure 
4-3 A).   Collagen IA mRNA was significantly reduced at all time points in hypoxic 
compared to normoxic conditions. In contrast, collagen IIIA mRNA was 
significantly up-regulated at 24 & 48 hours in hypoxic compared to normoxic 
cultures (Figure 4-3 B&C). Commensurate with this at the protein level, hypoxia 
significantly elevated total collagen production compared to normoxia after 24 
hours (mean 328µg/ml ±81 hypoxia; 520µg/ml ±98 normoxic) and 48 hours 
(712µg/ml ±66 hypoxia; 909µg/ml ±74 normoxic). Semi-quantitative 
immunocytochemistry revealed no marked change in type I collagen protein 
expression in hypoxic compared to normoxic cultures, whereas collagen III 
staining was markedly increased at all time points by hypoxia (Figure 4-3 D). 
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Figure 4-3 Collagen I and III mRNA in hypoxic conditions 
(A) The levels of mRNA for Collagen type IIIA and (B) Collagen type IA were determined by 
real time PCR. Data shown as the mean ± SD of triplicate samples and represent 
experiments on five individual patient samples. *p<0.05, **p<0.01 compared to normoxic 
A B 
B 
A 
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Figure 4-4 Collagen I and III protein expression in hypoxic conditions 
(A) Collagen I and III concentrations (ηg/ml) were assessed using ELISA. Data represents 
mean collagen production (ηg/ml) ± SD in 10 biopsies of torn supraspinatus, matched 
subscapularis and control tendon samples (B). Immunostaining for Collagen types I and III 
in normoxic and hypoxic conditions at 24 hours incubation. Cells were plated onto chamber 
slides and incubated in different oxygen conditions for 24 hours then fixed in methanol and 
stained with antibodies
A 
B 
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4.5 ) Hypoxia promotes Cytokine production in tenocytes 
 Since our initial histological examination revealed a significant association 
between inflammatory infiltrate and hypoxic markers, we next explored the extent 
to which hypoxia could regulate the local cytokine milieu directly via modulating 
tenocyte behaviour. Hypoxic conditions rapidly induced significantly elevated 
production of IL-6, and of the chemokines IL-8 and MCP-1 commensurate with the 
notion that hypoxic tenocytes could initiate leukocyte recruitment  (Figure 4-5). In 
contrast, we found no production over time of a range of other cytokines including 
IL-4, IL-5, IL-10, IL-12, IL-13, IL-15, TNF-α, IL-1β by tenocytes, suggesting that the 
prior detection of such entities in early tendinopathy likely reflects infiltrating 
leukocyte populations [137].
146	  
 
 
 
 
 
 
 
 
Figure 4-5 Effects of hypoxia on cytokine production in cultured tenocytes. 
Cultured tenocytes were incubated in a normoxic and hypoxic environment over a time 
course from 0-48 hours. Data shows levels of MCP-1, IL-8 and IL-6 in supernatants removed 
from culture at various time points analysed using Luminex. Data shown are as the mean ± 
SD of triplicate samples and are representative of five individual experiments. *p<0.05, 
**p<0.01 compared to normoxic samples. 
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4.6 ) Hypoxia, MAP Kinase expression and collagen synthesis 
 As expected, tenocytes cultured in a hypoxic environment exhibited a 
generalized increase in MAPK phosphorylation. In particular, we observed 
increased phosphorylation of ERK 1, ERK 2 and the α & β isoforms of p38 
(Figures 5 A&B). To explore the functional consequences of this, we employed 
ERK and p38 MAPK inhibitors in our tenocyte cultures. We observed partial but 
significant abrogation of the hypoxia-induced increase in total collagen production 
by tenocytes (24 hours DMSO 592±32µg collagen (mean ± SD); p38 inhibitor 
461±35µg; ERK inhibitor 390±38µg) (Figure 5C). In contrast, p38 or ERK inhibition 
in normoxic conditions resulted in an increase in total collagen production (24 
hours DMSO 402±33µg collagen (mean ± SD); p38 inhibitor 541±35µg; ERK 
inhibitor 509±55µg).  
Collagen subtype synthesis was evaluated by RT-PCR. Both ERK and p38 
inhibition abrogated the hypoxia-induced enhancement of collagen type III in 
tenocytes and significantly increased the relative expression of Collagen III in 
normoxic conditions (Figure 5D).
148	  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6 Hypoxia induced phosphorylation of MAPK in cultured tenocytes and matrix 
response to p38 and ERK inhibition 
Whole-cell lysates were examined for the phosphorylation of ERK1, ERK2 and  p38 isoforms  
at 1 hour after exposure to normoxic and hypoxic conditions (A). The fold change of 
MAPK's was determined by densitometry and normalised to the control sample on the 
array(B). Data are shown as the mean fold change ± SD of duplicate samples and are 
representative of experiments using five individual donors of tendon explant tissue.  
Cells were preincubated for 24 h with specific inhibitors for p38 [SB 203580], or ERK (FR 
180204), which also were included assay media. Total collagen production was assessed 
using Sircol assay(C). Data represents percentage change in total collagen production 
compared to normoxic control sample  ± SD in normoxic and hypoxic conditions over a 48 
hour time course.  *p<0.05, **p<0.01 compared to normoxic samples. The levels of mRNA 
(D) for Collagen type IA and Collagen type IIIA were determined by real time PCR.
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4.7) ERK and p38 inhibitors reduce proinflammatory cytokine / 
chemokine production but do not modulate apoptosis in 
tenocytes 
 Tenocyte production of IL-6, MCP-1 and IL-8 under normoxic and 
particularly hypoxic conditions was reduced by both p38 and ERK inhibition 
(Figure 6A). ERK appeared more important in this regard. Annexin V staining 
revealed a moderate reduction (p=0.06) in the percentage of apoptotic cells in 
hypoxic conditions using either p38 (hypoxia control 62 ± 10%, inhibitor 55 ± 10%) 
and ERK inhibitors (hypoxia control 63 ± 8%, inhibitor 52 ± 12%). While ERK 
inhibition did induce a small but significant reduction in clusterin gene expression 
in hypoxic conditions neither p38 and ERK inhibition had significant effect on other 
key apoptotic genes in normoxic nor hypoxic environments suggesting that 
p38/ERK pathways do not significantly contribute to tenocyte apoptosis. 
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Figure 4-7 The effects of ERK and p38 MAPK inhibition on cytokine production and 
apoptosis. 
(A) Cells were preincubated for 24 h in a normoxic and hypoxic environment with specific 
inhibitors for p38 [SB 203580], or ERK (FR 180204), which also were included assay media. 
Data shows levels of MCP-1, IL-8 and IL-6 in supernatants removed from culture analysed 
using Luminex. Data shown are as the mean ± SD of triplicate samples and are 
representative of five individual experiments.  
(B) Whole-cell lysates were examined for the expression HIF 1α, Caspase 3, Bcl-2 and 
Clusterin, at 24 hours after exposure to normoxic and hypoxic conditions with specific 
inhibitors for p38 [SB 203580], or ERK (FR 180204).Expression was determined by 
densitometry and normalised to the control sample on the array. Data are shown as the 
mean fold change ± SD of duplicate samples and are representative of experiments using 
five individual donors of tendon explant tissue. 
B 
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4.8) Discussion 
 These experiments provide convincing evidence that hypoxia could operate 
as an initiator and thereafter regulator of early tendinopathy. Herein we 
demonstrate that hypoxia related proteins are present in early tendinopathy 
biopsies and thereafter in mechanistic studies demonstrate that hypoxia regulates 
inflammatory and apoptotic mediators in tendon cells associated with a significant 
shift in collagen matrix synthesis.     
 Approximately 95% of collagen in normal tendon is type I; type III is present 
in small amounts under physiological conditions [370]. Biopsies from normal and 
ruptured Achilles tendon demonstrate that ruptured tendons contain reduced 
quantities of type I collagen together with a significantly increased proportion of 
type III collagen [371] that in turn accounts for the decreased resistance of tendon 
to tensile forces and thereby subsequent rupture [372]. Hypoxic cell damage has 
long been considered a mechanism underpinning degenerative tendon disorders 
[4, 64]. Conventionally, stress responses such as oxidative damage are 
considered to operate through MAPK pathways [373]. These are up regulated by 
cyclical strain [79] and subsequently involved in apoptosis [78] in tendinopathy; 
however there remains limited investigation into signalling events involved in 
tendon biology. Our work suggests a functional role for ERK and p38 in the matrix 
and inflammatory response to hypoxia. Hypoxia not only increases the total 
collagen production but seems to 'switch' the production towards an increase in 
collagen III compared to type I suggesting a detrimental phenotypical change in 
the extracellular matrix. In particular ERK inhibition reduces the total collagen and 
collagen III production in hypoxia whilst has the opposite effect(increased collagen 
and collagen III) in normoxia suggesting that the ERK pathway is oxygen sensitive.  
 Experimental models provide good evidence for an early inflammatory 
response in tendinopathy [74]. A running rodent model of tendinopathy is 
associated with upregulation of key inflammatory modulators including the 5-
lipoxygenase activating protein (FLAP) and cyclo-oxygenase [342] while rabbit and 
equine models show excessive mechanical load induces acute inflammatory cell 
infiltrates [93, 343]. Recently we have shown a distinct inflammatory infiltrate in 
early human tendinopathy [374] and increased levels of proinflammatory cytokine 
in torn supraspinatus samples [137]. Hypoxia has been shown to induce the 
expression of cytokines and proinflammatory molecules including PDGF, IL-6, IL-8 
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and PAF in several animal and human models [375-377]. Our data now 
demonstrate in human tenocytes that a hypoxic environment is capable of 
inducing key inflammatory cytokines that may ultimately disturb the balance 
between reparative and degenerative changes in the extracellular matrix. In 
particular increased levels of MCP-1, IL-6 and IL-8 which have previously been 
shown to effect matrix metalloproteinases production in fibroblasts [378] likely 
have downstream affects on tenocyte collagen matrix production. Inhibition of ERK 
in hypoxia significantly reduced cytokine production and thus may provide a 
mechanism for reducing proinflammatory. We and others have highlighted the key 
presence and therefore putative functional role of a large mast cell infiltrate in 
tendinopathy [66, 359, 374] and this combined with evidence from Gulliksson et 
al[379] demonstrating hypoxic induced IL-6 production in mast cells provides 
growing importance to the role of chemokines in the initiation and perpetuation of 
the  inflammatory cascade in tendon biology (Figure 6C).   
 Dysregulated apoptosis has also been postulated as a primary cause of 
tendinopathies [107]. Several causal factors, including mechanical overuse [380], 
hypoxia [52] and oxidative stress [56] have been proposed. We have previously 
shown increased expression of pro-apoptotic genes in a rodent overuse models 
and in torn human supraspinatus tendons compared to controls [340]. Increased 
mechanical loading [77] and loss of homeostatic tension [380] increases tenocyte 
apoptosis in rodents and HIF-1α is induced during cyclical strain of tenocytes 
[274]. Increased HIF-1α has been shown in rotator cuff tears although since these 
represent by definition advanced disease it is difficult to evaluate its relative role in 
early disease [68]. Our study now reveals HIF 1α expression in early tendinopathy 
biopsies. Clusterin [381] and Bcl-2 [382] have been functionally implicated in DNA 
repair, cell cycle regulation, while both have a prosurvival role during cell death 
[383]. Their abundant expression in early tendinopathy biopsies and over 
expression under hypoxic conditions at both the protein and mRNA level strongly 
supports the concept of hypoxia as a regulator of apoptosis. Moreover parallel 
changes were noted in collagen subtype synthesis in our studies. Thus the 
equilibrium between pro/anti apoptotic markers during hypoxic conditions in a 
tissue rescue/wound healing process may play a critical role in determining the 
functional outcome. The Jun N-terminal kinases/stress-activated protein kinases 
(JNK/SAPKs) have been implicated in tenocyte apoptosis [79]and whilst a 
moderate increase was noted in JNK/SAPKs in our culture system this did not 
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prove significant. At a mechanistic level we could not identify a functional role for 
ERK and p38 in the apoptotic response to hypoxia which may suggest a 
mitochrondrial regulatory pathway as that in synovial fibroblasts [384]. 
 On the basis of these results we propose hypoxia as a critical 
pathophysiological regulator in tendon healing (Figure 4-8) - better 
understanding of its pathological cascade should lead to the development of 
cell targeted treatment modalities for early supraspinatus tendinopathy. 
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Figure 4-8 Schematic diagram illustrating the manner in which early tendinopathy may arise 
due to hypoxic injury.  
An increase in hypoxic stress that a tendon cell experiences results in the release of 
various inflammatory mediators with associated MAPK activation that interact to drive the 
tendon matrix toward a degenerative or reparative process. 
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Chapter 5 Interleukin 17 in tendinopathy 	  	  
Content of this chapter has been presented as abstracts at the following meetings: 
Orthopaedic Research Society Annual Meeting New Orleans 2010 
Shortlisted as NIRA Prize finalist 
 
American Shoulder and Elbow Surgeons Speciality Day San Diego 2011 	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5.1) Aims and Introduction 
 Cytokines are critical in the response of soft tissue to injury and wound 
healing and have been shown to be involved in the regulation of matrix turnover in 
tendinopathy[42]. Endogenous increased expression of TNFα, IL-1β, IL-6, IL-10, 
VEGF and TGFβ has been demonstrated in tenocytes [111-114]  while the 
mechanical properties of healing tendons in IL-6 -/- mice were inferior compared 
with normal controls. Cytokines also play a key role in oxidative stress-induced 
cellular apoptosis[385] which is mediated by the activation of a variety of 
caspases. IFN-γ or TNF-α increased, whereas with TGF-β or IL-10 decreased 
caspase 8 driven Fas mediated apoptosis in dermal fibroblasts[386] while IL-1β 
and TNF-α induce mitochondrial DNA damage, and mitochondrial transcription 
with a subsequent induction of apoptosis in human chondrocytes[387].  By this 
means an inflammation / apoptotic cascade of molecular events promotes tissue 
degeneration[348].  
Interleukin-17 is a pro-inflammatory mediator increasingly implicated in a 
variety of immune and inflammatory disease states. IL-17A expression is reported 
in several cell types including Th17 cells[388], γδT cells[389] and some non 
lymphocyte lineages[162]; its receptor is ubiquitously expressed on many cell 
types, including myeloid cells, epithelial cells and fibroblasts[390]. IL-17A exerts 
various biological activities that could promote tissue destruction and degeneration 
during inflammation. In particular, it induces the production of cytokines, including 
IL-1, IL-6, TNF-α, chemokines, inducible NO synthase, and matrix 
metalloproteinases (MMPs) by fibroblasts, macrophages, and endothelial 
cells[177]. Experimental models provide good evidence for an early inflammatory 
response in tendinopathy[78, 93, 342]. Recently we have shown a distinct 
inflammatory infiltrate in early tendinopathy[374] and increased levels of 
proinflammatory cytokines including TNF-α, IL-6,  in torn supraspinatus 
samples[137]. Based on these observations and the plausible biological profile 
exhibited by IL-17A, we hypothesized that IL-17 may play a role in tendinopathy. 
The purpose of this section of my thesis was to formally assess the 
expression of IL-17 within the human model of tendinopathy previously 
described and thereafter explore the mechanistic outcome of IL-17 on 
inflammation, apoptosis and matrix production in tenocytes in vitro. 
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5.2) Early tendinopathy shows increased IL-17A expression with 
localization particularly to mast cells 
I first examined mRNA expression in my tissue cohort. Subscapularis 
tendon samples exhibited significantly (p < 0.01) greater IL-17A mRNA levels than 
torn supraspinatus or control tendon. Additionally immunohistochemical staining 
for IL-17A, macrophages, mast cells and T cells exhibited significantly greater 
levels of expression for each marker in subscapularis compared to both matched 
torn supraspinatus samples and control tissue (Figure 1). To formally identify 
these IL-17A+ cells in human tendinopathy, we performed co localisation studies 
and calculated the proportion of IL-17A+ cells contained in each cellular subset 
Although occasional CD3+IL-17A+ cells were identified, the majority of IL-17A+ 
cells were CD3-negative (<1%). Only 1% of IL-17A–expressing cells were found to 
express CD3. CD4 cells were extremely limited in number throughout the samples 
and we identified no co-expression of IL-17. Up to 20% of IL-17A+ cells were 
CD68+. The majority of IL-17A+ cells double-stained strongly with MCT (50–
100%) of IL-17A–expressing cells per tissue area across patients, clearly 
demonstrating that mast cells are key producers of IL-17A in human tendinopathy 
(Figure 5-3). The validity of the antibody was assured by staining in rheumatoid 
arthritis samples which were previously noted to be positive in the laboratory.
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Figure 5-1Quantification of IL-17A in tendon biopsies 
Scoring for T cells (CD3), macrophages (CD68) and mast cells (MCT) in tendon biopsies 
using Modified Bonar score.  Double positive cells per high power field (mean of 5 HPF’s) 
showed the greatest concentration to be IL-17/MCT cells. Extremely low numbers of IL-17 
positive T cells were detected.The levels of IL-17 mRNA was determined by real time PCR. 
Data shown as the mean ± SD of triplicate samples and represent experiments on ten 
samples of control tendon, torn supraspinatus and matched subscapularis tendon biopsies. 
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Figure 5-2 Immunohistochemistry and double immunofluoroencse for IL-17A and CD68  
Large areas of CD68 positive areas with single light microscopy suggesting double positive 
cells. Confirmed on immunofluorensce. Sections were counterstained with DAPI (blue). 
Bottom row show merged staining. Images are shown at 40x magnification.
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Figure 5-3 Immunohistochemistry and double immunofluorensce for IL-17A and Mast cell 
tryptase 
Large areas of MCT positive areas with single light microscopy suggesting double positive 
cells. Confirmed on immunofluorensce. Sections were counterstained with DAPI (blue). 
Bottom row show merged staining. Images are shown at 60x magnification. 	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5.3) IL-17A induces apoptosis in tenocytes in vitro 
 We next wished to examine the functional implications of IL-17A expression 
in early tendinopathy. Addition of 50ng or 100ng of rhIL-17A to human tenocyte 
cultures significantly increased the number of cells undergoing apoptosis 
assessed by Annenix V staining at 24 hours (control mean 6±2%, IL-17A mean 
56% ±8%) and 48 hours (control 9±4%, IL-17 48% ±5%) (Figure 5-4A&B).Limited 
proteomic profiling of these cells after 24 hours, revealed relative over expression 
of pro and cleaved caspase 3, with the most profound effects mediated upon 
expression of heat shock proteins (HSP) 27, 70 and second mitochondria-derived 
activator of caspases (Smac) (p<0.01) (Figure 5-4C).These protein expression 
changes were confirmed at the mRNA level by quantitative PCR that confirmed 
elevated expression of caspase 3, HSP 27, HSP 70 and Smac (p<0.01) in 
tenocytes (Figure 5-4D).
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Figure 5-4 Apoptosis and IL-17A 
(A) Apoptosis was evaluated after 24h control conditions IL-17 stimulation. Flow cytometry 
profile represents Annexin V-FITC staining in x axis and 7-AAD in y axis. (B) % of apoptotic 
cells at various time points and concentrations of  rh IL-17. (C) Whole cell lysates from 
control and IL-17 conditions were harvested and apoptotic markers evaluated using an 
apoptotic proteome profiler (D). The levels of mRNA Caspase 3 and HSPs were determined 
by real time PCR. Data shown as the mean ± SD of triplicate samples and represent 
experiments on five discrete patient samples. 
A 
B 
C D 
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5.4) IL-17A alters tenocyte collagen matrix regulation  
 Since type III collagen expression is a dominant feature of tendinopathy, we 
next considered whether IL-17A might alter differential collagen synthesis by 
tenocytes. rhIL-17A significantly elevated total collagen production (Figure 4A) 
compared to untreated cells at 24 hours (mean 300µg ±62 control; 590µg ±71 IL-
17A) and 48 hours (712µg ±82 control; 1200µg ±92 IL-17). Collagen 1A mRNA 
levels were unchanged at 12, 24 and 48 hours whereas in contrast, Collagen 3A 
mRNA was significantly up-regulated at 24 & 48 hours by rhIL-17A compared to 
controls. Immunocytochemistry revealed no change in expression of type 1 
collagen in rhIL-17 treated samples at all time points compared to controls 
whereas collagen 3 staining demonstrated a significant increase 48 hours post 
incubation with rhIL-17A (Figure 4C). This was confirmed by ELISA which 
revealed a significant increase in collagen III (mean ηg ± control; ηg ± IL-17A) 
production at 24 hours and 48 hours post treatment with rhIL-17A.
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Figure 5-5 The effect of IL-17A on collagen matrix production 
(A)Total collagen production assessed using Sircol assay(A). Data represents mean 
collagen production(µg)  ± SD in control and IL-17 treated cultures over a 48 hour time 
course.  *p<0.05, **p<0.01 compared to control samples. (B) The levels of mRNA for 
Collagen type IA and IIIA were determined by real time PCR. Data shown as the mean ± SD 
of triplicate samples and represent experiments on five individual patient samples. *p<0.05, 
**p<0.01 compared to control samples.(C) Collagen I and III (C) Collagen I and III protein 
levels as determined by ELISA. Data shown are mean ± SD of five individual patient 
samples. 
A 
B 
C 
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5.5) IL-17A promotes cytokine production in tenocytes 
 We next explored the extent to which IL-17A could regulate the local 
cytokine milieu directly via modulating tenocyte behaviour. Incubation with rhIL-
17A resulted in significantly elevated production of TNF-α, MIP1α, IL-6, IL-8 and 
MCP-1 at 24 and 48 hours post incubation by tenocytes (Figure 5-6). In contrast 
we found no production over time of a range of other cytokines including IL-4, IL-5, 
IL-10, IL-12, IL-13, and IL-15, consistent with our expectations of the known 
cellular sources of such cytokine production.
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Figure 5-6 IL-17 induced cytokine production in cultured tenocytes 
(A) Cultured tenocytes were incubated in with recombinant IL-17 over 24 hours. Data shows 
levels of MCP-1, TNF-α, IL-8 , IL-6 and MIP-1α in supernatants removed from culture at  24 
hrs analysed using Luminex.  
(B) Cells were preincubated for 24 h with 100ng recombinant IL-17 and specific inhibitors for  
ERK (FR 180204) and Atk, which also were included assay media.  
Data shown are as the mean ± SD of triplicate samples and are representative of five 
individual experiments. *p<0.05, **p<0.01 compared to normoxic samples
A 
B 
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5.6) MAP Kinases mediate some of the effects of IL-17A in 
tenocytes. 
 Tenocytes cultured with rhIL-17A exhibited a generalized increase in MAPK 
phosphorylation. In particular, we observed increased phosphorylation of ERK 1, 
ERK 2 and Akt 1 & 2 (Figure 5-7A).To explore the functional consequences of this, 
we employed ERK and Akt inhibitors in our tenocyte cultures using doses 
previously shown to offer optimal inhibition at minimal off target effect. We 
observed significant reduction in production of MCP-1, IL-6, and IL-8 with both 
ERK and ATK inhibition, while TNF-α production was reduced by ERK inhibition 
and not Atk inhibition and no change was noted in MIP-1α production after 
addition of either inhibitor (Figure 5-6 B).  
  To assess if MAP kinases were involved in an IL-17A induced apoptotic 
mechanism tenocytes were treated with 100ng of IL-17A with and without the 
aforementioned MAPK inhibitors. ERK (7% mean reduction in apoptosis compared 
to IL-17 treated cells alone) and Atk (9% mean reduction compared to IL-17 
treated cells alone) inhibition caused a generalised decrease in tenocyte apoptosis 
which approached significance (p=0.06). Interestingly both ERK and Atk inhibition 
resulted in a significant increase in HSP 27 and 70 gene expression with no 
associated changes in caspase 3, or Smac (Figure 5 D) suggesting that ERK/Atk 
pathways may be at least involved in modulating part of the apoptotic response 
while having little ultimate phenotypical effect on ultimate tenocyte apoptosis.
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Figure 5-7 IL-17 induced phosphorylation of MAPK in cultured tenocytes and matrix 
response to ERK and Atk inhibition 
Whole-cell lysates were examined for the expression of ERK1, ERK2 and  Atk 1 & 2  at 24 
hours after exposure to 100ng rh IL-17 (A). The fold change of MAPK's was determined by 
densitometry and normalised to the control sample on the array (B). Data are shown as the 
mean fold change ± SD of duplicate samples and are representative of experiments using 
five individual donors of tendon explant tissue.  
Cells were preincubated for 24 h with specific inhibitors for ERK (FR 180204), or Atk which 
also were included assay media. Total collagen production was assessed using Sircol 
assay(C). Data represents percentage change in total collagen production compared to 
normoxic control sample  ± SD in normoxic and hypoxic conditions over a 48 hour time 
course.  *p<0.05, **p<0.01 compared to normoxic samples. The levels of apoptotic proteins 
following incubation with ERK and Atk inhibitors (D) was determined by densitometry and 
normalised to the control sample on the array. Data are shown as the mean fold change ± 
SD of duplicate samples and are representative of experiments using five individual donors 
of tendon explant tissue. 
A B 
C D 
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5.7) Discussion and Conclusion 
 This section provides evidence that IL-17 could operate as a key cytokine 
modulator of early tendinopathy. The experiments herein demonstrate that IL-17 is 
present in early tendinopathy biopsies and thereafter in mechanistic studies 
demonstrate that IL-17 regulates inflammatory and apoptotic pathways in tendon 
cells associated with a significant shift in collagen matrix synthesis.   
 These data suggest in human tenocytes that IL-17 is capable of inducing 
key inflammatory cytokines that may ultimately disturb the balance between 
reparative and degenerative changes in the extracellular matrix. In particular 
increased levels of IL-6 and IL-8 which have previously been shown to modulate 
matrix metalloproteinases production in fibroblasts [378] likely have downstream 
effects on tenocyte collagen matrix production.  We and others have highlighted 
the potential role of the large mast cell infiltrate in tendinopathy [66, 359, 374]. This 
combined with recent evidence demonstrating that significant proportion of IL-17 
producing cells in RA synovium [391, 392] ,psoriatic skin lesions [34] and psoriatic 
spondlyoarthropathy [393] are in fact mast cells provides growing emphasis on the 
role of the mast cell / cytokine / chemokine axis in the initiation and perpetuation of 
the  inflammatory cascade in tendon biology. Indeed these results add growing 
credence to the idea that innate immune cells are an early source of IL-17 in 
response to stress and injury [162]. Strategies to interfere with mast cell 
activation/degranulation and the ability of ERK/Atk inhibitors to reduce IL-17 
associated cytokine production may provide novel targets for human tendinopathy. 
 We have previously shown increased expression of pro-apoptotic genes in 
a rodent overuse models and in torn human supraspinatus tendons compared to 
controls [340]. These experiments now reveal IL-17 expression in early 
tendinopathy biopsies. The addition of IL-17 to tenocyte cultures causes over 
expression of caspases at both the protein and mRNA level strongly supporting 
the concept of IL-17 as a regulator of apoptosis. This work also shows the most 
significant change in small molecules regulating the mitochondrial pathway of 
apoptosis. HSP 27 indirectly interferes with cell death due to its ability to modulate 
intracellular glutathione, a parameter that is also regulated by exercise while HSP 
70 interacts with Apaf-1 thereby preventing its interaction with the caspases 
preventing apoptosis [394, 395]. Smac binds to inhibitor of apoptosis proteins 
(IAPs) and deactivates them, preventing the IAPs from suppresses caspase 
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activity [396]. We have previously suggested heat shock proteins as modulators of 
apoptosis in early tendinopathy [340] and our mechanistic studies now emphasize 
the concept of that these small molecular chaperones as potential apoptotic 
regulators in tendinopathy.  
 My experiments reveal that IL-17 not only increases the total collagen 
production but seems to 'switch' the production towards an increase in synthesis of 
collagen type III compared to collagen type I suggesting that IL-17 may cause 
detrimental phenotypical changes in the extracellular matrix – at least in terms of 
force conduction and functional strength in practice. Inhibition of ERK/Atk 
signalling had no effect on IL-17 induced matrix production suggesting an 
alternative pathway must operate. Further investigation is required to understand 
the signalling biology of IL-17 on collagen synthesis and thus fully appreciate any 
translation targets.  
 Many questions remain to be explored. In particular the ability of mast cells 
to actively produce IL-17 in vitro. This has recently been demonstrated in mast 
cells cultured from skin biopsies and treated with IL-1β and IL-23 [397]. We are 
currently addressing this in our own experiments. We have isolated CD133+ cells 
from human buffy coats and are stimulating them toward a mast cell lineage. Once 
confirmed to be mast cells with FACS staining for FcεRI  I plan to undertake 
experiments to reproduce mast cell IL-17 production in vitro. Secondly the 
literature still regards the main source of IL-17 to be derived from T cells whilst my 
results suggest a greater role for the innate mast cell and macrophage. Other 
groups have shown similar staining patterns to those presented above using the 
same goat polyclonal antibody however this does increase the possibility of cross 
reactivity to other epitopes. I am currently undertaking further IL-17 
immunostaining using a mouse monoclonal antibody to confirm my findings. The 
fact that tendon biopsies contain relatively few T cell infiltrates does however 
provide a useful ex vivo tissue to safely interpret IL-17 innate producing cells. A 
final question is the interaction between tenocytes and mast cells both in vitro and 
in vivo. The former is to be tested in vitro using transwell cell contact experiments 
where various concentrations of mast cells will be incubated with tenocytes and 
both matrix and inflammatory changes noted. Our group has previous experience 
with mast cell-deficient Kit(W)/Kit(W-v) mice and I intend to run the patellar tendon 
injury model in these mice to ascertain an in vivo changes. This should provide 
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novel insight into how targeting of mast cells may influence the outcome of tendon 
injury/tendinopathy.  
 On the basis of these results we propose IL-17 as a 
pathophysiological regulator in tendon healing (Figure 5-8) - better 
understanding of its pathological cascade may lead to the development of 
cell targeted treatment modalities for early supraspinatus tendinopathy. 
172	  	  
 
 
 
 
 
Figure 5-8 Schematic diagram illustrating the manner in which early tendinopathy may arise 
due to IL-17 induction.  
An increase stress that a tendon cell experiences results in the release of various 
inflammatory mediators such as IL-17 that interact to drive the tendon matrix toward a 
degenerative of reparative process. 
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Chapter 6 Interleukin 33 and related pathways in the 
pathogenesis of tendinopathy 	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Introduction 
My foregoing experiments clearly show an important role for inflammatory 
changes in the early tendinopathy lesion.  This may be regulated in part and may 
in turn regulate apoptosis operating at least partially through hypoxia dependent 
pathways.  In other tissue systems an important role has been demonstrated for 
alarmins in such circumstances.  I therefore investigated a potential role for a 
novel IL-1 superfamily member, IL-33 that is a postulated alarmin in the context of 
a variety of human pathologies. 
 Interleukin 33, similar to IL-1β and IL-18, is a member of the IL-1 family that 
has a major role in innate immune responses driven through its receptor ST2. IL-
33 is expressed in endothelial cells and fibroblasts and is found associated with 
chromatin in the nucleus [189]. IL-33 is released by these cells following necrotic 
cell death, hence this cytokine has been referred to as an 'alarmin'; proteins that 
are rapidly released from cells in response to infection or tissue damage, alarming 
the immune system by promoting activation of innate and adaptive immunity [233]. 
MicroRNA has recently been discovered to be a new class of post transcriptional 
regulators of gene expression. The miRNA mediate this regulation by binding to 
partially complementary sites in the 3’UTR of target messenger RNA. The 
formation of MiRNA-mRNA complexes leads to mRNA degradation or translational 
repression. Recent evidence has emerged of a novel role of the miRNA 29 family 
in the post transcriptional regulator of collagen synthesis in several human 
pathologies [324, 398-400] which is extremely pertinent to collagen matrix 
changes associated with tendon disorders.  
Herein, based on the key role of fibroblast-derived IL-33 that is emerging in 
inflammatory and fibrotic disorders and previous investigations showing increased 
mast cells in torn rotator cuff tendons [66] I investigated the role of the IL-33/ST2 
signalling pathway on tendon pathology in animal and human models of 
tendinopathy. In addition due to an emerging role for miRNA in post transcriptional 
collagen matrix regulation I show that miRNA 29a is a key regulator of IL-33 
induced collagen matrix changes through its direct targeting of soluble ST2. This 
data collectively suggests that IL-33 may function as an endogenous DAMP in 
tendon disease and that miRNA 29a is critical regulator of collagen matrix changes 
and thus may be a novel translational target for tendon disorders. 
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6.2) IL-33 and ST2 is expressed in human tendinopathy 
6.2.1)	  Expression	  of	  IL-­‐33,	  ST2	  and	  IL-­‐1RAcP	  in	  tendon	  biopsies	  
IL-33 has been reported to be expressed in cells of body barriers but also in 
associated inflammatory tissues for example tonsils. The aim of the following 
experiments was to investigate IL-33 expression in human tendinopathy. To 
evaluate IL-33 expression, IHC staining was performed on tonsil tissue serving as 
a positive control. Consistent with previous reports, IL-33 was detected in the 
nuclei of endothelial cells. By topography and their morphology, these cells could 
also be fibroblast reticular cells described by Moussion [401]. After establishing the 
methodology for IHC of IL-33, tendon from healthy individuals, torn supraspinatus 
and matched subscapularis was investigated. Strong nuclear staining was 
detected in endothelial cells (black arrows), but also weak staining of IL-33 was 
noted in the cytoplasmic compartment (red arrows) (Figure 6-1). 
Next, the expression of the IL-33 receptor, ST2 was determined in tendon 
biopsies. Positive cells were detected in the endothelium (black arrows) but also 
on numerous fibroblast like tenocytes cells (red arrows). The cellular staining 
pattern was associated with membrane and cytosolic localisation, but 
unexpectedly, was also partly nuclear. Controls demonstrated no non-specific 
binding of the isotype antibody. To complete the staining of the known molecular 
components of IL-33 and its signalling complex, we next evaluated IL-1RacP 
expression in tendon. In a similar pattern to that observed for ST2 staining, 
positive cells were mainly endothelial and fibroblast like in terms of phenotype. 
However, in marked contrast to IL-33 and ST2 which were found in lower levels in 
control tissue, but commensurate with its reported homeostatic role and global 
distribution, IL-1RacP was noted to be expressed in high levels in normal healthy 
tendon.  
Together these data suggest a predominate staining pattern of IL-
33/ST2/IL-1RAcP  in subscapularis tendon. This finding is centrally important and 
it strongly suggests that IL-33/ST2 interaction is important during the early 
tendinopathy stages which many studies have failed to explore in human samples. 
In particular we have previously shown this tissue to be representative of early 
'stressed' tendinopathy [340] and promotes the concept of IL-33 as a mechanically 
response cytokine particular in the mechano-sensitive tenocyte. 
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 Thus further investigation of the IL-33/ST2 axis was performed due to its 
proposed role as a tissue alarmin, which could prove important in early 
tendinopathy. 
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Figure 6-1 IL-33, ST2 and IL1-RacP  immunostaining 
Staining in control (Ctl), Torn supraspinatus (TSup) and Matched Subscapularis (MSub). 
Black arrows show nuclear staining for IL-33 and red arrows show staining for ST2. Graphs 
illustrate Bonar scoring for samples of tendon with mean and SEM shown. n= 10 for control 
tendon, n=15 for torn supraspinatus and matched subscapularis. Scoring system depicts 
mean score per sample based on 10 high power field. 0= no staining, 1=<10%, 2=10-20%, 3= 
> 20% +ve staining of cells per high power field.
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6.2.2)	  Co-­‐localisation	  of	  IL-­‐33/ST2	  and	  endothelial	  markers	  
To definitively define the expression pattern, double staining was 
established using fluorescence microscopy. With this technique exact overlay is 
possible and thus the confidence in true cellular identification is enhanced. Cells 
were stained as described in the methods chapter. Expression of IL-33 was 
compared initially with ST2 and CD34 as a endothelial marker. IL-33 stained with 
FITC is shown in green in figure 6.2 where cellular markers are in red. The IL-33 
staining pattern observed confirmed previous IHC appearances with nuclear 
expression located predominantly around vascular structures. To visualize nuclei 
DAPI (in blue) was employed. Merged pictures clearly show distinct cells that 
exhibit IL-33 and ST2/CD34 co-expression.
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Figure 6-2 Double immuofluroscence staining for IL33, ST2 and CD34 in tendon biopsies 
Tendon samples were stained for IL33, ST2 and CD34 in ten patients. (A) ST2 localised around 
perivascular channels in subscapularis tendon. Nuclear IL-33 staining appears to be in some 
endothelial cells and also in cytoplasm. Merge shows double staining in vascular region. There 
were very few double stained fibroblast like tenocytes in all tendon samples with the majority 
around neovascularised regions. (B) To further clarify the staining pattern of ST2 double 
staining with ST2/CD34 (red) was undertaken. Sections were counterstained with DAPI (blue). 
Images are shown at 40x magnification. 
A 
B 
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6.3) Induction of IL-33 in tenocytes 
 IL-33 has been reported to be expressed in fibroblasts derived from 
synovial tissue. Therefore, a logical progression from this was to examine 
expression in tenocytes.  Human tendon derived fibroblasts were examined for 
their expression of IL-33 by IHC. Tendon fibroblasts were cultured until 80 % 
confluency and then split and plated on chamber slides. Although no specific cell 
surface markers exist for tenocytes we chose the surface marker CD55 that has 
been used by a collaborating laboratory (Prof P.P.Tak, AMC, Amsterdam) as a 
fibroblast marker to assure ourselves that cultured cells were indeed of fibroblast 
lineage. CD55 staining proved positive for >95% of the cultured cells. Additionally 
immunostaining for scleraxis was also performed as a marker of tenogenic cells as 
previously described [17].  Subsequently tendon fibroblasts were stimulated with 
or without TNF-α and IL-1. Twenty-four hours later cells were fixed and stained for 
IL-33 and ST2 using the same protocol as for synovial tissue staining previously 
described by the laboratory. As expected, IL-33 was detected in a predominantly 
nuclear expression pattern in in vitro cultured tenocytes and up regulated with 
stimulation by pro-inflammatory cytokines (Figure 6-3). ST2 staining revealed 
constitutive expression of ST2 in un-stimulated fibroblast like tenocytes in contrast 
to IL-33. Stimulation with IL-1 and TNF showed no significant increase in protein 
expression in ST2. Quantitative PCR confirmed significant up-regulation of IL-33 at 
the mRNA level while also showing that total ST2 message was significantly 
elevated with stimulation with TNFα and IL-1β (Figure 6-4). Finally FACS staining 
was undertaken to evaluate the constitutive expression of membrane ST2 on 
tenocytes and whether cytokine stimulation up regulated the IL-33 receptor. FACS 
showed approximately 20-30% of tenocytes to express membrane ST2 in normal 
culture conditions and showed no up regulation of membrane ST2 with TNF or IL-
1 stimulation (Figure 6-4B). 
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Figure 6-3. Immunostaining of explant cultures.  
(A) CD55 marker used to verify that cells are of fibroblast lineage. (B) IL-33 and ST2 staining 
in explant cultures of tenocytes with no stimulation, 100ηg/ml TNFα and 100ηg/ml TNFα and 
IL-1β showing upregulation of nuclear IL-33 expression 24 hours post incubation. No 
definite changes were noted in ST2 expression.  
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Figure 6-4 Expression of IL-33 and ST2 with TNF/IL-1 stimulation 
(A)Fold change in gene expression of IL-33, and ST2, 24 hours post incubation with 
respective doses of TNFα alone, IL-1β alone and in combination. Data shown as the mean ± 
SD of triplicate samples and represent experiments on three individual patient samples. 
*p<0.05, **p<0.01 compared to control samples 
(B) FACS analysis for ST2L in tenocytes treated with a variety of cytokines. No up 
regulation Of ST2L was noted with TNFα alone, IL-1β alone and in combination. Addition of 
IL-33 resulted in a small but significant shift of the curve to the right indicating up regulation 
of ST2L through IL-33 stimulation 
A 
A 
B 
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6.4) IL-33 induces collagen matrix changes and increased 
production of proinflammatory cytokines in vitro 
 As matrix dysregulation is a key phenotypic change in tendinopathy we next 
sought to investigate the effect of addition of recombinant IL-33 to tenocytes in 
vitro. Concentrations of 50 and 100ng/ml of rhIL-33 were chosen based on 
previous investigation within the host laboratory. Initial quantitative PCR data 
revealed significant up regulation of Collagen I ( 50ng/ml mean fold change ± 
SEM, 1.45 ± 0.2, 100ng/ml, 2.45 ± 1.0)  and III ( 50ng/ml, 2.2 ± 0.4, 100ng/ml 7.08 
± 1.7) mRNA at 24 hours post incubation with rhIL-33, with by far the greatest 
change observed in collagen III mRNA expression (Figure 6-5 A). A time course 
experiment using 100ng/ml of rhIL-33 was then employed to examine collagen 
mRNA production over a 48 hour period. The most striking change was seen in 
Collagen III mRNA at 24 hours with an almost 7 fold increase which then was 
reduced to 4 fold change (relative to baseline) at 48 hours. In keeping with findings 
at the mRNA level, total collagen protein production was significantly increased at 
24 (648µg/ml ± 42) and 48 hours (790 µg/ml ± 74 post incubation with 100ng/ml of 
rhIL-33 (Figure 6-5 B). The addition of rhIL-33 caused a significant increase in 
protein expression of Collagen III (control 13.2ng/ml ± 1.4, 50ng/ml rhIL-33, 
22.7ng/ml ± 2.5, 100ng/ml rhIL-33 35.6± 3.4) at 24 hours post incubation with no 
significant changes in Collagen I protein expression observed. Thus IL-33 seems 
to switch collagen matrix production toward a type III phenotype at early time 
points. 
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Figure 6-5 IL-33 induced matrix changes in tenocytes. 
 (A) Fold change in gene expression of IL-33, ST2, COL I and III with 50 and100ηg/ml rhIL-33 
24 hours post incubation (B) Total collagen production over time course following 
incubation with 50 and100ηg/ml rhIL-33 . (C) Fold change in COL I and III gene expression 
following incubation with100ηg/ml rhIL-33  and (D) Collagen I and III protein expression 24 
hours post incubation with respective rhIL-33. Data are shown as the mean fold change ± 
SD of duplicate samples and are representative of experiments using five individual donors 
of tendon explant tissue.
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Figure 6-6 IL-33 induced COL I and III protein changes and cytokine production in cultured 
tenocytes  
(A) Collagen I and III protein expression 24 hours post incubation with respective rhIL-33. 
Data are shown as the mean fold change ± SD of duplicate samples and are representative 
of experiments using five individual donors of tendon explant tissue. 
(B) Cultured tenocytes were incubated in with recombinant IL-33 over 24 hours. Data shows 
levels of IL-6, IL-8 and  MCP-1, in supernatants removed from culture at  24 hrs analysed 
using Luminex. 	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6.5) Signalling mechanisms mediating rhIL-33 effects manifest in 
tenocytes in vitro 
Next, in an attempt to elucidate the mechanistic pathway involved in IL-33 
mediated matrix changes, I decided to analyse the phosphorylation of key 
downstream signalling targets, including particularly ERK1/2 and NFkB.   Previous 
time courses in our laboratory using synovial fibroblasts revealed that 100ng/ml of 
rhIL-33 produced maximal effects on MAPK phosphorylation between 30 mins to 1 
hour post stimulation[244]. I subsequently undertook a time course looking at the 
MAPK array results at 30,40,50 and 60 mins post incubation and noted maximal 
effects at 50 and 60 minutes post stimulation. Conversely I undertook  a time 
course for NFkB at 5,10,15 and 20 minutes post incubation as again previous in 
house experiments had shown maximal effects between these time points. 
Ultimately NFkB. Activation was maximal 15 minutes post incubation with 
100ng/ml of rhIL-33.   These experiments analysed the phosphorylation status of 
mitogen-activated protein kinases (MAPKs), extracellular signal regulated kinases 
(ERK1/2), c-Jun N-terminal kinases (JNKs) and p38 isoforms using the Human 
Phospho-MAPK Array (R & D Systems Europe, UK). In addition, NFkb activation 
status was assessed using the NFkB p65 ( Total/Phospho) InstantOne™ ELISA ( 
eBioscience, UK).    
Although a generalised increase in phosphorylation was noted in the array, 
the only significant changes noted were manifest in ERK1/ERK2 phosphorylation 
after the addition of 100ng/ml of rhIL-33 one hour post treatment. Stimulation of 
tenocytes with IL-33 resulted in a significant down regulation of total NFkb while 
caused a significant up regulation of phosphorylated NFkB. TNFα stimulated cells 
were use as a positive control to assure the assays validity. 
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Figure 6-7 ERK and NFκB phosphorylation in IL-33 treated tenocytes 
(A) Whole-cell lysates were examined for the phosphorylation of MAPK’s at 1 hour after 
exposure to 100ng/ml rhIL-33 (A). The fold change of MAPK's was determined by 
densitometry and normalised to the control sample on the array(B). Data are shown as the 
mean fold change ± SD of duplicate samples and are representative of experiments using 
five individual donors of tendon explant tissue. 
(B) Whole-cell lysates were examined for the total NFκB and phosphorylated NFκB  in 
tenocyte cultures treated with 100ng TNF and IL-33. Data shown are mean± SD of three 
individual experiments.    
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6.6) ERK and NFκB inhibition abrogates collagen changes and 
reduces IL-33 induced proinflammatory changes 
To understand if downstream IL-33 signalling influenced collagen matrix 
production I next sought to investigate whether inhibition of the previously noted 
ERK and NFkB activation mediated any effect on the changes in collagen 
synthesis patterns that I had observed.. 
 The ERK (FR180204, 50µM) and NFκB (SN050, 18µM) inhibitors were 
applied alone or in combination with 100ng rhIL-33. The rationale for choosing 
these inhibitors was based on experiments carried out by Dr Kurowska-Stolarska, 
within our laboratory group on IL-33 in macrophages[244] where she had noticed 
significant reductions in IL-33 induced ERK and NFκB activity at IC50. The protocol 
from these set of experiments was followed.    
SN050 significantly reduced collagen I mRNA compared to control while FR 
180204 had no effect on Collagen I. Following incubation with rhIL-33, SN050 was 
able to significantly (p<0.05) reduce Collagen I message compared to IL-33 alone 
(ΔΔCT ±SEM, IL-33 -3.4±0.6, SN050 +IL-33 -1.3±0.6). FR180204 had no 
significant effect on IL-33 induced Collagen I message. Collagen III message was 
significantly reduced by FR18024 treatment alone and significantly reduced in IL-
33 treated tenocytes. 
 These changes were confirmed at the protein level in experiments in which 
SN050 was able to significantly reduce collagen I alone and in combination with 
IL-33. Again FR18024 was able to reduce collagen III alone and in combination 
with IL-33(Figure 6-8B). 
 rhIL-33 incubation resulted in significantly (p<0.05) reduce IL-6, IL-8 and 
MCP-1 production by tenocytes in the control environment and in the presence of 
100ng rhIL-33. Thus both NFκB and ERK pathways appear to be involved in IL-33 
induced cytokine production by tenocytes in vitro. 
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Figure 6-8  ERK and NFκB inhibitors effects on collagen synthesis 
(A) The levels of mRNA for Collagen type IA and IIIA were determined by real time PCR. (B) 
Collagen I and III protein levels as determined by ELISA. ERK inhibition significantly 
affected type III collagen synthesis alone and in combination with IL-33 while NFκB 
significantly affected collagen I synthesis in a similar manner. Data shown as the mean ± SD 
of triplicate samples and represent experiments on five individual patient samples. *p<0.05, 
**p<0.01 compared to control samples 
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Figure 6-9 ERK and NFκB inhibitors effects of cytokine production in tenocytes 
Cells were preincubated for 24 h with specific IL-33 and inhibitors for ERK (FR 180204) or 
NFκB (SN050) which also were included assay media. Data shows levels of MCP-1, IL-8 and 
IL-6 in supernatants removed from culture analysed using Luminex. Data shown are as the 
mean ± SD of duplicate samples and are representative of five individual experiments. 
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6.7) IL-33 in tendon healing in vivo 
Having identified expression and a potential functional role for IL-33 in 
tissue biopsies and subsequent in vitro work, I next sought to explore the 
functional relevance of this in an in vivo model. The host laboratory was the first to 
discover ST2L and since then have been at the forefront of discovery of its 
biology. As such the next logical step was to investigate tendon pathology in an 
animal model. At the time of designing experiments IL-33 knockout mice were not 
available to the group and indeed had been shown to be embryonically lethal 
(personal communication, Dr D Gilchrist, University of Glasgow). However the 
laboratory had used ST2-/- mice in numerous occasions and these were readily 
available. Thus it was decided to explore the functional relevance of IL-33 in ST2 
knockout mice. As discussed in section 1.3 the use of a running rodent model has 
not translated well to mouse experiments mainly through lack of convincing 
running by mice and subsequent pathological changes. With this in mind I chose 
to investigate tendon healing in ST2-/- with the use of the patellar tendon healing 
model previously discussed in the methods section.  
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6.7.1)	  Increased	  expression	  of	  IL-­‐33/ST2	  in	  early	  tendon	  healing	  
I first induced tendon healing using a well established tendon injury model 
as described in chapter 2. I examined expression of relevant factors in the area of 
the damaged and healing tendon at proscribed time points after the induction of 
the injury. Quantitative PCR revealed significant up regulation of IL-33 on days 1 
(mean ΔΔCt±SEM to uninjured, 12.5±3.3)  and 3 (ΔΔCt 4.9± 1.4) post tendon 
injury in WT mice (Figure 6-10 A). While injured ST2-/- mice on days 1 (ΔΔCt 5.4±  
0.9) and 3 (ΔΔCt 3.4±1.2) also showed a significant fold increase compared to 
controls this was markedly less when compared to the WT mice. 
I next analysed the expression of soluble versus membrane bound ST2 in 
vivo. Soluble ST2 was significantly up regulated at all time points (mean 
ΔΔCt±SEM, Day 1, 8.0±2.6, Day 3, 4.6±3.3, Day 7, 5.2±1.3 and Day 21 2.4 ±0.9) 
post injury in WT mice compared to uninjured controls (Figure 6-10 B). Message 
for membrane ST2 only showed significant changes on Day 3 (ΔΔCt 4.2±2.3) post 
injury with no other significant changes noted (Figure 6-10 C). 
Immunohistochemical analysis confirmed similar findings for IL-33 protein in 
WT mice at early time points (Figure 6-11). No significant changes in IL33 or ST2 
message or protein expression was found in WT mice at days 7 or 21 post injury. 
This was also true for IL-33 expression in ST2-/- mice suggesting that IL-33 
production ± release is an early hit phenomenon in keeping with a possible 
‘alarmin’ type role in tendon injury/repair.
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Figure 6-10. Relative expression of IL33, soluble and receptor ST2 in vivo  
(A) IL-33 gene expression on Days 1, 3, 7 and 21 post injury. The most significant 
increase is noted in WT injured mice on Day 1 post injury with globally reduced 
IL-33 message in ST2-/- mice. Soluble and receptor ST2 gene expression on days 
1,3,7 and 21 post injury. The most significant increase is noted in WT injured 
mice on Day 1 and 3 post injury suggesting this an early mediator in tendon 
healing. Data are shown as the mean fold change ± SD of duplicate samples and 
are representative of experiments using four mice per group. 
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Figure 6-11. Immunohistochemistry of IL-33 and ST2 expression in vivo. 
IL-33 and ST2 immunostaining in WT and ST2-/- injured and uninjured mice on 
Day 1 post injury highlighting increased IL-33 and ST2 staining in WT injured and 
uninjured mice compared to ST2-/- controls.  	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6.7.2)	  Altered	  collagen	  synthesis	  responses	  in	  ST2-­‐/-­‐	  mice	  	  	  
Total collagen production was significantly (p<0.01) increased in WT injured 
(mean collagen production± SEM, Day 1;1254 µg/ml±102, Day 3; 1852 
µg/ml±154, Day 7; 1545µg/ml±68 and Day 21; 1078µg/ml±98) and ST2-/- injured 
(Day 1;845 µg/ml±412, Day 3; 1056 µg/ml±82, Day 7; 986µg/ml±33 and Day 21; 
702µg/ml±41) mice at all-time points compared to uninjured WT mice (Day 1;602 
µg/ml±50, Day 3; 758 µg/ml±65, Day 7; 654µg/ml±41 and Day 21; 701µg/ml±85) 
and ST2-/- uninjured (Day 1;845 µg/ml±412, Day 3; 1056 µg/ml±82, Day 7; 
986µg/ml±33 and Day 21; 702µg/ml±41). The patellar tendons of WT mice 
however had significantly ( p<0.05) greater total collagen content at Days 1, 3 and 
7 post injury compared to ST2-/- injured mice at the same time points.  
 Sub analysis of collagen type at the mRNA level revealed that WT mice 
showed significantly greater expression of collagen III at days 1(ΔΔCt 14.7±6.5), 3 
(ΔΔCt 8.5± 1.6) , 7(ΔΔCt 5.8± 2.4)  and 21(ΔΔCt 4.2± 1.4) post injury compared to 
uninjured controls and injured ST2-/- mice at the same time points. Collagen I was 
initially  down regulated at day 1 (ΔΔCt -3.6± 2.2) and day 3 (ΔΔCt -4.6 ± 1.6) in 
WT injured mice which then recovered to be relatively up regulated on Days 7 
(ΔΔCt 2.3± 1.0) and 21 (ΔΔCt 4.6± 0.5) (compared to baseline). ST2-/- injured 
mice showed down regulated Collagen I on days 1(ΔΔCt -3.3± 1.7), 3 (ΔΔCt -1.1± 
0.6) and 7 (ΔΔCt -1.5± 0.7) which returned to baseline on Day 21 (ΔΔCt 1.2± 0.4). 
These results suggest that ST2-/- mice are unable to mount the same collagen 
healing response compared to WT controls implicating IL-33 as an early modulator 
of collagen changes in tendon injury.
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Figure 6-12.Total collagen production and Collagen III mRNA expression in vivo 
(A) Total collagen production (µg/ml) in WT and ST2-/- mice post injury.  
(B) Collagen III message levels in WT and ST2-/- post injury. Collagen III is significantly up 
regulated at all-time points post injury which is significantly abrogated in ST2-/- mice. Data 
are shown as the mean fold change ± SD of duplicate samples and are representative of 
experiments using four mice per group.  
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Figure 6-13 Collagen changes in vivo 
(A) Collagen I message levels in WT and ST2-/- post injury. Collagen I is significantly down 
regulated at day 1 & 3 in WT injured mice and day 1 in ST2-/-. (B) Collagen I and III protein 
levels at time points post injury. WT mice show  significantly greater production of Collagen 
I at days 7 and 21 post injury compared to WT injured tendons. ST2-/- mice produce 
significantly more Collagen I on days 1,7 and 21 compared to WT injured mice. There is also 
a  significant difference (p<0.01) in the lack of collagen III production in ST2-/- mice at all-
time points post injury compared to the injured WT group. Data are shown as the mean fold 
change ± SD of duplicate samples and are representative of experiments using four mice 
per group. 
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6.7.3)	  WT	  and	  ST2-­‐/-­‐	  mice	  showed	  reduced	  biomechanical	  tendon	  strength	  at	  early	  time	  
points	  post	  injury	  
Whilst changes at the molecular level may provide novel insight into 
pathophysiological mechanism, I next sought to evaluate the biomechanical 
strength implications of such molecular changes in the injured and uninjured 
tendons.  This was designed to ultimately assess whether this line of 
experimentation could have any clinical relevance. This work was undertaken with 
the help of collaborators (Dr A Deakin, Dr P Riches) at the University Of 
Strathclyde Department Of Bioengineering. 
Four tendons from each group (WT injured/uninjured and ST2-/- 
injured/uninjured) were analysed at all-time points as discussed in Materials and 
Methods. Injury to WT tendons resulted in a significant decrease in load to failure 
or ultimate strength at Days 1 and 3 post injury which recovered by day 7 and 21. 
ST2-/- uninjured mice showed no significant difference between WT uninjured 
mice at all-time points but there was a trend toward a lower tensile strength 
compared to WT uninjured. ST2-/-  injured mice had a significantly reduced 
reduced load to failure on day 1 post injury compared to ST2-/-  uninjured mice but 
interestingly had a greater tensile strength than WT injured mice on day 1.  At all 
subsequent time points the ST2-/- injured mice showed a trend toward a 
decreased load to failure compared to ST2-/- uninjured mice but this was not 
significant. This suggests that the collagen matrix changes seen in vivo in the ST2-
/- mice have no detrimental effect on the ultimate strength of injured tendons and 
indeed ST2-/- mice . These data are consistent with the notion that IL33/ST2 
signalling could represent a novel pathway of early matrix and inflammatory 
changes in tendon healing/ tendinopathy with a direct effect on the ultimate 
strength of the tendon and subsequent clinical rupture or damage.
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Figure 6-14 Biomechanical testing of tendon injury model in WT and ST2-/- mice 
(A) Load/Displacement curve for full loading cycle of tendon showing preconditioning of 
tendon during cycling and then ramp to failure load and displacement. (B) Load to failure 
data for WT and ST2-/- injured and uninjured tendons over time course.  Data are shown as 
the mean fold change ± SD of duplicate samples and are representative of experiments 
using four mice per group.
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6.7.4)	  Addition	  of	  rhIL-­‐33	  induces	  collagen	  matrix	  changes	  in	  vivo	  and	  reduces	  
biomechanical	  strength	  
Due to the observation that ST2-/- mice were unable to mount a similar 
genotypic and phenotypical collagen response in tendon healing, I next sought to 
ascertain if the addition of recombinant IL-33 would have any effect on matrix 
changes in vivo in WT and ST2 -/- mice. 
rhIL-33 was injected on day -3, -2, -1 and 0 prior to injury. Following this, 
tendons were harvested from the respective group at days 1, 3, 7 and 21 post 
injury for analysis of total collagen production, collagen I and III message and 
protein levels. Total collagen production was increased in WT injured and ST2-/- 
mice as previously mentioned with a significant reduction in the knockout group. 
Addition of rhIL-33 significantly increased total collagen on day 7 (mean collagen 
production± SEM, WT injured; 1668 µg/ml±80 WT, WT injured +rhIL-33 1782 
µg/ml±95) and 21 (mean collagen production± SEM, WT injured; 988 µg/ml±49, 
WT injured +rhIL-33 1200 µg/ml±40)  in WT injured mice compared to PBS 
injected controls. Addition of rhIL-33 significantly increased the production of 
Collagen III at both the mRNA and protein level in uninjured but most noticeably in 
injured tendons.  
As a specificity control, we also demonstrated that IL-33 treatment did not 
affect the changes in collagen matrix synthesis or ultimate tensile strength of the 
healing tendon in ST2−/− mice confirming that IL-33 acted via an ST2-dependent 
pathway. 
The addition of IL-33 significantly reduced the strength of tendons at all time 
points post injury compared to WT injured tendons injected with PBS (Figure 
6-16A).  The removal of IL-33’s ligand in ST2-/- mice reduced the loss of strength 
significantly (Figure 6-16B) strongly implicating the loss of strength directly to the 
addition of IL-33 and its associated collagen matrix changes. 
201	  
 
Figure 6-15 rhIL-33 and collagen matrix changes in vivo 
(A) Total collagen production and (B) Collagen III protein in WT and ST2-/- mice treated with 
rhIL-33. The most significant shift was in the production of Collagen III protein in WT ice 
treated with rhIL-33 at all-time points post injury. Data are shown as the mean fold change ± 
SD of duplicate samples and are representative of experiments using four mice per group. 
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Figure 6-16 Biomechanical testing of WT and ST2-/- mice treated with rhIL-33 
(A) rhIL-33 resulting in a significantly decreased load to failure in WT uninjured mice on 
Days 1 and 3of the treatment protocol. More significantly WT injured mice had 45% less 
load to failure if treated with rhIL-33 on days 1 and 3 post injury with a 20% decrease in 
strength at 21 says post injury compared to PBS injection alone. Data are shown as the 
mean fold change ± SD of duplicate samples and are representative of experiments using 
four mice per group. 
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6.8) A role for micro RNA 29 in tendon healing 
Due to parallel studies of mir-155 in rheumatoid arthritis alluded to before 
and in an effort to accelerate my understanding of some of the post transcriptional 
regulatory events underpinning the above observations, I next performed 
screening for miRNA targeting Collagen I/III , IL-33 and ST2 genes. To do this I 
merged the results of several computational prediction algorithms provided at the 
miRGen database. Bio computational predication screening tools are well 
established screening tools for miRNA profiling. Among other miRNA, such as the 
let-7 family, miR-26, and miR-155, the miR-29 family members were identified as 
potential post-transcriptional regulators of  type I collagen, type III collagen and 
ST2.  
Given that most miRNA act as post-transcriptional repressors and that in 
tendinopathy the expression of collagen genes are up regulated I sought to 
explore a role for the microRNA 29 family in tendon biopsies. 
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6.8.1)	  Down	  regulation	  of	  miR	  29	  expression	  in	  tendinopathy	  
We therefore analysed the expression of the miR29 family in torn 
supraspinatus, matched subscapularis and control tendon samples having 
previously carried out collagen analysis on the same samples which are shown in  
Figure 4-4A. We found that all members of the miR-29 family were expressed in 
control, torn and matched tendon. Control tendon showed the highest level of 
miR29 family expression with miR-29a showed the highest level of expression 
(mean ±SEM ΔCt, control 17±0.5, supraspinatus, 20±1.9, subscapularis 25±2.4), 
followed by 29b (control 23±1.9, supraspinatus, 26±2.4, subscapularis 28±2.8), 
and 29c (control 21±0.6, supraspinatus, 24±1.3, subscapularis 21±0.9). Both torn 
and matched subscapularis showed significantly decreased levels of miR29 a and 
b compared to control tendon. No significant difference was noted in miR 29c 
levels compared to control tendon.  
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Figure 6-17 Micro RNA 29 family expression in tendon biopsies 
miR 29 family gene expression in Control (Ctl), torn supraspinatus (TSup) and matched 
subscapularis tendon ( MSub). Data shown as the mean ± SD of duplicate samples and 
represent experiments on ten patient samples. *p<0.05, **p<0.01  
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6.8.2)	  Altered	  collagen	  expression	  following	  over	  expression	  of	  miR29	  a	  and	  b	  
I next aimed to evaluate the functional effects of altered miR-29 a & b 
expression on Collagen matrix synthesis on tenocytes in vitro. Evidence exists 
showing that mir29 a and b can act by directly targeting Collagen III and I 
respectively[324]. Thus to test whether miR-29 a & b indeed regulate the levels of 
the candidate target mRNAs, we transfected miR-29a & b mimics into tenocytes. 
Tenocytes were also transfected in parallel with a control mimic miRNA. 
Transfection efficiency was calibrated by FACS analysis of the labelled control 
mimic. The mean transfection rate of all experiments was 58±10 %. Transfection 
with pre-miR-29a/29b increased the level of the respective miRNAs by a mean ± 
SEM of 80.2 ± 23.2 fold and 57.8 ± 10.6 fold.  
Collagen I and III mRNA were reduced significantly by miR29 a &b mimic 
transfection respectively. miR 29 mimic transfection reduced collagen III mRNA 
almost 6 fold compared to scrambled control whereas collagen III protein was 
reduced by 50% at 24 hours post transfection. miR 29 b mimic reduced Collagen I 
mRNA 2 fold with a 43% reduction in Collagen I production at the protein level. 
Thus collagen changes in vitro may possibly reflect 'cross talk' between the miR 
29 family with subsequent post transcriptional effects on collagen matrix synthesis.    
 
 
.
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Figure 6-18 Collagen expression following transfection with miR 29a &b  
(A) FACS of labelled c547 mimic control showing shift of curve to right indicating 
transfection of tenocytes with miR29a mimic. Image show represents 65% transfect ion 
efficiency in tenocyte culture.(B) Collagen I and III gene expression following transfection 
with scrambled mimic or mimic for miR29 a and b. (C) Collagen I and III protein levels in 
tenocytes transfected with mimic miR 29a or b. miR29 a significantly (p<0.01) reduces 
Collagen III message and protein while miR29b significantly (p<0.01) reduces Collagen I 
message and protein.
A 
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= untransfected with    
unlabelled mimic 
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6.8.3)	  Collagen	  I	  and	  III	  are	  directly	  targeted	  by	  miR29a	  and	  b	  	  
To confirm whether there was direct regulation of collagen genes, we 
created a luciferase reporter gene system by cloning a part of the 3’UTR of Col 
3A1 and Col1A1 with respective biding sites for miR-29a and miR-29b. In the 
reporter gene assay, co-transfection of cells with pre-miR-29a or b and the 
lucerifase reporter plasmid containing the 3’UTR of COL3A1 or COL1A1 
decreased the relative lucerifase assay 
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Figure 6-19 Collagen III is a direct target of miR29a 
The human miRNA target site was generated by annealing the oligos: of COL I/COLIII 3’UTR 
which were cloned in both sense and anti-sense orientations downstream of the luciferase 
gene in pMIR-REPORT luciferase vector (Ambion). These constructs were sequenced to 
confirm inserts and named pMIR-COL I/COL III-miR29a/b/c and pMIR(A/S)-COL I/III 
miR29a/b/c, and used for transfection of HEK293 cells. HEK293 cells were cultured in 96-
well plates and transfected with 0.1 µg of either pMIR-COL I/III miR29a/b/c, pMIR(A/S)-COL 
I\III-miR29a or pMIR-REPORT, together with 0.01 µg of pRL-TK vector (Promega) containing 
Renilla luciferase and 40 nM of miR-29 or scrambled miRNA (Thermo Scientific 
Dharmacon®). This was repeated in 3 independent experiments. 	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6.8.4)	  IL-­‐33	  treated	  tenocytes	  show	  altered	  miR	  29a	  expression	  
As I had previously discovered that the addition of rhIL-33 significantly 
increased the production of Collagen III compared to collagen I, I sought to 
investigate whether there was a role for the microRNA family 29 in IL-33 induced 
matrix changes in vitro.  
 Following incubation with 100ng rhIL-33 the levels of miR 29 a,b &c were 
analysed in tenocytes cultures at 4,6,12,24 and 48 hours post incubation (Figure 
6-20A). IL-33 significantly reduced the expression of miR 29a at 6 (ΔΔCT -2.7 ),12 
(ΔΔCT -3.1) and 24 hours (ΔΔCT -3.9) post incubation.  IL-33 mediated significant 
effects on mir 29b expression only at 12 hours (ΔΔCT -2.5) post incubation but no 
other time points. This set of experiments suggested that IL-33 mediated collagen 
III changes may be in part regulated by miR 29a. 
 To assess the validity of the observed effects of exogenous IL-33 on miR 
29a I then introduced a miR 29a mimic to the culture system. Tenocytes were 
transfected with miR 29 mimic as previously described. At 24 hours post 
transfection 100ng of rhIL-33 was added to the culture system and the levels of 
Collagen I and III were assessed. miR 29a mimic was able to significantly 
abrogate both collagen III message (+IL-33 ΔΔCT 4.9 , mimic + IL-33 ΔΔCT 1.7) 
and protein (+IL-33 34±3 ng/ml, mimic +IL33 16±5 ng/ml). miR 29a had no 
significant effect on Collagen I protein or message levels. The addition of miR 29a 
mimic ± IL-33 had no significant effect on IL-33 gene expression.
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Figure 6-20 The effects of IL-33 on miR 29a expression 
(A) The addition of 100ng/ml of rh IL-33 resulted in a significant and persistent reduction in 
miR 29a expression whilst there was no obvious pattern to miR 29b expression. (B) The 
addition of mimic± rhIL-33 had no significant effect on IL-33 gene expression.   
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Figure 6-21 The effects of mir 29a mimic ad IL-33 on Collagen expression 
The addition of 100ng/ml of rhIL-33 significantly reduced the gene and protein expression of 
type III collagen in vitro highlighting a possible interaction between microRNA 29a and IL-33 
mediated collagen matrix changes. 	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6.8.5)	  Soluble	  ST2	  is	  a	  direct	  target	  of	  miR29a	  
Computational analysis had already suggested miR 29a as a possible 
target for soluble ST2. In an attempt to link IL-33 mediated collagen changes and 
miR 29a ability to directly target the 3’UTR of collagen III I next investigated 
whether the miR29 family was a direct target of sST2. A luciferase reporter gene 
system was generated by cloning a part of the 3’UTR of soluble ST2 with 
respective biding sites for miR-29a and miR-29b. In the reporter gene assay, co-
transfection of cells with pre-miR-29a and the lucerifase reporter plasmid 
containing the 3’UTR of sST2 decreased the relative lucerifase assay (Figure 
6-22). 
To confirm whether miR-29a did indeed regulate the levels of the candidate 
target mRNAs, we again transfected miR-29a mimic into tenocytes. Tenocytes 
were also transfected in parallel with a control mimic miRNA. Transfection 
efficiency was ensured by FACS analysis of the labelled control mimic as 
previously described. Soluble ST2 message was significantly (p<0.01) down 
regulated by transfection with miR 29a mimic by approximately 5 fold with a 
corresponding modest, yet significant (p<0.05), reduction in soluble ST2 protein 
(mean sST2 protein µg/ml ±SEM, scrambled 55 µg/ml ± 6, miR 29a mimic 34 
µg/ml ±7) confirming mi29a as a target for soluble ST2. Indeed, miR29a was able 
to significantly (p<0.05) reduce the IL-33 induced increase in soluble ST2 protein 
(IL-33 66 µg/ml ± 5, miR 29a mimic + IL-33 42 µg/ml ±10).
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Figure 6-22 Soluble ST2 is a direct target of miR29a 
The human miRNA target site was generated by annealing the oligos: of sST2 3’UTR which 
were cloned in both sense and anti-sense orientations downstream of the luciferase gene in 
pMIR-REPORT luciferase vector (Ambion). These constructs were sequenced to confirm 
inserts and named pMIR-sST2-miR29a/b/c and pMIR(A/S)-sST2-miR29a/b/c, and used for 
transfection of HEK293 cells. HEK293 cells were cultured in 96-well plates and transfected 
with 0.1 µg of either pMIR-sST2-miR29a/b/c, pMIR(A/S)-sST2-miR29a or pMIR-REPORT, 
together with 0.01 µg of pRL-TK vector (Promega) containing Renilla luciferase and 40 nM of 
miR-155 or scrambled miRNA (Thermo Scientific Dharmacon®). This was repeated in 3 
independent experiments. 
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Figure 6-23 miR29a targets soluble ST2 message and protein in tenocytes 
Confirmation of direct targeting of sST2 by miR29a was analysed using quantitative PCR (A) 
showing a significant negative fold change in sST2 and a human sST2 ELISA which show a 
modest but significant reduction of soluble ST2 with miR29a mimic (B). miR-29a was also 
able to significantly reduce sST2 message and protein following stimulation with rhIL-33 	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6.8.6)	  miRNA	  29	  a	  &	  b	  altered	  in	  tendon	  healing	  in	  vivo	  	  
Based on the foregoing experiments I next sought to explore the functional 
relevance of this in an in vivo model of tendon healing.  Levels of miR 29 a, b and 
c were analysed at all-time points post injury in the patellar tendon healing mouse 
model. 
 The most profound effect was seen with miR 29a (Figure 6-24). Tendon 
injury in WT mice resulted in a 22 fold decrease in mir29a on day 1 which was 
reduced to a 6 fold decrease on day 3. By days 7 and 21 no significant difference 
was noted in miR29a expression. This effect was significantly abrogated in ST2-/- 
mice with a 7 fold decrease in miR29a on day 1 and a 2 fold decrease on day 3. 
There was a significant up regulation of miR29a on day 7(ΔΔCT 2.3) and day 21 
(ΔΔCT 2.6)   in ST2-/- mice. Thus in WT injured mice at early time points there is 
concurrent downregulation of miR29a and up regulation of soluble ST2 message 
and Collagen III production in keeping with our in vitro findings. ST2-/- injured mice 
have a significantly reduced capacity to down regulate mir29a partially explaining 
their reduced early collagen matrix response.
217	  
 
 
Figure 6-24 miRNA 29 a&b in tendon healing in vivo 
Quantitative PCR showing mean fold change ±SEM in miRNA 29 a (A) and b (B) in WT and 
ST2-/- mice in injured versus uninjured animals. Data are shown as the mean fold change ± 
SD of duplicate samples and are representative of experiments using four mice per group.
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6.8.7)	  NFκB	  signalling	  modulates	  miR29a	  activity	  in	  IL-­‐33	  treated	  tenocytes	  
Having previously identified NFκB as potential downstream regulators of IL-
33 induced collagen III changes and recent evidence that NFκB mediates the 
suppression of miR29 by directly binding to the promoter of the miR29 gene[402] 
or activating the transcription repressor YY1[403] we investigated whether 
inhibition of NFκB had an effect on miR29a expression. SN050 treatment alone 
had no significant effect on endogenous miR29a expression in tenocyte culture 
(Figure 6-25). However SN050 attenuated miR29a expression following IL-33 
stimulation promoting NFκB as a repressor of miR29a particularly as ERK 
inhibition appeared to have no direct effect on miR29a expression.
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Figure 6-25 ERK and NFκB inhibitors effects on miR29a expression 
The levels of miRNA 29a were determined by real time PCR. NFκB inhibition significantly 
reduced the IL-33 induced down regulation of miRNA 29a while ERK inhibition had no direct 
effect. Data shown as the mean ± SD of triplicate samples and represent experiments on 
three individual patient samples. *p<0.05, **p<0.01 compared to control samples 	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6.8.8)	  Addition	  of	  rhIL-­‐33	  alters	  miR	  29	  a	  and	  b	  expression	  in	  vivo	  	  
The effect of rhIL-33 was next analysed on micro RNA 29a as the most 
profound effect had been noted in this miR in vivo. The addition of rh-IL33 
significantly reduced miR29a expression in uninjured tendons at all-time points 
compared to PBS injected controls (Figure 6-26) suggesting that IL-33/ST2 
signalling reduces mir29a expression with a subsequent change in the collagen 
matrix. 
 The affect was most profound in injured WT mice with a further 10 fold 
reduction in miR 29a with the addition of rhIL-33. Addition of rhIL-33 in ST2-/- mice 
had no significant effect on miR 29a expression in injured or uninjured tendons 
again suggesting that miR29a down regulation is in part directly affected by IL-
33/ST2 signalling. 	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Figure 6-26 miRNA 29a following IL-33 treatment in vivo. 
Quantitative PCR showing mean fold change ±SEM in miRNA 29a in WT and ST2-/- mice in 
injured versus uninjured animals following treatment with rhIL-33 or PBS. rh-IL33 
significantly reduced mi29a expression in uninjured tendons at all-time points compared to 
PBS injected controls  Data are shown as the mean fold change ± SD of duplicate samples 
and are representative of experiments using four mice per group. 	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6.9) Discussion and Conclusions 
These experiments clearly demonstrate a role for IL-33 as a possible 
alarmin in early tendon injury and indeed human tendinopathy.  The novel finding 
of a possible role for microRNA 29a in the regulation of IL-33 mediated effects 
provides further detailed and entirely novel mechanistic insight and thus targets in 
tendinopathy. 
   The previous chapters of this thesis have illustrated a key role for 
inflammation and the subsequent production of cytokines in human tendon 
disease. IL-33 has become increasingly associated with musculoskeletal 
pathologies over the past few years [233]. The experiments in this section show 
IL-33 to be present in human tendon biopsies at the early stage of disease and 
localisation studies appear to suggest that the majority is expressed in endothelial 
cells but also a proportion in fibroblast like tenocytes. This is in keeping with the 
current immunohistological evaluations in the published literature. End stage 
biopsies have significantly less IL-33 expression at the message and protein level 
promoting the concept of IL-33 as an early tissue mediator in tendon injury and 
subsequent tissue remodelling. Upon cell injury endogenous danger signals, so 
called damage associated molecular patterns, are released by necrotic cells 
including heat shock proteins [404], HMGB1 [405], uric acid [406] and IL-1 family 
members [407, 408] including IL-33 [199, 401]. These danger signals are 
subsequently recognised by various immune cells that initiate inflammatory 
responses. These sentinel cells are prepositioned in tissue allowing a rapid 
response and are capable of producing and secreting selective mediators required 
for the induction of an inflammatory response.  
Mast cells possess these important characteristics [365] and have their 
activation has been strongly associated with IL-33 [210]. Recent work has 
demonstrated a key role for mast cells in responding to cell injury by recognising 
IL-33 released from necrotic cells [409] while IgE activated mast cells produce IL-
33 [410] thus initiating proinflammatory responses. Importantly IL-33 has also 
been shown to be released from endothelial cells following mechanical injury [199] 
and may be relevant to IL-33's egress in tendon injury/damage. The studies in this 
thesis have shown a significant proportion of mast cells in human tendinopathic 
biopsies and tendon healing in vivo. Therefore the IL-33/mast cell axis may 
provide a mechanism whereby early tendon injury results in IL-33 release/up 
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regulation , in turn activating mast cells located in close proximity to the 
injury/degeneration thus perpetuating an inflammatory or healing process. Indeed 
IL-33 induces mast cell production of IL-1, IL-6, IL-13, and a range of chemokines 
[155]  all of which have previously been shown to effect matrix metalloproteinases 
production in fibroblasts [330] may also be important in matrix remodelling. Based 
on these findings I propose IL-33 as an important DAMP in early tendon damage. 
 Interestingly the biomechanical data suggests a pathogenic role for IL-33 in 
tendon injury/healing. The addition of rhIL-33 significantly reduced the load to 
failure of WT mice by approximately 30% at early time points and could be as a 
result of the concomitant collagen III matrix changes, which are known to result in 
mechanically inferior tendon. Although the patellar tendon injury model is not a 
model of tendinopathy my data may give an insight into the repetitive tendon micro 
trauma and mechanical stress that tendinopathic tendon suffers. Thus one 
plausible mechanism may be that upon repeated micro injury IL-33 is up regulated 
with its subsequent release through apoptosis/necrosis, which in turn drives the 
matrix degeneration and proinflammatory cytokine production propelling the 
tendon toward a pathological state such as that seen in early tendinopathy 
biopsies. Further work is now required with neutralising antibodies to IL-33 to 
ascertain whether the pathogenic role for IL-33 in tendinopathy may have any 
translational benefits.  
 In vitro experiments suggest IL-33 switches collagen matrix production 
significantly toward a Collagen III phenotype. Tendon injury in vivo results in a 
large increase in IL-33 message immediately post injury with the appearance of 
nuclear and cytosolic protein expression. The subsequent change in Collagen III 
message and protein levels strongly promotes a mechanistic role for IL-33 in 
collagen matrix changes in tendon healing/injury. Others have implicated IL-33 in 
collagen synthesis. In an elegant study soluble collagen levels were increased 4-
fold in skin punch biopsies with the majority of infiltrating leukocytes found to be 
eosinophils in mice administered with IL-33 s.c [247]. Administration of IL-33 
resulted in significant modulation of collagen III and VI and increased expression 
of IL-13 mRNA. They established that IL-33 induced fibrosis required IL-13 using 
IL-13 KO mice and eosinophils using ΔdblGATA mice. Increasing evidence points 
toward IL-33 release from necrotic cells [200] which is a plausible mechanism for 
release in post injury tendons. IL-33 activates ERK1/2 and NFκB in tenocytes both 
of which are known to modulate both collagen I gene expression through activated 
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of NFκB [411, 412] and collagen III which is a target for ERK 1&2 [413, 414]. 
Indeed we were able to marginally reduce the amount of collagen type III through 
ERK inhibition. The substantial collagen change in vivo with IL-33 administration 
may provide novel therapeutic approaches through selective inhibition of 
downstream targets such as ERK1/2 and warrants further investigation 
The current set of experiments provide convincing evidence for a functional 
role for miR-29 in murine and human tendon injury. The direct posttranscriptional 
regulation of collagens by miR-29 adds a novel aspect to the complex network of 
factors that regulate the expression of collagen genes in tendinopathy/tendon 
healing at the level of transcription which include TGF-β [415], Smad-7 [416], 
angiotension receptor [417], TGF-1 [418] and mechanical stress [419]. The 
regulation of collagen by the mir 29 family has been highlighted in studies of 
human liver fibrosis, prostate cancer and systemic sclerosis. miR29 mediates the 
regulation of collagen matrix genes through TGF-β and NFκB downregulation of 
miR 29 family members in hepatic stellate cells(HSCs) [420]. Indeed in another 
study on HSCs miR 29b was the most effective suppressor of type I collagen at 
the mRNA and protein level via its direct binding to the Col1A1 3'UTR [399]. 
Elegant studies in human systemic sclerosis reveals miR 29a was strongly down 
regulated in SSc fibroblast compared to controls [324]. Functional studies 
suggested a direct regulation of collagen by miR29a whilst TGFβ, PDGF-B and IL-
4 reduced miR 29a levels in fibroblasts. This was confirmed in a bleomycin model 
of skin fibrosis where inhibition of PDGF-B and TGFβ pathways by imatinib 
resorted the levels of miR-29a.Our results suggest that miR-29a acts as a 
repressor to fine-tune collagen expression in tendon healing. The decreased 
expression in human biopsies also permissively implicates it in tendinopathy.  
 The precise mechanisms that lead to downregulation of miR29, especially 
miR 29a in tendon injury/tendinopathy remain to be determined but these 
experiments show that IL-33, decreased the expression of miR 29a in tenocytes 
and in vivo. Moreover the stimulatory effect of IL-33 on collagen synthesis could 
be partially rescued with miR29a, suggesting that the reduced levels of miR 29a 
occur downstream of IL-33 and at least partially regulates its collagen effects. 
Indeed the discovery that soluble ST2 is a direct target of mi29a promotes the 
hypothesis that IL-33 is a central early mediator of tendon matrix changes driving a 
collagen 'switch' than may ultimately change the phenotypical tendon structure 
with fundamental clinical implications.  Indeed the targeting of miR-29 family 
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members as posttranscriptional regulators could be a potent modulator of collagen 
changes in tendinopathy. This needs to be tested in future studies. Specifically the 
effects of modification of miR-29a levels on the synthesis of extracellular matrix 
proteins should be analysed in an animal tendinopathy model. Optimally miR-29-
KO mice could be created and tested in the patellar tendon healing model.  So far 
miRNA based therapeutic approaches in animal studies of other diseases have 
been promising since toxic effects have not been observed and a recent human 
trial targeting a liver specific miRNA involved in hepatitis C has yielded promising 
results. Thus the development of strategies to maintain expression or to prevent 
repression of miR-29a in tendinopathy may be a promising future therapeutic. 
 Further investigation in this area are now required. To tie up the role of 
endogenous IL-33 on mi29a expression and matrix changes I intend to administer 
neutralising antibody to IL-33 in WT and ST2-/- mice and carry out biomechanical 
studies to appreciate any benefit to IL-33 targeted therapy in tendinopathy.     
 Based on the experiments in this chapter I propose IL-33 as an important 
and influential alarmin in early tendon injury and tendinopathy which may be 
influential in the balance between reparation and degeneration in tendon disease 
(Figure 6-27). A novel role for miR29a as a posttranscriptional regulator of matrix 
genes in tendon healing and tendinopathy has been discovered and may provide 
a targeted path for matrix remodelling in tendinopathy.  
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Figure 6-27 Schematic diagram illustrating the role of the IL33/ST2 axis in tendinopathy. 
An tendon injury or repetitive micro tears causing stress that a tendon cell experiences 
results in the release interleukin 33 and the downstream phosphorylation of NFkB which in 
turn represses miR29a causing an increase in collagen type III  and soluble ST2 production. 
An increase in collagen III reduces the tendons ultimate tensile strength lending it to early 
failure while soluble ST2 acts in an autocrine fashion which may ultimately be a protective 
mechanism whereby excess IL-33 is removed from the system. 
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Chapter 7 Discussion and Future work 	  	  
As always, experiments leave more questions than answers. However this 
thesis has I believe opened a debate on the key role of inflammation and its 
downstream molecular events in the role of tendon disease. For many years 
inflammation has been regarded throughout the tendinopathy field as misnomer 
and to have no influence in the pathogenesis of the disease mainly based on 
examination of end stage surgical specimens lacking an inflammatory infiltrate. I 
always believed this was a rather ‘missed the boat’ situation where something that 
had already happened was being checked for and was thus unlikely to be there. 
Inflammation is a key mechanism whereby injured tissue and cells recover and 
protect themselves against further insult with the attraction of leukocytes and 
sentinel immune cells. Many musculoskeletal pathologies including osteoarthritis, 
tendon rupture, seronegative/ positive spondyloarthropathies and muscle damage 
have a key inflammatory component. My findings of inflammation in an early 
human model of tendinopathy were chance findings when I hypothesised that 
subscapularis tissue would be normal. Nonetheless the fact that this showed early 
tendinopathy changes and was reproducible has finally allowed cellular and 
mechanistic studies into the early disease where clearly inflammation is a key 
molecular process.   
Many studies on tendinopathy have lacked mechanistic investigation. My 
studies have shown a key role for the cytokines IL-17 and IL-33 in tendinopathy. 
Rigorous mechanistic investigation has yielded exciting results around the 
modulation of extracellular matrix genes and proteins by these cytokines and their 
by-products. Firstly the deciphering of a molecular role for hypoxia in tendinopathy 
adds credence to hypoxia as an important regulator of tendinopathy. Since Jozsa’s 
classic manuscript on this subject in 1982 many textbooks and review articles 
have hypothesised that hypoxia is a key factor in tendon disease. While recent in 
vivo evidence from Professor Carr’s group in Oxford have shown altered O2 
tensions in human rotator cuff, the investigations in this thesis add substance to 
the theory of hypoxic tendon injury. We show that hypoxia alters collagen matrix 
production at the message and protein level but also show how tenocytes may 
regulate this process through MAPK activation and cytokine production with a 
possible drive toward tenocytes apoptosis. 
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Secondly through parallel studies in RA with a colleague I investigated the 
presence and subsequent mechanisms behind IL-17 in tendinopathy. Whilst 
surprising that a tissue process that has relatively few T cells, which are still 
considered in the literature to be the main source of IL-17A, has IL-17 present at 
the message and protein level on single and double immunofluroscent staining it 
does support the growing body of evidence that mast cells are important immune 
sentinel cells and are capable of producing a significantly potent cytokine such as 
IL-17. IL-17 in particular was able to drive a significant proportion of tenocytes 
toward apoptosis, result in a significant increase in type III collagen and increase 
the production of proinflammatory cytokines such as TNFα and MIP-1α. This in 
addition to recent microarray analysis of torn supraspinatus samples from the US 
which has highlighted IL-17F in near end stage biopsy tissue may well suggest 
that targeting of IL-17 and its downstream events could be important in 
tendinopathy 
Thirdly is the significant role that IL-33 may play as an alarmin in 
tendinopathy/tendon injury. Whilst at the start of these studies I hypothesised that 
IL-33 may be a novel discovery in tendinopathy and play a role in inflammation my 
studies have revealed it as an important regulator early tendon injury. In particular 
the role of IL-33 as early warning system to the tendon with subsequent matrix 
changes has for the first time given us a true molecular regulator whose 
downstream effects translate to biomechanical weakness. The US microarray that 
I mentioned has also shown a significant increase in IL-13RA2 compared to 
controls. Rankin and colleagues found IL-13 to be a key component of IL33 
mediated collagen changes in a skin healing model and although not specifically 
investigated in this thesis further work to explore a possible role for IL-13/IL-33 
mediated collagen changes in tendinopathy would be appropriate. The elusive 
nuclear function of IL-33 and its probable role as a repressor are currently being 
investigated at our laboratory. The information yielded from microarray analysis of 
nuclear regulated IL-33 genes will hopefully give us an insight into its role in the 
nuclear compartment. 
Finally again due to parallel studies in the laboratory this thesis has 
identified a role for microRNA in the post transcriptional regulation of collagen in 
tendon injury and likely tendinopathy. Collagen regulation and subsequent matrix 
changes particularly the replacement of Collagen I with III have long been 
identified as the key pathophysiological mechanisms in reducing biomechanical 
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strength with subsequent damage and possible clinical rupture of tendons. The 
miRNA 29 family is slowly becoming a key molecule in collagen matrix regulation 
in numerous diseases including liver fibrosis, prostate cancer and systemic 
sclerosis. Indeed Maurer and colleagues work in systemic sclerosis has led to a 
patent request for mir29a therapy in systemic sclerosis which is extremely 
promising and exciting. Thus the identification that miRNA 29a is significantly 
altered in vivo along with in vitro work highlighting it as direct target of Collagen III 
and indeed soluble ST2 it may well translate into a possible target to alter the 
collagen III switch in tendinopathy particularly if IL-33/ST2 signalling is an 
upstream modulator of collagen genes. These experiments have brought up to 
date cutting edge science to the field and hopefully identified a key target for future 
work. 
In summary whilst previous investigations have painted the tenocyte as a 
mere bystander in the pathological process I would argue based on these results 
that the biology and mechanistic investigation of up and downstream regulators of 
molecular processes in tenocytes including collagen synthesis, apoptosis and 
cytokine production should be studied as a means to unravel the pathophysiology 
of tendon disease for true translational benefits to patients.
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